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Abstract 
Hyperglycaemia in critical care is common and has been linked to increased 
mortality and morbidity. Tight control of blood glucose concentrations to more 
normal levels can significantly reduce the negative outcomes associated with 
hyperglycaemia. However, hypoglycaemia and glycaemic variability have also 
been independently shown to increase mortality in critically ill patients. Further 
complicating the matter, critically ill patients exhibit high inter- and intra patient 
metabolic variability and thus consistent, safe control of glycaemia has proved 
very difficult. 
 
Model-based and model-derived tight glycaemic control methods have shown 
significant ability to provide very tight control with little or no hypoglycaemia in 
the intensive care unit (ICU). The model-based control practised in the 
Christchurch Hospital ICU uses a physiological model that relies on a single, 
time-varying parameter, SI, to capture the patient-specific glycaemic response to 
insulin. As an identified parameter, SI is prone to also capturing other, 
unintended, dynamics that add variability on multiple timescales. The objective 
of this research was to enable enhanced glycaemic control by addressing this 
variability of the SI parameter through better modelling and implementation. 
 
An improved model of insulin secretion as a function of blood glucose 
concentration was developed using data collected from a recent study at the 
Christchurch Hospital ICU. Separate models were identified for non-diabetic 
patients and diagnosed, or suspected type II diabetic patients, with R2 = 0.61 and 
0.69, respectively. The gradients of the functions identified were comparable to 
data published in a number of other studies on healthy and diabetic subjects.  
 
The transcapilliary diffusion (nI) and cellular clearance (nC) rate parameters 
were optimised using data from published microdialysis studies. Interactions 
between these key parameters determine maximum interstitial insulin 
concentrations available for glucose disposal, and thus directly influence SI. The 
optimal values of these parameters were determined to be nI = nC = 0.0060 min-1.  
xiii 
 
Models of endogenous glucose production (EGP), as functions of blood glucose 
concentration and time, were assessed. These models proved unsatisfactory due 
to difficulties in identifying reliable functions with the available data set. Thus, it 
was determined that EGP should continue to be treated as a population constant, 
except during real-time glycaemic control, where the value may be adjusted 
temporarily to ensure valid SI values. 
 
The first 24 hours of ICU stay proved to be a period of significantly increased SI 
variability, both in terms of hour-to-hour changes and longer-term evolution of 
level. This behaviour was evident for the entire study cohort as a whole and was 
particularly pronounced during the first 12-18 hours. The subgroup of 
cardiovascular surgery patients, in which there was sufficient data for analysis, 
mirrored the results of the whole cohort, but was found to have even lower and 
more variable SI. Glucocorticoid steroids were also found to be associated with 
clinically significant reductions in overall level and increases in hour-to-hour 
variability of SI. 
 
To manage variability caused by factors external to the physiological model, the 
use of several stochastic models was proposed. Using different models for the 
early part of ICU stay and for different diagnostic subgroups as well as when 
patients were receiving certain drug therapies would permit control algorithms 
to reduce the impact of the SI variability on outcome glycaemia.  
 
The impact of measurement timing and BG concentration errors on the 
variability of SI was assessed. Results indicated that the impact of both sources of 
errors on SI level was unlikely to be clinically significant. The impact of BG 
sensor errors on hour-to-hour SI variability was more pronounced.  
Understanding the effect of sensor and timing errors on SI allows their impact to 
be reduced by using the 5-95 percentile forecast range of stochastic models 
during glycaemic control.  
 
The performance of the model incorporating the proposed insulin kinetic 
parameters and secretion enhancements was validated for clinical glycaemic 
xiv 
 
control and virtual trial purposes. This validation was conducted by self- and 
cross validation on a cohort independent to that with which the model was 
developed. The use of multiple stochastic models to reduce the impact of this 
extrinsic variability during glycaemic control was validated using virtual trials. 
  
xv 
 
 
 
1 
 
Chapter 1. Introduction 
Stress-induced hyperglycaemia is prevalent in critical care and can occur in 
patients with no history of diabetes [Capes et al. 2000; Krinsley 2004; Van den 
Berghe et al. 2001]. Hyperglycaemia used to be seen as a positive adaptive 
response in the critically ill [Mesotten & Van den Berghe 2009]. However, two 
landmark studies, by Van den Berghe et al. [2001] and Krinsley [2004] showed 
that actively controlling blood glucose (BG) concentrations to more normal 
levels with insulin, significantly reduced mortality in critical care patients. These 
papers signalled a new era of research into hyperglycaemia and its prevention in 
the ICU. 
 
Hyperglycaemia was found not only to be associated with mortality [Chase et al. 
2008; Krinsley 2003,2004; Van den Berghe et al. 2001; Van den Berghe et al. 
2003], but also with increases in other negative clinical outcomes. These other 
outcomes include severe infection [Bistrian 2001], sepsis and septic shock 
[Branco et al. 2005; Das 2003; Marik & Raghavan 2004; Oddo et al. 2004], 
myocardial infarction [Capes et al. 2000], and polyneuropathy and multiple-
organ failure [Langouche et al. 2005; Van den Berghe et al. 2001]. In each of 
these cases or patient subgroups, lower blood glucose levels were associated 
with reduced mortality and/or complications. 
 
Further, there was also evidence of significant reductions in the need for dialysis, 
bacteraemia testing and the number of blood transfusions with aggressive blood 
glucose control using intensive insulin therapy [Krinsley 2004; Van den Berghe 
et al. 2001; Van den Berghe et al. 2003]. All these results pointed towards the 
conclusion that the control of blood glucose to normal levels in critical care had a 
significant clinical impact. Equally, they create a very strong case that links 
elevated glycaemia and glycaemic variability to poor outcomes. Thus, conversely, 
lower glycaemic levels, regardless of how obtained, yield better outcomes. 
 
2 
 
1.1 Aetiology of hyperglycaemia in critical care 
Hyperglycaemia in critically ill patients is generally considered a result of the 
stress response [Weissman 1990]. The counter-regulatory hormones: cortisol, 
glucagon, the catecholamines, as well as growth hormone, are significantly 
elevated almost immediately post critical-insult, but decline rapidly over the first 
12-48 hours [Chernow et al. 1987; Frayn 1986; Jaattela et al. 1975; Weissman 
1990]. These hormones are known to cause increased hepatic glucose 
production, inhibition of insulin secretion and peripheral insulin resistance 
[Weissman 1990], all of which cause elevated blood glucose concentrations 
during the acute phase of critical illness.  
 
This acute phase evolves into the ‘flow’ phase of injury, which can last days or 
weeks and is characterised by hypermetabolism and muscle catabolism. 
Hyperglycaemia often persists into the flow phase, but the causes are not as well 
understood, as the time-course of the counter-regulatory hormones does not 
match that of the metabolic changes [Frayn 1986]. 
 
In addition to these injury-related causes, pre-existing glucose intolerance and 
the administration of some medications in the ICU may play a role in 
hyperglycaemia. In particular, glucocorticoid steroids [Bradley 2002; Pretty et al. 
2010], the catecholamines, and β-blockers [Luna & Feinglos 2001; Sarafidis & 
Nilsson 2006] are commonly used drugs that have been recognized to increase 
hyperglycaemia. The situation is exacerbated by exogenous nutritional support 
regimes with high glucose content [Krishnan et al. 2003; Woolfson 1980]. 
 
Currently, the exact reasons for the benefits derived from tight glycaemic control 
(TGC) are not fully known, but have been extensively analysed in the literature 
[Bellomo & Egi 2005; Diringer 2005; Finney et al. 2003; Krinsley 2004; 
Langouche et al. 2005; Mesotten et al. 2004; Van den Berghe 2004; Van den 
Berghe et al. 2005]. However, recent studies by Weekers et al. [2003] and 
Langouche et al. [2005] indicated some major causes. Specifically, tight 
glycaemic control reduces glucotoxicity due to high blood glucose, which in turn 
reduces oxidative stress and superoxides, stress hormone responses, damage to 
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the endothelium and vascular walls. Hyperglycaemia was also shown to reduce 
immune response and bactericidal activity.  
 
Thus, tight control of blood glucose concentrations in critical care can be 
beneficial. However, there is little consensus on what constitutes desirable 
glycaemic performance, or how to achieve it [Gale & Gracias 2006; Mackenzie et 
al. 2005; Schultz et al. 2006; Suhaimi et al. 2010]. 
 
1.2 Glycaemic control in critical care 
Van den Berghe et al. [Van den Berghe et al. 2001] showed that tight blood 
glucose control to less than 6.1 mmol/L reduced cardiac surgical ICU patient 
mortality by 18-45% in a randomised controlled trial. Krinsley [2004] reported a 
17–29% total reduction in mortality over a wider, more critically ill, ICU 
population with a higher glucose limit of 7.75 mmol/L in a retrospective study. 
However, repeating these results that reduced mortality and other outcomes has 
been difficult [Griesdale et al. 2009]. 
 
Several large trials [Brunkhorst et al. 2008; Finfer et al. 2009; Preiser et al. 2009] 
were unable to repeat the early results of Van den Berghe et al. [2001] or other 
successes by Krinsley [2004] and Chase et al. [2008]. For example, the VISEP 
study by Brunkhorst et al. [2008] was stopped for safety due to unacceptable 
rates of hypoglycaemia, while the Glucontrol trial of Preiser et al. [2009] had 
numerous unintended protocol violations. Thus, the role of TGC during critical 
illness and suitable glycaemic ranges have been under scrutiny in recent years 
[Chase & Shaw 2007; Kalfon & Preiser 2008; Moghissi et al. 2009; Preiser et al. 
2009; Schultz et al. 2008; Van den Berghe et al. 2006b].  
 
Overall, conclusions are varied with both success [Chase et al. 2008; Krinsley 
2004; Van den Berghe et al. 2001], failure, [Finfer et al. 2009] and, primarily, no 
clear outcome [Brunkhorst et al. 2008; Chase & Shaw 2007; De la Rosa et al. 
2008; Preiser et al. 2009; Schultz et al. 2008; Treggiari et al. 2008; Van den 
Berghe et al. 2006a; Vanhorebeek et al. 2007; Wiener et al. 2008], as summarised 
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by Griesdale et al. [2009]. These conflicting results, coupled with safety concerns 
arising from increased incidences of hypoglycaemia during some trials have 
shrouded TGC with controversy [Chase et al. 2011b; Griesdale et al. 2009]. 
 
The review by Chase et al. [2011b] suggests that the controversy surrounding 
the efficacy of TGC and its application are primarily due to lack of understanding 
of both the control problem and patient-specific dynamics. Specifically, while the 
overall cohort control statistics may appear good, the individual patients may 
not have received adequate tight control. The paper goes on to suggest that as 
mortality and morbidity are highly patient-specific outcomes, they will depend 
on how well each patient was controlled, rather than the overall cohort results. 
Hence, TGC is effective at reducing mortality and improving outcomes for a 
whole cohort, if and only if it is equally effective for every patient in that cohort. 
 
Further complicating the control problem are the issues of hypoglycaemia and 
glycaemic variability. These factors have both been independently linked to 
mortality in critically ill patients [Egi et al. 2006; Egi et al. 2010; Hermanides et 
al. 2010; Krinsley 2008]. More specifically, Bagshaw [2009] showed that 
hypoglycaemia and variability within the first 24 hours of ICU stay are each 
associated with increased mortality. In vitro, high glycaemic variability was 
shown to increase oxidative stress [Piconi et al. 2006] and apoptosis [Risso et al. 
2001], thereby suggesting a rationale to explain the clinical association with poor 
outcome.  
 
The glycaemic control problem is thus defined by the simultaneous constraints 
of maintaining blood glucose concentrations within a relatively tight band for 
each individual patient, while avoiding excess variability. The ‘actuators’ 
available in exercising control are insulin and glucose inputs. Blood glucose 
concentration is the only state that is observable in clinical real-time. These 
conditions present a situation in which only model-based approaches may 
currently provide the robust, adaptive and patient-specific solution required to 
manage highly dynamic ICU patient metabolism. 
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1.3 Model-based glycaemic control 
Model-based and model-derived TGC methods have shown significant ability to 
provide very tight control with little or no hypoglycaemia in the ICU [Chase et al. 
2006; Chase et al. 2008; Chase & Shaw 2007; Cordingley et al. 2009; Evans et al. 
2011; Hovorka et al. 2007; Le Compte et al. 2009]. Model-based control relies on 
a physiological model that captures the glucose-insulin system dynamics and 
allows blood glucose concentrations to be accurately predicted, knowing the 
insulin and glucose inputs. A control algorithm can use these predictions to 
select optimal insulin and carbohydrate-nutrition interventions for forthcoming 
periods. 
 
A common aspect of the models that have successfully been used for TGC is one 
or more identified parameters capturing the glycaemic response to insulin, often 
termed insulin sensitivity [Chase et al. 2008; Cordingley et al. 2009; Evans et al. 
2011; Hovorka et al. 2007; Le Compte et al. 2009]. The insulin sensitivity 
parameter(s) varies over time and between patients, allowing the models to 
adapt and provide safe, effective control for each individual. The specific form of 
the parameter(s) is dependent upon the model that defines it. In the model used 
throughout this thesis (detailed in Chapter 2), insulin sensitivity is represented 
by a single parameter, SI, that captures the whole-body glycaemic response to 
exogenous insulin. Regardless of the specific definition of the insulin sensitivity 
parameter(s), for effective prediction and thus model-based control, it must be 
relatively free from unwanted variability. 
 
SI naturally varies between critically ill patients and over time within the 
individual patient as the stress response progresses. The pharmacokinetic-
pharmacodynamic (PK-PD) model must capture these changes to enable 
accurate BG prediction. However, being a parameter identified from limited 
clinical measurements, SI is prone to also capturing other, unwanted, dynamics 
that are not strictly related to insulin sensitivity, but have nowhere else to go 
within the model. These unintended artefacts influence the SI parameter on 
multiple timescales and thus, analysis of variability must address longer-term 
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changes in level, in addition to hour-to-hour changes. This unwanted variability 
in SI can be lumped into two broad categories:  
 
1. Unmodelled variability of other parameters within the physiological 
model (Intrinsic Variability). 
2. Physiological changes external to the specific PK-PD model that are not 
explicitly modelled (Extrinsic Variability). 
 
Unwanted variability in SI degrades the quality of control that can be achieved 
with model-based TGC. Hence, this variability must be minimised. The objective 
of this thesis is thus to understand and manage unwanted variability by 
improved modelling, where possible, and better application of the model to the 
control problem where the cause is extrinsic. 
 
1.4 Preface 
This thesis presents the analysis and management of several important causes of 
intrinsic and extrinsic SI variability in the ICING (Intensive Control Insulin-
Nutrition-Glucose) model, used for tight glycaemic control and analysis [Evans et 
al. 2011; Lin et al. 2011]. Where possible, for intrinsic variability, the modelling 
is enhanced through the analysis and application of improved data and concepts. 
The impact of extrinsic variability is assessed, quantified, and where necessary, 
means are proposed to mitigate the impact of these sources of variability on the 
outcome of model-based TGC. The proposed measures are validated with self- 
and cross validation analyses and virtual trials using the recently developed 
STAR protocol [Evans et al. 2011]. 
 
The specific components of the PK-PD model that this thesis addresses are: 
Insulin secretion, insulin transport kinetics, and endogenous glucose production. 
These components have a direct and substantial impact on the SI parameter, as it 
represents the metabolic balance between glucose appearance and insulin-
mediated glucose uptake. New data and concepts have become available to apply 
to these areas, providing the opportunity to reduce unwanted intrinsic SI 
variability. 
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Sources of extrinsic variability examined in this thesis are: Patient type and 
condition, drug therapies and measurement errors. These factors are thought to 
result in significant variability that is not explicitly modelled and thus cannot be 
reduced by improved modelling. Hence, the impact of these elements must be 
mitigated through understanding, and smarter use of SI in the control 
application. 
 
Chapter 2 reviews the model of the glucose-insulin regulatory system and the 
methodology that is used in Christchurch for glycaemic control in critical care.  
 
Intrinsic variability 
 
Chapter 3 develops a model for pancreatic insulin secretion as a function of 
blood glucose concentration, based on data collected during a prospective trial at 
the Christchurch Hospital ICU. This improved treatment of endogenous insulin 
results in a more accurate insulin sensitivity parameter. 
 
Chapter 4 improves the modelling of interstitial insulin kinetics, primarily 
through the refinement of population constant kinetic parameters, based on 
published data. More accurate transport kinetics reduce unmodelled artefacts in 
identified values of SI. 
 
Chapter 5 investigates EGP and how its treatment within the model may be 
improved. Modelling EGP as functions of time and blood glucose concentration 
are explored.  
 
Chapter 6 presents the enhanced ICING-2 model, incorporating the changes 
proposed in Chapters 3-5.  
 
Extrinsic variability 
 
Chapter 7 assesses the impact of patient type and condition on the variability of 
SI. This analysis formalises the anecdotal experience that certain periods of 
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patient stay and diagnostic categories are more variable, and thus harder to 
control.   
 
Chapter 8 examines the effects of two common drug therapies, glucocorticoid 
steroids and Metoprolol, thought to reduce insulin sensitivity. Knowledge of the 
way drug therapies impact SI can lead to improved application of the model 
during control.  
 
Chapter 9 quantifies and analyses the influence of measurement errors, in the 
form of measurement timing and BG sensor errors, on the identified SI 
parameter.  
 
Validation 
 
Chapter 10 presents the validation of ICING-2 model, using self- and cross 
validation analyses on a critically ill cohort, independent to that on which the 
model was developed. 
 
Chapter 11 presents simulated control trials on ‘virtual patients’ as a tool to 
validate the measures proposed to reduce the impact of extrinsic SI variability on 
outcome glycaemia. 
 
Chapters 12 and 13 summarise the key aspects of the thesis and present 
possible future improvements and applications for this research.  
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Chapter 2. Background 
2.1 Modelling and physiology 
A physiological model that captures the glucose-insulin system dynamics and 
allows accurate blood glucose prediction is the basis for model-based glycaemic 
control. Metabolic modelling of the glucose-insulin system has a very deep 
history in the published literature. The vast majority of these models have their 
roots in basic compartment modelling with differential equations [Carson & 
Cobelli 2001]. These models and, in particular, those from which the model in 
this thesis is derived, have been extensively reviewed by Razak [2011], Le 
Compte [2009] and Lin et al. [2011]. This section provides a summary of the 
basic requirements for a compartment model that can be used in clinical real-
time and introduces the ICING model used throughout the rest of this thesis. 
 
A compartment model consists of five basic elements: 
1. Compartments in which substances exist at varying concentrations. 
2. Kinetics describing the transport of substances between compartments. 
3. Dynamics that describe the interaction of substances with each other or 
the environment. 
4. Appearance of substances into the compartment system from the external 
environment. 
5. Clearance of substances back to the external environment. 
 
In addition to these five basic elements, a successful model for clinical control 
should also be physiologically valid, clinically applicable and mathematically 
identifiable [Chase et al. 2011a]. These additional factors ensure that the output 
of the model provides useful information about the physiology of a patient and 
can be identified in clinical real-time using the limited data available.  
 
The model used throughout the first part of this thesis, investigating intrinsic SI 
variability, is the ICING model described by Lin et al. [2011]. This model was 
developed to be more physiologically comprehensive than its predecessors [Lin 
et al. 2011; Razak 2011], primarily by incorporating more detailed insulin 
kinetics. The current ICING model definition is presented in Equations 2.1 - 2.7. 
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The current associated parameter values and descriptions are listed in Table 2.1. 
Table 2.2 shows the exogenous input variables to the model. 
 
Table 2.1 Parameter values and descriptions for the ICING model.  
Parameter Value Unit Description 
pG 0.006 min
-1 Non-insulin mediated glucose removal 
EGP 1.16 mmol/min Endogenous glucose production rate 
CNS 0.3 mmol/min Central nervous system glucose uptake 
VG 13.3 L Plasma glucose distribution volume 
VI 3.15 L Plasma and interstitial insulin distribution volume 
αG 0.0154 L/mU Insulin binding saturation parameter 
αI 0.0017 L/mU Hepatic insulin clearance saturation parameter 
nI 0.003 min
-1 Trans-endothelial diffusion rate  
nC 0.003 min
-1 Interstitial insulin degradation rate 
nK 0.0542 min
-1 Renal insulin clearance rate 
nL 0.1578 min
-1 Hepatic insulin clearance rate 
xL 0.67   Fractional first-pass hepatic insulin extraction 
d1 0.0347 min
-1 Glucose transport rate from stomach to gut 
d2 0.0069 min
-1 Glucose transport rate from gut to plasma 
Pmax 6.11 mmol/min Maximum glucose flux from gut to plasma 
k1 45.7 mU/min Maximum endogenous insulin secretion rate 
k2 1.5  
Insulin secretion suppression factor 1 
k3 1000  
Insulin secretion suppression factor 2 
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Table 2.2 Exogenous input variables to the ICING model. 
Variable Unit Description 
PN(t) mmol/min Intravenous glucose input rate (parenteral nutrition) 
D(t) mmol/min Oral glucose input rate (enteral nutrition) 
uex(t) mU/min intravenous insulin input rate 
 
 
Figure 2.1 shows a schematic diagram of the ICING model. This diagram includes 
both the glucose-insulin system and the gastric component, which models the 
movement of glucose from nutrition through the stomach to the gut and 
subsequent absorption into the glucose compartment. The glucose, plasma 
insulin and interstitial insulin compartments of the glucose-insulin system are 
shown as circles, denoted G(t), I(t) and Q(t), respectively. The kinetics, 
appearance and clearance of insulin and glucose are indicated with solid arrows. 
The dynamic interaction between interstitial insulin and insulin-mediated 
glucose uptake, governed by the SI model parameter, is indicated with a dashed 
arrow. 
 
 
Figure 2.1. Schematic diagram of the ICING compartment model showing the 
compartments, kinetics and dynamics, appearance and clearance. 
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In the ICING model, insulin sensitivity, SI, is the critical patient-specific 
parameter that is fitted hourly to clinical blood glucose measurements using an 
integral-based fitting method [Hann et al. 2005]. The identification of SI relies 
not only on measured BG concentrations, but also the interstitial insulin 
concentration and total glucose flux through the compartment, both of which 
cannot be measured directly in clinical real-time. These other factors are 
primarily influenced by insulin kinetics, defined by nI and nC, and the modelled 
endogenous insulin (Uen) and glucose (EGP) appearance rates. However, with 
limited clinical data available, only one model parameter, SI can be uniquely 
identified [Docherty et al. 2011]. Hence, these other parameters must be treated 
as population constants or modelled independently.  
 
Thus, the task of reducing intrinsic SI variability boils down to using the best 
data available to determine or model these particular parameters as accurately 
as possible for a fairly broad, critically ill population. A major goal of this thesis is 
to explore the impact of several specific model parameters and incorporate new 
physiological data to improve clinical performance and physiological relevance: 
 
Chapter 3 uses recently obtained clinical data to develop a more accurate model 
of endogenous insulin secretion for critically ill patients. This sub-model is of 
particular importance as endogenous insulin can make up a large part of the 
total insulin appearance rate and consequently has a significant impact on SI.  
 
Chapter 4 investigates the kinetic parameters nI and nC, which define the 
diffusion of insulin between the plasma and interstitium and cell-receptor 
binding and clearance. The interactions between these two parameters 
determine the maximum interstitial insulin concentrations and thus insulin-
mediated glucose disposal.  
 
Chapter 5 investigates modelling EGP as functions of blood glucose 
concentration and time, to better capture the enhanced glucose appearance rate 
characteristic of the acute stress response [Weissman 1990]. Endogenous 
glucose production can constitute a large part, if not all, of the glucose 
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appearance, particularly during the early part of a patient’s ICU stay. Thus, as 
with insulin secretion, EGP can have a significant impact on SI. 
 
2.2 Role of SI in model-based control 
The model-based glycaemic control approach used in this thesis is known as 
STAR (Stochastic, TARgeted) [Evans et al. 2012; Evans et al. 2011]. The STAR 
approach relies on the physiological model (Equations 2.1- 2.7) and one or more 
stochastic models of SI that describe the probability density of SI for the 
forthcoming hour, given the value identified over the previous hour. These 
stochastic models of SI enable BG concentrations to be forecast one or more 
hours ahead with associated confidence levels, given known or proposed insulin 
and nutritional inputs. This process is illustrated schematically in Figure 2.2. 
 
 
Figure 2.2. BG forecasting based on a stochastic model of SI.  
 
The generation and validation of these stochastic models are described in detail 
by Lin [2007]. Briefly, existing data from critically ill patients are used to identify 
SI profiles with the ICING model. The SI profiles are broken down into paired 
(SIn, SIn+1) data points and kernel density estimation methods used to create a 
smooth, continuous model surface that reflects the sample data pattern. 
Specifically, SIn+1 ~ F(SIn) and thus, for any identified value of SIn,, the stochastic 
model provides a continuous, empirical estimate of the probability function of 
SIn+1, for the subsequent hour. Experience has shown that a minimum of 
approximately 1300 hours of data is required to generate reliable stochastic 
models. 
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The ability to forecast BG concentrations with associated confidence levels 
enables the STAR control algorithm to optimise insulin and nutrition inputs, 
while keeping the risk of hypoglycaemia below a clinically specified limit 
(typically 5%). The STAR approach explicitly targets the 5th and 95th percentile 
forecast BG outcomes (Figure 2.2.) to the clinically selected target BG range. 
Hence, STAR aims to maximise the likelihood that the next BG measurement will 
be in the desired target range, given constraints on the risk of hypoglycaemia 
and nutrition and insulin administration. 
 
The stochastic method captures behaviours of the cohort used to generate the 
models. However any particular patient is not guaranteed to follow cohort-
defined behaviour, and can be influenced by external factors such as individual 
disease state and therapy. The task of reducing the impact of extrinsic SI 
variability on outcome glycaemia thus becomes one of selecting appropriate 
additional stochastic models to use with the STAR protocol. However, to 
maintain reliability over broad cohorts, particularly for managing risk of 
hypoglycaemia, the models must derive from large numbers of data points and 
thus be relatively few in number given the finite data set. Therefore, additional 
stochastic models should only be considered for conditions where there is a clear 
need for them, justified by significant differences in SI variability associated with 
clear, defined causes, as investigated in Chapters 7 and 8. 
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Chapter 3.   Endogenous Insulin Secretion Model 
This section investigates intrinsic SI variability, resulting from the unmodelled 
variability of other parameters within the physiological model. The endogenous 
insulin secretion model is of particular importance as endogenous insulin can 
make up a large part of the total insulin appearance rate. Thus, endogenous 
insulin has a significant impact on identified values of SI and consequently, 
intrinsic SI variability. 
 
3.1 Introduction 
Correctly modelling endogenous (pancreatic) insulin secretion is important to 
the overall accuracy of any glucose-insulin system model. In the absence of 
exogenous insulin or with low-doses, endogenous secretion is responsible for a 
significant percentage of insulin-mediated glucose disposal. Therefore, it has a 
significant impact on the identified SI parameter, particularly in these situations. 
Hence, reducing error in the insulin secretion model can reduce intrinsic SI 
variability and thus increase the accuracy and utility of the parameter for 
glycaemic control. 
 
A number of studies have established models of endogenous insulin secretion as 
a function of blood glucose level and its derivative, almost exclusively in healthy 
and diabetic individuals [Camastra et al. 2005; Ferrannini et al. 2005; Mari et al. 
2002a; Mari et al. 2002b]. These models primarily focus on the endogenous 
response to glycaemic change resulting from meals. However, during critical 
illness, endogenous secretion may be enhanced, [Black et al. 1982; Watters et al. 
1997] possibly due to stress hyperglycaemia. Equally, it may be suppressed by 
counter-regulatory hormones such as adrenaline, cortisol and glucagon [Bessey 
& Lowe 1993; Deibert & DeFronzo 1980; Gelfand et al. 1984]. Hence, healthy and 
diabetic insulin secretion models may not be appropriate to critically ill patients.  
 
Importantly, a thorough search of the literature has not located any studies in 
which endogenous secretion was determined for critically ill patients. During a 
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clinical trial studying sepsis in the Christchurch Hospital ICU, 19 patients had 
blood samples taken to determine pre-hepatic endogenous insulin secretion. 
From this data, a model of insulin secretion as a function blood glucose could be 
identified.  
 
3.2 Subjects and Methods 
3.2.1 Patients and samples 
19 patients from the Christchurch Hospital ICU enrolled in a prospective clinical 
trial studying sepsis each had an additional two sets of blood samples assayed 
for insulin and C-peptide. Patients were included in the study if they met all of 
the following criteria: 
 Age ≥ 16 years. 
 Expected survival ≥ 72 hours. 
 Expected ICU length of stay ≥ 48 hours. 
 Entry to the SPRINT TGC protocol (2 sequential BG measurements ≥ 8 
mmol/l). 
 Suspected sepsis or SIRS score ≥ 3. 
 
Patients with suspected sepsis received treatment for sepsis with antibiotics. No 
diagnosed Type I diabetic patients were included. This study was approved by 
the Upper South Regional Ethics Committee, New Zealand. 
 
Table 3.1 Summary of patient characteristics. Data are shown as median [IQR] where 
appropriate. 
N 19 
Age (years) 68 [57-75] 
Gender (M/F) 10/9 
APACHE II score 22.0 [18.3-26.8] 
Confirmed sepsis 79% 
Hospital mortality (L/D) 13/6 
Diagnosed T2DM 3 
 
 
One additional patient admitted to the ICU after pancreatoduodenectomy 
(Whipple procedure) was excluded from this analysis as this procedure involved 
removing a section of the pancreas and may thus have affected insulin secretion. 
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Two further patients each only had one set of blood samples assayed as one was 
discharged from the ICU within 48 hours and the other did not meet the criteria 
for the second set to be taken. 
 
Table 3.2 Summary of patient diagnoses.  
APACHE III diagnoses Number 
Non-
operative 
Respiratory 9 
Gastrointestinal 1 
Neurological 2 
Sepsis 4 
Operative 
Gastrointestinal 2 
Trauma 1 
 
 
Each patient had two sets of blood samples taken, where each set consisted of 4 
separate samples. The first set of samples was taken at the commencement of the 
SPRINT TGC protocol. The second set was taken when the patient consistently 
met less than 2 of the SIRS criteria (Systemic Inflammatory Response Syndrome) 
[1992].  
 
The first sample of each set was taken immediately prior to bolus delivery of 
insulin as required by SPRINT (t = -1 min). The remaining three samples were 
taken at t = 10, 40 and 60 min. Plasma was separated from the blood samples 
and frozen for subsequent analysis. The testing laboratory reported that one 
sample (out of 143) was extremely haemolysed, to the extent that it may have 
lowered the measured C-peptide concentration and was thus excluded from the 
analysis. 
 
Plasma glucose levels were not sampled at the same time points as insulin and C-
peptide. As per normal clinical practise with the SPRINT protocol, blood glucose 
measurements were taken 1-2 hourly. Blood glucose levels corresponding to the 
insulin and C-peptide samples were linearly interpolated from these clinical 
measurements. 
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Insulin and C-peptide concentrations were determined using immunometric 
assays (Elecsys 2010, Roche Diagnostics, Germany). Blood glucose levels were 
measured with a bedside glucometer (Super-Glucocard II, Arkray Inc., Japan). 
The reported coefficients of variation (CVA) for the insulin and C-peptide assays 
were 3.8% and 4.5% respectively [Roche 2004,2005]. Measurement error for the 
BG sensors was typically around 10% [Arkray 2007] (Chapter 9). 
 
3.2.2 Analysis methods 
Endogenous insulin secretion (Uen) can be determined from a series of plasma 
C-peptide measurements. C-peptide is produced by the pancreatic β-cells as a 
by-product of splitting insulin from its precursor, proinsulin, and is secreted in 
equimolar ratio with insulin [Rubenstein et al. 1969]. Unlike insulin, C-peptide is 
cleared almost entirely by the kidneys, making it a much more reliable marker of 
endogenous secretion than plasma insulin concentrations. Therefore, models 
independently linking C-peptide kinetics and insulin kinetics can be used to 
determine and capture pre-hepatic insulin secretion [Polonsky et al. 1986; Van 
Cauter et al. 1992]. 
 
The pharmacokinetic model and population kinetic parameters reported by Van 
Cauter et al. [1992] were used to deconvolve insulin secretion rates from 
measured C-peptide data. Age-based kinetic parameters were used for non-
diabetic patients, while the population parameters reported for T2DM subjects 
were used for patient with diagnosed or suspected type II diabetes. 
 
The resulting secretion rates were taken only from the approximately steady-
state regions of the profile (-1, 40 and 60 mins) as the bolus insulin prescribed 
by SPRINT at 0 mins may have reduced pancreatic secretion for some period. 
Insulin infusions over 2 U/hr have been shown to suppress endogenous insulin 
secretion in healthy subjects 30-45% [Argoud et al. 1987]. Measured 
concentrations suggest that plasma insulin had returned to pre-bolus levels by 
40 mins. The data density from this study was not high enough to reliably 
capture any suppression effects resulting from the bolus insulin. 
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Model fitting was performed by minimising the sum of the geometric means of 
the squared deviations in each dimension. This method allows for uncertainty in 
both the dependent and independent variables, while maintaining scale 
invariance [Draper & Yang 1997; Tofallis 2002]. Goodness of fit was assessed 
using the coefficient of determination, R2, calculated for the constrained model. 
 
3.3 Results and Discussion 
3.3.1 Calculated endogenous secretion rates 
Figure 3.1 shows calculated pre-hepatic insulin secretion plotted against blood 
glucose, its derivative and plasma insulin. The distinct group at the lower right of 
the left panel of Figure 3.1 (shown in red) consists of the three diagnosed type II 
diabetic patients and two others with a significantly impaired insulin response to 
hyperglycaemia. The clear separation between these patients and the remainder 
of the cohort suggests two separate models for insulin secretion; one for non-
diabetic patients and one for diagnosed or suspected type II diabetic patients. 
 
Figure 3.1 Pre-hepatic insulin secretion plotted against each of the measured 
variables. Data indicating patients with an impaired insulin response to 
hyperglycaemia are shown in red. 
 
0 5 10 15 20 25 30
0
2000
4000
6000
8000
10000
12000
Blood Glucose, (BG), [mmol/L]
E
n
d
o
g
e
n
o
u
s
 I
n
s
u
lin
 S
e
c
re
ti
o
n
, 
(U
e
n
),
 [
m
U
/h
r]
-6 -4 -2 0 2 4 6
d(BG)/dt, [mmol/L.hr]
0 50 100 150 200 250 300
Plasma insulin (I), [mU/L]
20 
 
3.3.2 Secretion rate bounds 
It is likely that there is a physiological upper limit on pancreatic secretion rate.  A 
non-zero minimum secretion rate is also required by the ICING model to prevent 
large insulin sensitivity changes when exogenous insulin is started or stopped. 
With little or no exogenous insulin and low pancreatic secretion rates (<500 
mU/hr) the concentration of the remote insulin compartment (Q) approaches 
zero. Hence, mathematically, SI must be very large to maintain the observed 
glucose flux.  
 
In a study of the potentiating effects of glucagon-like-peptide-1 (GLP-1) on 
insulin secretion, Kjems et al. [2003] achieved some very secretion high rates 
that suggest a reasonable physiological upper bound. The study involved 
stepped glucose infusions at 4 rates of GLP-1 infusion (0, 0.5, 1.0 & 2.0 
pmol/kg.min) given to type II diabetic patients and healthy controls. Insulin 
secretion rates were deconvolved using the method and population parameters 
of Van Cauter et al [1992]. Figure 3.2, reproduced from Kjems et al. [2003], 
shows the calculated insulin secretion rates (ISR) as a function of BG for healthy 
subjects receiving the maximum GLP-1 infusion, when insulin secretion is 
maximally stimulated. Estimating the maximum achieved at 20 pmol/kg.min 
corresponds to 16000 mU/hr for an 80kg subject. 
 
 
Figure 3.2 Mean dose-response relationship between plasma glucose and pre-
hepatic insulin secretion rates of healthy subjects during graded glucose infusion 
with a GLP-1 dose of 2.0 pmol/kg.min. [Kjems et al. 2003]. 
 
Kjems et al. [2003] reported mean baseline, fasted secretion rates for diabetic 
and healthy patients of 1.9 and 1.8 pmol/kg.min, corresponding to 1500 mU/hr 
for an 80kg person. Ferrannini et al. [2005] reported a median fasting secretion 
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rate of 53 pmol/min.m2 for lean, non-diabetic subjects. Assuming a body surface 
area (BSA) of 1.8m2, this value corresponds to a rate of 954 mU/hr. The values 
reported by Kjems et al. [2003] and Ferrannini et al. [2005] suggest that upper 
and lower bounds on pre-hepatic insulin secretion rates of 16000 mU/hr and 
1000 mU/hr would be appropriate. 
 
3.3.3 Model fitting 
As in previous studies [Camastra et al. 2005; Ferrannini et al. 2005; Mari et al. 
2002a; Mari et al. 2002b], models of the form shown in Equation 3.1 were fitted 
to the data. Where xj denotes the independent variables (BG, dBG/dt, plasma 
insulin) and c is a bias constant. 
 
             
 
 3.1 
Model fitting was performed by minimising the sum of the geometric means of 
the squared deviations in each dimension [Tofallis 2002]. Endogenous secretion 
was constrained between upper and lower bounds of 16000 mU/hr and 1000 
mU/hr. The resulting model coefficients (aj) and goodness of fit values are 
shown in Table 3.3. 
 
Table 3.3 Coefficients for endogenous insulin secretion models fitted with 1, 2 and 3 
independent variables (dimensions). 
 
Model 
Coefficients 
Goodness 
of fit  
(R2) 
Constant 
c 
[mU/hr] 
Blood glucose 
a1 
[mU.l/mmol.hr] 
BG derivative 
a2 
[mU.l/mmol] 
Plasma insulin  
a3  
[l/hr] 
N
o
n
-d
ia
b
et
ic
 
1-dim. -2996 893 
  
0.61 
2-dim. -2573 760 -773 
 
0.59 
3-dim. -2811 848 -931 -23 0.41 
T2
D
M
 
1-dim. -1644 296 
  
0.69 
2-dim. -1466 302 -586 
 
0.69 
3-dim. -691 286 -563 -17 0.57 
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The best model for insulin secretion, in terms of both fit to data and simplicity is 
the 1-dimensional model based on blood glucose level alone. Figure 3.3 shows 
the data and both non-diabetic (blue) and T2DM models (red). Equations 3.2 and 
3.3 describe the non-diabetic and T2DM models, respectively.  
 
 
Figure 3.3 Pre-hepatic insulin secretion data and 1-dimensional model fits. Non-
diabetic data and model shown in blue (R2 = 0.61); T2DM data and model shown in 
red (R2 = 0.69). 
 
Two points of particular note regarding the model fit are the variability in 
secretion rate and the number of points below the lower bound. There is 
considerable variability in secretion rates for any given blood glucose level, 
particularly in the range 6-10mmol/l. For example, blood glucose measurements 
in the range 6.5-7.0 mmol/l are associated with secretion rates between 1319-
6076 mU/hr, a 4.5-fold range. In addition, individual patients show a range of 
secretion rates spanning up to 2385 mU/hr within a 60-minute period. There are 
numerous data points (23%) below the minimum secretion level of 1000 mU/hr 
including one identified at –52.5 mU/hr (not shown).  
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Both the inter- and intra patient variability and the number of points below the 
lower bound are likely a result of using population kinetic parameters for the C-
peptide model. The study by Van Cauter et al. [1992] shows considerable 
variation between patients. Coefficients of variation for the kinetic parameters of 
normal and T2DM subjects were reported in the range 16-36% and the linear 
regression of long half-life against age had a correlation coefficient, r=0.28. Thus, 
there was significant variation around the best-fit population parameters. 
 
Physiologically, the cause of the secretion rates below the lower bound could 
also be due to diminished secretion capacity. Of the 24 data points (23%) below 
1000 mU/hr, 13 were from the five type II diabetic individuals or suspected, 
undiagnosed individuals.  
 
3.3.4 Model validation 
To validate the secretion model, comparisons were made to published data. 
There is very little data available in the literature concerning insulin secretion 
rates in critically ill patients. Most studies tend to focus on healthy subjects and 
those with diabetes. Table 3.4 presents the results of a number of published 
studies in which insulin secretion profiles have been related to blood glucose 
levels. All these studies used the method and kinetic parameters of Van Cauter et 
al. [1992] to calculate insulin secretion rates from plasma C-peptide 
concentrations. 
 
Table 3.4 shows reported results for the glucose coefficient in the range 432-
2754 mU.l/mmol.hr for healthy subjects and 160-1113 mU.l/mmol.hr for 
diabetic subjects. The glucose coefficients of 893 and 296 mU.l/mmol.hr 
identified in this study for non-diabetic and diabetic critically ill patients are 
comparable with this widely spread published data. It is interesting to note that 
the glucose coefficients reported by studies involving Ferrannini [Camastra et al. 
2005; Ferrannini et al. 2005; Mari et al. 2002a; Mari et al. 2002b] tend to be 
considerably higher than those reported by others, or those resulting from this 
study, possibly reflecting an unreported difference in methods or approach. 
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Table 3.4 Glucose coefficient data from the literature. Results have been converted 
to the units of measurement used in this study where necessary. Assumptions used 
for these conversions were: w = 80 kg; BSAlean = 1.8 m
2; BSAobese/T2DM = 2.1 m
2.  
Study Cohort 
Glucose coefficient 
a1  
[mU.l /mmol.hr] 
Ferrannini et al. 
[2005] 
Lean normal glucose tolerance 2646 
Obese normal glucose tolerance 1932 
Impaired glucose tolerance 1155 
T2DM 294 
Mari et al. 
[2002b] 
Control 2664 
T2DM 1113 
Mari et al. 
[2002a] 
Healthy 24 hr meal test (5-7 mmol/l) 2196 
Healthy 2 hr protocol  (5-7 mmol/l) 2592 
Healthy OGTT  (5-7 mmol/l) 2754 
Camastra et al. 
[2005] 
Healthy controls 1290 
20 Obese Non-Diabetic 1860 
Kjems et al. 
[2003] 
Healthy saline infusion 480 
T2DM saline infusion 160 
Healthy GLP-1 max. infusion  rate 5360 
T2DM GLP-1 max. infusion rate 1040 
Jones et al. 
[1997] 
Non-diabetic insulin sensitive 485 
Non-diabetic insulin resistant 664 
Byrne et al. 
[1995] 
No MODY1 mutation baseline 761 
No MODY1 mutation glucose-primed 1400 
Chang et al. 
[2003] 
T2DM with NN2211 (GLP-1 derivative) 1008 
T2DM with Placebo 432 
Controls 1152 
 
3.3.5 Limitations 
The two major limitations of this study were the blood glucose measurements 
and the population C-peptide parameters. Blood glucose measurements were not 
taken simultaneously with insulin and C-peptide samples and the measurements 
that were taken used bedside glucometers. The normal, clinical BG 
measurements that were available 1-2 hourly necessitated linear interpolation 
to estimate levels associated with the insulin and C-peptide measurements. 
Additionally the clinical measurements had an estimated coefficient of variation 
of 10% compared with 2-3% for laboratory results. 
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Linear interpolation of BG values resulted in a single value for dBG/dt for each 
set of measurements, possibly compromising the utility of this specific 
parameter as an independent variable in the model. However, the utility of 
dBG/dt is questionable in a critical care model where BG is kept relatively 
constant with a glycaemic control protocol and patients are fed by constant 
infusion (enterally or parenterally). This term has more relevance in secretion 
models in response to a bolus meal or glucose challenge as seen in studies on 
type II diabetic subjects [Ferrannini et al. 2005; Mari et al. 2002a; Mari et al. 
2002b], where the dBG/dt term is only used when the change in BG is positive. 
 
Insulin secretion rates calculated in this study relied on the population kinetic 
parameters reported by Van Cauter et al. [1992] for healthy and diabetic 
subjects. Use of these values assumed that renal uptake of C-peptide in critically 
ill patients was not significantly different to healthy subjects. No published 
studies were found reporting renal C-peptide metabolism in critically ill patients. 
Hence, short of repeating the work of Van Cauter in a critically ill population, the 
values used provided the best available estimates of the transport parameters, 
and have been used by others in this setting [Hovorka et al. 2008].  
 
In the ICU, renal dysfunction is relatively common. Changes to the renal 
metabolism of C-peptide resulting from kidney dysfunction would cause errors 
in the calculated insulin secretion rates from this study as the deconvolution 
depends upon population estimates of the renal C-peptide clearance rate. In this 
study one patient was diagnosed with renal failure, however their circulating C-
peptide levels and resulting insulin secretion rates were not substantially 
different from the other patients, so they were not excluded from the analysis. 
 
3.3.6 Impact on SI 
The endogenous insulin secretion functions proposed in this study result in a 
much wider range of secretion levels than previously used with this glucose-
insulin system model [Lin et al. 2011]. The previous secretion model provided a 
relatively constant pancreatic output of approximately 2800 mU/hr for 
physiological plasma insulin concentrations. For non-diabetic patients with BG in 
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the range 4.0-7.0 mmol/L, the model developed in this analysis would result in 
secretion rates of 1000-3300 mU/hr, which are comparable to 2800 mU/hr and 
thus unlikely to have a significant impact on SI. At higher BG levels, the secretion 
rates could be significantly higher and thus, the identified value of SI would be 
lower. Hence, the impact of the proposed models on SI is dependent upon the 
specific BG concentration and diabetic status of the patient.  
 
The models proposed in this study better capture the variability of insulin 
secretion, evident in Figure 3.3, than the current, relatively constant, secretion 
model. However, considerably variability in secretion rate, not accounted for by 
BG concentration, still remains. Thus, while these new models represent a 
significant improvement over the current model, and will reduce unwanted 
intrinsic variability from SI, some variability will persist and affect the identified 
values of SI.  
 
3.4 Summary 
The results of this study show that a simple constrained linear function of blood 
glucose provided the best model of pre-hepatic insulin secretion in critically ill 
patients. Separate models were identified for non-diabetic patients and 
diagnosed or suspected type II diabetic patients with R2 = 0.61 and 0.69 
respectively. The glucose coefficients of 893 and 296 mU.l/mmol.hr identified for 
non-diabetic and diabetic patients were comparable to data published in a 
number of other studies.  
 
The proposed model of endogenous insulin secretion based on physiological 
measurements should reduce unwanted intrinsic variability from SI and 
therefore increase the accuracy and utility of the parameter in control and 
analysis applications. 
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Chapter 4.  Interstitial Insulin Kinetics 
Like endogenous insulin secretion, insulin kinetics are a potential source of 
unwanted variability in model-based estimations of SI. The parameters 
describing insulin clearance and transport vary between individuals and over 
time. However, unlike insulin secretion, identifying the transport parameter 
values directly is difficult, if not impossible, and there are as yet no models 
relating them to readily measurable clinical variables. Population constants 
based on data from healthy individuals are therefore the best available 
estimates, for example [Sherwin et al. 1974; Van Cauter et al. 1992]. Nonetheless, 
these constant parameters need to be optimised to the target population to 
ensure maximum accuracy and utility of the insulin sensitivity parameter. 
 
4.1 Introduction 
Insulin-mediated glucose uptake primarily occurs from the interstitial fluid. 
Insulin from plasma is transported to the interstitial fluid surrounding tissue 
cells where it binds to cell-wall receptors, activating glucose uptake [Jefferson & 
Cherrington 2001]. Hence, correctly modelling interstitial insulin kinetics is 
important to reducing unwanted intrinsic variability in model-based SI. 
 
In general, insulin kinetics models developed for healthy or diabetic subjects are 
used quite successfully and without modification for critically ill patients [Chase 
et al. 2006; Hovorka et al. 2008; Lin et al. 2011; Van Herpe et al. 2006].  The 
insulin kinetics of the ICING model were derived from the model developed by 
Lotz et al. [2008] primarily for impaired glucose tolerance and type II diabetic 
subjects. The study by Lin et al. [2011] showed that the ICING model worked 
well in critically ill patients, with parameter values remaining largely unchanged. 
However, interstitial insulin kinetic parameters, transcapilliary diffusion (nI) and 
cellular clearance (nC) rate, were identified as being 16-times smaller than those 
by Lotz et al. [2008] for healthy and diabetic subjects, leading to a significantly 
longer ‘effective’ insulin half-life. 
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The parameter identification conducted by Lin et al. [2011] utilised a grid-search 
to minimise the fitting and prediction errors of the model over 42941 hours of 
data from 173 critically ill patients. Although providing the mathematically 
optimal parameter values for that particular cohort, the grid-search method did 
not necessarily enhance the physiological foundations of the model. In particular, 
the optimal parameters were centred in parameter spaces with consistently low 
errors so that a wide range of parameter values was admissible for very limited 
difference in model performance. 
 
This study extended the fitting and prediction error grid-search identification of 
the interstitial insulin kinetic parameters of Lin et al. [2011] to two further, 
independent, critically ill cohorts. Additionally, data from published 
microdialysis studies was used to directly determine the kinetic parameters 
from physiological measurements. These better data are used to more accurately 
justify and validate the parameters chosen. 
 
4.2 Subjects and Methods 
This investigation of interstitial insulin kinetic parameters was conducted in two 
stages. Initially, the grid-search of Lin et al. [2011] was repeated on two 
independent cohorts to confirm a suitable domain of values consistent with 
acceptable model performance. This step was followed by the analysis of data 
from 6 published studies (12 data sets) that used microdialysis to assay 
interstitial insulin levels simultaneously with plasma insulin levels, enabling 
direct determination of the kinetic parameters. 
 
4.2.1 Patients 
Two separate cohorts, independent from those used by Lin et al. [2011] and 
independent from each other were used to determine suitable domains for nI 
and nC by grid-search. The two cohorts consisted of 9 patients from the STAR-
Liege pilot trial [Penning et al. 2011] and 20 patients from the Christchurch 
Hospital ICU sepsis study. Details of these cohorts are shown in Table 4.1. 
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The two cohorts spanned a range of ICU patient types. The STAR-Liege patients 
were from a clinical pilot trial of a tight glycaemic control protocol conducted at 
the Centre Hospitalier Universitaire (CHU) in Liège, Belgium in July 2010. The 
pilot trial was 24 hours long and included 9 primarily cardiovascular or cardiac 
surgery (7) patients from the hospital’s intensive care units. The Christchurch 
ICU sepsis cohort consisted of 20 patients enrolled in a prospective clinical trial 
studying sepsis during 2009-10. These patients were predominantly non-
surgical (16) and diagnosed with sepsis (79%).  
 
Table 4.1 Summary of patient characteristics. Data are shown as median [IQR] where 
appropriate. 
  STAR-Liege Sepsis Christchurch 
N 9 20 
Age (years) 74 [69-79] 66 [57-75] 
Gender (M/F) 6/3 10/10 
APACHE II score N/A 22.5 [18.8-27.3] 
Hospital mortality (L/D) 6/9 14/6 
Operative/Non-operative 9/0 4/16 
Diagnosed T2DM 4 3 
 
 
Blood glucose levels in Christchurch were measured with Super-Glucocard II 
glucometers (Arkray Inc., Japan). BG levels in Liege were measured with Accu-
Chek Inform (Roche Diagnostics, Mannheim, Germany) glucometers. 
Measurement errors associated with these devices are approximately 10% and 
3%, respectively [Arkray 2007; Roche 2008]. 
 
Ethical consent was granted by the Comité d’éthique hospitalo-facultaire de 
l’Universitaire de Liège (B70720108843) for the performance of STAR-Liege trial 
and the audit, analysis and publication of the data. The Upper South Regional 
Ethics Committee, New Zealand, approved the Christchurch ICU sepsis study.  
 
4.2.2 Fitting and prediction grid search analysis 
A grid search evaluating both model fitting and prediction error was performed 
over a wide domain for both nI and γ. The parameter γ is the steady-state ratio of 
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interstitial insulin (Q) to plasma insulin (I) concentrations and defines nC 
through Equation 4.1 provided the steady state concentration Q is low so that 
saturation effects are limited. It is defined: 
 
   
  
     
 4.1 
 
Studies indicated that the steady state interstitial to plasma insulin ratio is 
between 0.4 and 0.6 [Gudbjornsdottir et al. 2003; Sjostrand et al. 1999; Sjostrand 
et al. 2000]. Lotz et al. [2008] use a population value of 0.5 for this ratio. Hence 
the range of values of γ evaluated in the grid-search spanned 0.3-0.7. Values of nI 
were evaluated in the range 0.001-0.05 min-1, covering those proposed by Lin et 
al. [2011] and Lotz et al. 
 
At each coordinate pair of the grid-search (nI, γ), cohort and per-patient median 
BG fitting and prediction errors were evaluated, as per the study of Lin et al. 
[2011]. One-hour-ahead BG prediction values were calculated with the identified 
SI held constant from the previous hour to assess prediction performance. In 
cases where BG measurements were greater than 1 hour apart, errors were 
calculated to a linearly interpolated value. Errors were assessed as percentages 
of measured (or interpolated) BG values to enable fair comparison across a wide 
range of glycaemic levels. 
 
4.2.3 Microdialysis analysis 
To identify nI and γ in a more direct, physiological manner, data was used from 6 
published studies (12 data sets). These studies used microdialysis to directly 
sample interstitial insulin concentrations. Plasma insulin levels concentrations 
sampled simultaneously. The 6 independent studies were conducted using 
infused and endogenous insulin at varying physiological and supra-physiological 
levels.  Data used in this analysis was taken from the studies listed in Table 4.2.  
 
Using reported arterial insulin concentrations (I) as input, interstitial 
concentrations (Q) were simulated with the ICING interstitial insulin kinetics 
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sub-model described in Equation 4.2, repeated from Equation 2.2. These 
simulated results were then compared to the reported interstitial 
measurements. The beauty of this method was in the simplicity of the interstitial 
insulin sub-model. There are only two parameters that affect the kinetics at 
physiological insulin levels; nI and γ. Thus, only one equation is required, and the 
desired variables are separated from any other equations, data, or parameter 
values, eliminating any other potential biases 
 
            
   
     
 4.2 
 
Table 4.2 Published microdialysis studies used to investigate interstitial insulin 
kinetic parameters 
Study Study Method 
Study 
Population 
N 
Interstitial sampling 
location 
Jansson et al. 
[1993] 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy non-
obese 
5 
Abdominal 
subcutaneous fat 
Castillo et al. 
[1994] 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy:  
Body fat <=12% 
3 
Subcutaneous lymph 
vessel; lower leg 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy:  
Body fat 13-21% 
5 
Subcutaneous lymph 
vessel; lower leg 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy:  
Body fat 22-35% 
3 
Subcutaneous lymph 
vessel; lower leg 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy:  
Body fat >=36% 
2 
Subcutaneous lymph 
vessel; lower leg 
Sjostrand et al. 
[2002] 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy lean 10 Forearm muscle 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy obese 10 Forearm muscle 
Gudbjornsdottir 
et al. [2003] 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy lean 10 Forearm muscle 
Herkner et al. 
[2003] 
Oral glucose tolerance 
test 
Healthy lean 8 Mid thigh muscle 
Euglycaemic-
hyperinsulinaemic clamp 
Healthy lean 8 Mid thigh muscle 
Sjostrand et al. 
[2005a] 
Oral glucose tolerance 
test 
Healthy lean 10 Forearm muscle 
Oral glucose tolerance 
test 
Healthy obese 10 Forearm muscle 
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A grid-search was performed over a range of nI and γ values to find the region of 
minimum error between simulated and measured interstitial insulin 
concentrations. The error value was defined as the sum of absolute differences 
between the simulated and measured concentrations at the experimental 
sampling points, divided by the average interstitial insulin level during the 
experiment. Errors across all data sets were evaluated by two methods to ensure 
a robust minimum that was not skewed by data from a single study. Specifically:  
 
1. Each error value was weighted equally, by summing absolute error values 
at each (nI, γ) pair across all 12 data sets. 
2. Each study was weighted equally by scaling the calculated errors into the 
range 0-1 prior to summing across all data sets. 
 
4.3 Results and Discussion 
4.3.1 Fitting and prediction grid-search results 
Figure 4.1 and Figure 4.2 show the results of the grid-search over nI and γ for the 
two independent cohorts (STAR-Liege and Christchurch ICU sepsis). Cohort 
median fitting error (%) is shown on the top panel and cohort median 1-hour-
ahead prediction error (%) on the bottom.  
 
 
Figure 4.1 Fitting (top) and 1-hour-ahead prediction (bottom) errors (%) for the 
STAR-Liege cohort across a range of nI and γ values. 
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Figure 4.1 and Figure 4.2 shed little light on optimal parameter values. The 
profiles for STAR-Liege in Figure 4.1 are quite flat across the domain of 
parameter values and show no obvious minima. The profiles for the Christchurch 
ICU sepsis cohort in Figure 4.2 indicate that the optimal value of nI would be in 
the range 0.003-0.01 min-1, depending on the choice of γ. For γ = 0.5 assumed by 
Lin et al. [2011] and Lotz et al. [2008], prediction error was minimised for nI = 
0.007 min-1. However, fitting and prediction errors in this region were well 
below the BG measurement error of 10% for all values of γ tested. Hence, no 
significant performance improvement would be gained by selection of any 
particular parameter set within this restricted domain.  
 
 
Figure 4.2 Fitting (top) and 1-hour-ahead prediction (bottom) errors (%) for the 
Christchurch ICU sepsis cohort across a range of nI and γ values. 
 
4.3.2 Microdialysis results 
Grid-search results for the parameter optimisation using published microdialysis 
data are shown in Figure 4.3. The left panel shows the results from method 1 
where each error value was weighted equally. The right panel shows the results 
from method 2 where each study was weighted equally. Data from the Herkner 
et al. [2003] clamp study have been omitted as the minimum error was located at 
nI = 0, which does not make sense, physiologically. 
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Figure 4.3 shows the regions around the minimum error points, where the 
contours indicate errors 1% and 5% greater than the minimum values. The 
parameter set, nI =0.0060 min-1, γ = 0.5 (nI = nC) is enclosed within both these 
regions and provides a good compromise between the two identified minima. 
This set is also consistent with the results from the fitting and prediction error 
grid-search on the Christchurch ICU sepsis cohort. However, unlike the fitting 
and prediction error grid-search, this method used direct physiological 
measurements to identify well-defined error minima. Hence, the optimal 
parameter values identified are more physiologically relevant than those derived 
from ‘external’ assessments using blood glucose fitting and prediction errors. 
 
 
Figure 4.3 Grid-search error results from microdialysis analysis showing optimal 
parameter values. The left panel shows the results where each error value was 
weighted equally, and the right panel shows the results where each study was 
weighted equally. Contours are at error 1% and 5% greater than the minimum. 
Lighter areas represent lower error and darker areas, greater. 
 
Table 4.3 shows the individual optimal parameter values for each data set. The 
associated errors are shown along with the error obtained using the selected 
parameter set, nI =0.0060 min-1, γ = 0.5. 
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Table 4.3 Individual results from published microdialysis studies. Study minimum 
error is associated with the study optimal nI and γ. Overall error is associated with 
the selected parameter set, nI =0.0060 min
-1, γ = 0.5. The errors are unitless and 
represent mean absolute fractional error at each measurement point.  
Study 
Study 
Method 
Study Population 
Study 
optimal 
nI [min
-1] 
Study 
optimal γ 
Study 
minimum 
error 
Overall 
error 
Jansson et al. 
[1993] 
Clamp 
Healthy non-
obese 
0.0054 0.30 0.142 0.233 
Castillo et al. 
[1994] 
Clamp 
Healthy:  
Body fat <=12% 
0.0031 0.53 0.103 0.305 
Clamp 
Healthy:  
Body fat 13-21% 
0.0048 0.62 0.038 0.090 
Clamp 
Healthy:  
Body fat 22-35% 
0.0041 0.61 0.029 0.101 
Clamp 
Healthy:  
Body fat >=36% 
0.0040 0.44 0.044 0.204 
Sjostrand et al. 
[2002] 
Clamp Healthy lean 0.0128 0.48 0.060 0.191 
Clamp Healthy obese 0.0054 0.70 0.057 0.072 
Gudbjornsdottir 
et al. [2003] 
Clamp Healthy lean 0.0061 0.67 0.143 0.180 
Herkner et al. 
[2003] 
OGTT Healthy lean 0.0116 0.31 0.300 0.458 
Clamp Healthy lean 0 0 0.137 1.546 
Sjostrand et al. 
[2005a] 
OGTT Healthy lean 0.0600 0.57 0.101 0.610 
OGTT Healthy obese 0.0400 0.46 0.058 0.516 
 
 
Figure 4.4 shows two contrasting examples of the simulated and measured 
interstitial insulin concentrations using the selected parameter values. Panels A 
and B show data from the Castillo study [1994] for subjects with body fat in the 
range of 13-21%. Panels C and D show data from the oral glucose tolerance test 
(OGTT) study by Herkner et al. [2003]. Measured arterial insulin is presented in 
the top panels (A and C), with measured and modelled interstitial insulin in the 
bottom (B and D) along with the absolute error between them. These two studies 
had similar insulin concentrations and thus make a good comparison. 
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The model fit to data is very good for the Castillo study [1994] in the left panel 
and not so good for the Herkner study [2003] in the right panel. The interstitial 
insulin peak at 15 mins in the Herkner study does not correspond to any feature 
in the plasma insulin profile. The plasma insulin-sampling scheme may have 
missed a peak, the interstitial insulin peak may be spurious, or insulin may have 
been delivered to the interstitium independent of plasma as the authors’ 
propose. This study was conducted using oral glucose (75 grams) to stimulate 
insulin secretion. Therefore, a sharp plasma insulin peak would not be expected 
[Caumo & Luzi 2004], particularly within 15 minutes of glucose ingestion. The 
ICING model assumes passive diffusion of insulin across the endothelium. Hence, 
with no plasma insulin peak to create a sharp concentration gradient, the model 
could not reproduce the reported peak in interstitial insulin, resulting in the 
poor fit. 
 
 
Figure 4.4 Two contrasting examples from the simulation of microdialysis data using 
the selected parameter set, nI =0.0060 min
-1, γ = 0.5. The panels on the left show a 
good model fit to measured data from Castillo et al. [1994] (body fat 13-21%). The 
panels on the right show a poor fit from Herkner et al. [2003] (OGTT). The upper 
panels present plasma insulin concentrations and the lower panels measured and 
modelled interstitial insulin concentrations. 
 
Modelled interstitial insulin profiles did not fit either data set from the Herkner 
et al. [2003] study very well. The OGTT example from this study is shown in the 
right panel of Figure 4.4. The other data set from Herkner involved a 
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euglycaemic-hyperinsulinaemic clamp procedure, in which the interstitial insulin 
levels were lower than during the OGTT study (<10 mU/l), despite sustained 
higher plasma levels (>65 mU/l for 60 mins).  
 
There are no obvious reasons for these poor fits and they may be due to the 
complicated and difficult nature of microdialysis sampling of interstitial fluid. 
Data from the Herkner et al. [2003] clamp study were omitted as the minimum 
error was located at nI = 0 min-1, which does not make sense, physiologically. 
 
The remaining studies had mean absolute error values at their individual 
optimal parameter values of less than 15% of their average interstitial insulin 
concentration. At the selected parameter set, the errors were less than 30%, 
except for the OGTT study by Sjostrand et al. [2005a]. The optimal nI values for 
these two data sets were very high (nI = 0.060 and 0.040 min-1), though similar 
to those used by Lotz et al. [2008]. Hence, the errors for this study were large 
with the much smaller value of nI = 0.0060 min-1 selected.  
 
It should be noted that the data from the Sjostrand et al. study [2005a] was 
corrected prior to use in this analysis for the error present in the original article, 
as per their retraction [Sjostrand et al. 2005b].  
 
4.3.3 Comparison of results 
Using direct physiological measurements from 6 published microdialysis studies, 
the optimal parameter values nI = 0.0060 min-1, γ = 0.5 were identified. These 
values were optimal in terms of minimising the sum of absolute errors between 
simulated and measured interstitial insulin concentrations. γ = 0.5 (nI = nC) is 
unchanged from the values reported by Lin et al. [2011] and Lotz et al. [2008]. 
However, nI = 0.0060 min-1 is between the values reported in those two studies; 
nI = 0.003 min-1 and nI = 0.0486 min-1. 
 
The value of nI identified for the ICING model by Lin et al. [2011] was 
approximately 16-times smaller than that used by Lotz et al. [2008] for healthy 
and diabetic subjects. The result of this reduction in transcapillary diffusion (nI) 
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and cellular insulin clearance (nC, through γ) rates, was that insulin persisted 
much longer in the interstitial compartment, reflecting the insulin pooling and 
delayed utilization effects observed in critically ill patients by Doran et al. [2005].  
 
The parameter nI used by Lotz et al. [2008] was the transcapilliary diffusion rate 
for C-peptide identified by Van Cauter et al. [1992]. This choice was justified on 
the grounds that insulin and C-peptide have similar molecular weights (5800 Da 
and 3600 Da respectively) and passive properties. Parameter values were 
identified for each individual based on age, gender, body surface area and 
diabetic or obese status, as proposed by Van Cauter et al. The mean value 
identified across the study cohort was nI = 0.0486 min-1 [Lotz et al. 2008].  
 
A possible reason for the discrepancy between the values identified in this study 
and those of Lotz et al. [2008] is that trans-endothelial insulin diffusion is a 
saturable process [Lin et al. 2011]. The experimental diffusion rates adopted 
from Van Cauter et al. [1992] are determined by using C-peptide measurements. 
Although C-peptide has very similar molecular properties to insulin, it does not 
go through a high and variable degree of first pass extraction in the portal vein 
[Van Cauter et al. 1992]. Therefore, its concentration is several folds higher than 
insulin in plasma. If the diffusion process is to any level saturable [Thorsteinsson 
1990], the rates determined using C-peptide measurements would not be 
reflective of insulin. 
 
The ‘effective’ or interstitial half-life of insulin is defined by the interstitial 
kinetic parameters in Equation 4.3 [Lin et al. 2011]. This half-life characterizes 
the clearance rate of insulin from the interstitium where it effects the uptake of 
glucose into tissue cells. Previously published reports suggest values in the range 
25-130 mins [Mari & Valerio 1997; Natali et al. 2000; Turnheim & Waldhausl 
1988]. 
 
    
       
     
 4.3 
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The effective half-life associated with the kinetic parameters identified by Lin et 
al. [2011] was t½ = 116 mins. This value better matched data from previous 
studies than the short t½ = 7 mins used by Lotz et al. [2008]. The effective half-
life insulin determined from the values of nI and nC identified in this study is t½ = 
58 mins, is also within the range reported by previous studies.  
 
4.3.4 Impact on SI 
The overall impact on SI of the proposed increase in transport and clearance is 
limited. For a given blood glucose level, SI is proportional to the area under the 
interstitial insulin concentration curve (AUCQ). Hence, the impact on SI is 
proportional to the impact on AUCQ. 
 
During steady-state conditions, when no boluses or large changes to infusions 
have occurred, SI is unaffected as γ was unchanged. For non-steady-state 
conditions, the specific effect on SI resulting from changes to nI and nC depends 
on the delivery method of exogenous insulin.  
 
Bolus insulin delivery creates a large, short duration (10-15 mins) concentration 
gradient from the plasma to the interstitium. This large gradient, coupled with 
faster diffusion from an increased nI initially dominates the increased clearance 
rate and results in higher peak interstitial concentrations. However, the higher 
diffusion and clearance rates also serve to pull the interstitial concentration back 
towards the steady-state plasma level faster, once the transient peak has 
decayed. Thus, increases to AUCQ and concomitant reductions in SI are limited, 
provided the interstitial half-life of insulin is much greater than the plasma half-
life (3-7 mins).  
 
For infused insulin, SI is only affected when the infusion rate is altered. Faster 
diffusion and clearance result in decreases to SI when the infusion rate is 
increased and increases to SI when the infusion rate is reduced, for a given 
glucose level and all other effects presumed unchanged. The magnitude of the 
impact on AUCQ and SI is a function of the transport and clearance parameters, 
the length of time since the rate was altered and the size of the change relative to 
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the previous level. With large, regular (1-2 hourly) changes to the infusion rate, 
the impact on SI could be in the order of 20-30%, but this behaviour is not 
typical with infusions in the ICU. Equally, alterations in patient state will also 
play a role over these time periods. Hence, the likely changes to SI in clinical 
situations would be limited. 
 
4.4 Summary 
The results of this investigation suggest that optimal values for the interstitial 
insulin kinetic parameters are nI = nC = 0.0060 min-1. These parameter values are 
associated with an effective interstitial insulin half-life t½ = 58 mins, within the 
range of 25-130 mins reported by others.  
 
This study used two independent, critically ill cohorts and data from six 
published microdialysis studies to determine the optimal parameter values. The 
external clinical data and model performance metrics were unable to provide 
significant resolution in determining optimal values. However, using direct 
physiological measurement data from microdialysis studies provided a sound 
physiological foundation for the kinetic parameter values. 
 
The impact on SI of these parameter alterations from the original ICING model 
are likely to be limited in normal, clinical situations. In particular, as the 
parameters are population constants, they are unlikely to alter the overall 
variability of SI.  
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Chapter 5. Endogenous Glucose Production 
Endogenous glucose production can constitute a large part, if not all, of the 
glucose appearance, particularly during the early part of a patient’s ICU stay. 
Thus, as with insulin secretion and interstitial insulin kinetic parameters, EGP 
can have a significant impact on intrinsic SI variability. 
 
5.1 Introduction 
In the context of this metabolic system model, EGP represents net glucose 
produced by the body, primarily by the liver, and released into the blood. EGP 
can represent a significant proportion of the glucose appearance in plasma, 
particularly when patients are fasted or receiving little exogenous nutrition. 
Hence, EGP impacts on model-based insulin sensitivity by directly contributing 
to the net glucose flux that must be balanced by insulin-mediated glucose uptake.  
 
The current ICING model assumes constant EGP at a level that optimises model 
performance over the entire cohort [Lin et al. 2011]. However, instances where 
SI is forced to take non-negative, physiological values, particularly during the 
first 48 hours of SPRINT, indicate that the current assumption is inadequate for 
some patients, and potentially introduces unintended variability into the model-
based SI parameter. This study attempts to assess the impact and improve the 
handling of EGP in the ICING model using existing, fundamental clinical data. 
 
EGP can be directly measured in vivo by balance (arterial-venous difference) or 
tracer methods [Radziuk & Pye 2001]. Many studies have been carried out on 
critically ill populations to determine EGP in various disease and injury states 
[Black et al. 1982; Chiolero et al. 2000; Lattermann et al. 2003; Revelly et al. 
2005; Shaw & Wolfe 1989; Tappy et al. 1999; Thorell et al. 2004; Watters et al. 
1997; Wilmore et al. 1980; Wolfe et al. 1979], or simulated critical illness with 
stress hormone infusions [Bessey et al. 1984; Gelfand et al. 1984]. This study 
investigates glycaemic level as a surrogate marker for stress in critical illness 
that drives EGP. Additionally, EGP as a function of time is investigated, 
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particularly in the early, acute phase of critical illness, where these stress drivers 
are generally greatest. 
 
5.1.1 Background 
EGP includes glucose released into the blood from both stored glycogen 
(glycogenolysis) or de novo glucose production from non-carbohydrate 
substrates (gluconeogenesis). EGP in humans primarily occurs in the liver and to 
a lesser extent the kidneys [Cherrington 1999]. The rate of production is a 
function of both stimulus and availability of substrates. 
 
Both insulin and hyperglycaemia inhibit EGP. Hypoglycaemia and the counter-
regulatory hormones (glucagon, cortisol, the catecholamines and growth 
hormone) stimulate EGP [Cherrington 1999]. In healthy individuals, the fine 
balance between these mediators maintains relatively constant plasma glucose 
levels throughout life. However, in critical illness, counter-regulatory hormones 
are significantly elevated almost immediately post critical-insult, but decline 
rapidly over the first 12-48 hours [Chernow et al. 1987; Frayn 1986; Jaattela et 
al. 1975; Weissman 1990]. These hormones can stimulate excess hepatic glucose 
production resulting in or exacerbating, stress-induced hyperglycaemia [Gelfand 
et al. 1984; Weissman 1990; Wilmore 1981]. 
 
A number of published glucose dynamics models developed for healthy and 
diabetic subjects incorporate explicit glucose appearance from EGP. EGP rates 
have been modelled as functions of plasma insulin concentration [Hovorka et al. 
2002], blood glucose and insulin concentrations [Andreassen et al. 1994; Arleth 
et al. 2000; Lehmann & Deutsch 1992; Lotz et al. 2006], and glucose, insulin and 
glucagon concentrations [Cobelli et al. 1982; Parker et al. 2000]. The four 
published critical care specific models incorporate EGP as a function of insulin 
[Hovorka et al. 2008], BG and insulin [Pielmeier et al. 2010], a constant [Lin et al. 
2011], or not explicitly specified [Van Herpe et al. 2006]. In reality, EGP is 
modulated by the interaction of many hormones that are elevated in critical 
illness [Gelfand et al. 1984; Mizock 1995]. These interactions are too complicated 
to be accurately captured by relatively simple, clinically relevant models. 
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Additionally, the interactions are likely to have patient-specific and therapy-
specific variation that also cannot be readily captured. 
 
Specific to clinical use in the critical care setting, modelling EGP as a function of 
insulin and glucagon concentrations may be unnecessarily complicated. Without 
explicitly measuring these hormone concentrations, modelling errors are 
potentially added to what is already a complicated system with substantial inter- 
and intra patient variability. Equally, there are no current methods to assay these 
hormones in real-time at the bedside. Hence, a model for clinical use cannot rely 
on these physiologically critical hormones to provide and patient specificity or 
real-time insight to reduce variability in this model element. 
 
5.2 Subjects and Methods 
5.2.1 Patients and samples 
Two cohorts were used in this study. A cohort of 200 patients from the 
Christchurch Hospital ICU was used to investigate modelling EGP as a function of 
BG. A sub-cohort of 10 patients with fitting errors greater than 20% for short 
periods during the first 48 hours of SPRINT was used to investigate EGP as a 
function of time. All of these patients were on the SPRINT protocol for at least 48 
hours. Table 5.1 presents a summary of the two cohorts. 
 
Table 5.1 Summary of patient characteristics. Data are shown as median [IQR] where 
appropriate. 
Cohort SPRINT > 48hrs Poor fit 
N 200 10 
Age (years) 65 [49-73] 72 [66-75] 
Gender (M/F) 126/74 3/7 
APACHE II score 19.0 [16.0-25.0] 25.0 [18.3-26.5] 
Hospital mortality 27% 20% 
Operative/Non-operative 70/130 3/7 
Diabetic T1DM/T2DM 7/24 1/2 
Maximum fitting error (%) 5 [2-11] 28 [24-36] 
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The Upper South Regional Ethics Committee, New Zealand granted approval for 
the audit, analysis and publication of this data. 
 
5.2.2 Analysis methods 
In the absence of tracer or balance data, fitting error and SI level can provide 
information about the performance of the glucose dynamics model. For example, 
negative values of SI are not physiologically possible and are prevented during 
parameter identification by a non-negative constraint. This non-negative 
constraint can cause BG fitting errors when the glucose rate of appearance from 
nutrition and the modelled EGP is not high enough to balance glucose utilisation.  
 
5.2.2.1 EGP as a function of BG 
The basic form of the EGP(G) function was reasoned to be approximately ‘U’-
shaped, based on fundamental physiology [Guyton & Hall 2000]. At low BG 
levels, EGP should be high to restore normoglycaemia. Counter-intuitively, 
hyperglycaemia indicates stress and thus high EGP [McCowen et al. 2001]. Figure 
5.1 shows the proposed shape of the EGP function, defined parametrically by 
four coordinates. 
 
To reduce the scale of the identification process, four constraints were placed on 
the set of coordinates: 
 
1. x1 = 0  mmol/l 
2. x2 = 4  mmol/l 
3. y2 = y3  mmol/min 
4. x2 = 30  mmol/l 
 
The remaining four parameters (y1, y2, y4, x3) were identified using a non-linear 
least squares method minimising the sum of squared fitting errors. The non-
linear least squares parameter optimisation was performed in MATLAB (2011a, 
Mathworks, Natick, MA) using the trust-region-reflective algorithm [Coleman & 
Li 1996]. 
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The 200 SPRINT patients used in this investigation were split into 10 cohorts of 
20 patients. The parameter identification was performed separately on each of 
these cohorts. This method allowed the independent results to be compared, 
providing a degree of cross-validation. The cohorts were populated so that they 
each had a similar distribution of maximum BG fitting errors.  
 
 
Figure 5.1 Schematic plot of proposed EGP(G) function. 
 
Large BG fitting errors due to the non-negative constraint on SI predominantly 
occur during the first 24-48 hours of the SPRINT protocol, during the acute 
phase of critical illness [Frayn 1986; Weissman 1990]. To ensure an equal 
weighting from each patient-hour, the optimisation was performed over the first 
48 hours of SPRINT. As the cohort consisted of patients that spent more than 48 
hours on the protocol, this criterion prevented the results from being skewed by 
long-stay patients. 
 
During this investigation, EGP was held constant at the mean value determined 
by the two surrounding BG measurements. Using the mean value ensured that 
the modelled EGP was able to capture rapid changes in BG. The mean BG value 
cannot be used in real-time clinical situations, limiting the utility of this 
approach. However, in this proof of concept analysis, this method is justified as a 
first attempt to assess the efficacy and utility of the overall model hypothesis and 
approach. 
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5.2.2.2 EGP as a function of time 
To gauge the temporal, EGP(t) profile that would improve glucose dynamics 
modelling, the number of instances where SI was constrained to a non-negative 
minimum value was examined over time for both the 200 patient and poor fit 
cohorts. Further, the minimum value of EGP was determined that resulted in 
fitted SI = 10-5 l/mU.min. This value of SI is at the very low end of the typical 
physiological range for critically ill patients of 10-4 – 10-3 l/mU.min. The overall 
goal was to assess the potential range and inter-patient variability of EGP over 
the first 48 hours of SPRINT. Data was analysed in 6-hour blocks for each cohort 
from the commencement of the SPRINT protocol.  
 
The SPRINT protocol is often commenced shortly after admission to the ICU. 
However, this early start is not always the case. When SPRINT is commenced 
later in a patient’s stay, it typically follows an unexpected rise in BG 
concentration to above 8 mmol/l [Chase et al. 2008]. Thus, some significant 
change in patient state resulted in a spontaneous rise in the patient’s blood 
glucose concentration, either by increased EGP, reduced glucose uptake or a 
combination of both. This dysregulation of glycaemic level may indicate 
increased stress levels [McCowen et al. 2001]. Hence, EGP was modelled as a 
function of time on the SPRINT protocol, rather than explicit time in the ICU. 
 
5.3 Results and Discussion 
5.3.1 EGP from the literature 
To provide some context to the models of EGP proposed in this analysis, Table 
5.2 presents results from a number of published studies on critically ill patients 
and healthy controls. The subjects varied in nutritional state from fasted to 
receiving approximately ACCP goal feed (25 kcal/kg.day) with 50% glucose via 
the parenteral route [Cerra et al. 1997]. Most of the studies measured EGP at a 
single point in time ranging from during surgery to 96 hours post-ICU admission. 
The range of reported mean values of EGP for critically ill patients was 0.10-2.36 
mmol/min.  
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The published data from tracer studies with tabulated results was combined to 
calculate overall statistics. The resulting mean and standard deviation values for 
fasted and fed patients were 1.77 ± 0.55 mmol/min (N = 114) and 0.62 ± 0.36 
mmol/min (N = 75), respectively. These values span the constant 
1.16 mmol/min currently used in the ICING model. 
 
Table 5.2 EGP values measured in critically ill patients and healthy controls from the 
literature. Where reported values were normalised by anthropomorphic data, 80 kg 
and 1.8 m2 body surface area have been in this table. Abbreviations; Epi: Epidural 
block; N. anaes: Normal anaesthesia; TPN: Total parenteral nutrition; CHO: 
carbohydrate; IV: intravenous. 
Study Subject type 
Nutritional 
information 
N 
EGP 
(mmol/min) 
Wolfe et al.  
[1979] 
Burn patients Fasted 15 1.89 
Wilmore et al.  
[1980] 
Burn patients (non-infected) Fasted 7 1.14 
Burn patients (bacteremic) Fasted 8 1.50 
Burn patients (bacteremic 
with complications) 
Fasted 4 0.65 
Black et al.  
[1982] 
Trauma patients Fasted 3 1.51 
Shaw et al.  
[1989] 
Trauma patients Fasted 43 1.68 
Healthy controls Fasted 32 1.12 
Trauma patients TPN (50% CHO) 43 0.88 
Jeevanandam et al. 
[1990] 
Trauma patients Fasted 10 1.76 
Healthy controls Fasted 6 1.22 
Watters et al.  
[1997] 
Healthy controls: Young Fasted 5 1.73 
Healthy controls: Older Fasted 6 1.82 
Trauma patients: Young Fasted 14 2.00 
Trauma patients: Older Fasted 8 2.27 
Tappy et al.  
[1999] 
Surgical ICU patients TPN (75% CHO) 7 1.20 
Surgical ICU patients TPN (28% CHO) 7 1.04 
Chiolero et al.  
[2000] 
Cardiac surgery patients with 
cardiogenic shock 
Fasted 7 2.36 
Healthy controls Fasted 7 0.86 
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Table 5.2-continued. 
Study Subject type 
Nutritional 
information 
N 
EGP 
(mmol/min) 
Lattermann et al.  
[2003] 
Colorectal surgery patients: 
Epi. - pre-operative 
Fasted (36hrs) 8 0.89 
Colorectal surgery patients: 
Epi. - peri-operative 
0.89mmol/min 
IV glucose 
8 0.10 
Colorectal surgery patients: 
Epi. - post-operative 
0.89mmol/min 
IV glucose 
8 0.24 
Colorectal surgery patients: 
N. anaes. - pre-operative 
Fasted (36hrs) 8 0.85 
Colorectal surgery patients: 
N. anaes. - peri-operative 
0.89mmol/min 
IV glucose 
8 0.30 
Colorectal surgery patients: 
N. anaes. - post-operative 
0.89mmol/min 
IV glucose 
8 0.43 
Thorell et al.  
[2004] 
Trauma patients Fasted 6 1.38 
Healthy controls Fasted 6 1.07 
Trauma patients TPN (50% CHO) 6 0.67 
Healthy controls TPN (50% CHO) 6 0.36 
Revelly et al.  
[2005] 
ICU patients with severe 
sepsis/septic shock 
Fasted 7 1.18 
ICU patients with 
cardiogenic shock 
Fasted 7 1.20 
Healthy controls Fasted 7 0.58 
 
 
5.3.2 EGP as a function of BG 
Figure 5.2 shows the results of the shape optimisation of EGP as a function of BG 
(EGP(G)). There are 10 separate lines on the plot representing the optimal 
functions for each of the 10 cohorts of 20 patients. The results show considerable 
variability in optimal EGP values across the cohort, both at high BG 
concentrations and at more normal levels of 4.0-6.0 mmol/l. In addition, many of 
the functions can result in EGP values much larger than those listed in Table 5.2, 
particularly for patients receiving nutrition. 
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Figure 5.2 Results of the EGP(G) shape optimisation based on BG fitting error over 48 
hours using 10 cohorts of 20 SPRINT patients. 
 
Contrary to the initial reasoning presented, all the optimal EGP functions were 
monotonically increasing. The lack of a decreasing section at low-normal BG 
concentrations 2.0-4.0 mmol/l is likely a combination of the low number of 
hypoglycaemic episodes experienced during the SPRINT protocol [Chase et al. 
2008] and the choice of BG fitting error as the performance metric. 
 
Hypoglycaemia is uncommon to the SPRINT protocol. Chase et al. [2008] 
reported 3.8% of measurements below 4.0 mmol/l in an evaluation of the clinical 
implementation of the protocol. In the 200 patient cohort used for the 
optimisation of EGP, 3% (201 measurements) of the 6948 BG measurements 
were below 4.0 mmol/l and 0.16% (11 measurements) were below 3.0 mmol/l. 
Thus, there were only a small number of data points from a few patients 
contributing to the optimisation below 4.0 mmol/l. These limited points likely 
did not produce a strong signal for increased EGP at low BG concentrations. 
 
More importantly, for a given pair of BG measurements, the minimum fitting 
error tends to occur at the lowest value of EGP that results in a non-negative SI. 
The non-negative constraint on SI results in a steep negative relationship 
between EGP and fitting error for SI  0. This relationship is a result of the 
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constrained SI parameter being unable to balance glucose appearance and 
utilisation to correctly fit the measured glucose dynamics.  
 
The relationship between EGP and fitting error is slightly increasing for SI > 0. As 
EGP increases, SI also increases. This increasing SI amplifies the relatively 
constant error between the linear BG trajectory assumed for parameter 
identification and the subsequent solution of the glucose dynamics equation.  
 
Thus, for any given parameterisation of the EGP function, the sum squared fitting 
error and its gradient are dominated by those patient hours where the value of SI 
is close to zero. At these points, the model cannot capture the observed data and 
large fitting errors occur. Hence, there is a tendency towards lower EGP values 
and a non-decreasing EGP function as seen in Figure 5.2. This link between EGP 
and BG fitting error renders fitting error less than fully suitable as a performance 
metric for this analysis.  
 
Modelling EGP as an increasing function of BG may also result in instability 
during virtual patient simulations. During virtual patient simulations, the SI 
profile is taken from a real patient and the glucose-insulin model is used in 
conjunction with a control algorithm to determine the interventions and the 
resulting BG concentration profile [Chase et al. 2010]. In this situation, an 
increasing EGP(G) function could provide a form of positive feedback leading to 
high, non-physiological simulated BG concentrations.  
 
The aim of this part of the investigation was to model EGP as a function of BG 
concentration for critically ill patients. However, the relationship between EGP 
and BG fitting error and the possibility of positive feed-back during simulation 
render this approach unsuitable, given the available data and hypothesised form 
of EGP(G). 
 
5.3.3 EGP as a function of time 
Figure 5.3 shows the prevalence of instances where SI was forcibly constrained 
to non-negative values for both cohorts. The data are presented in 6-hour blocks 
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from the commencement of the SPRINT protocol. There is a clear relationship 
between the number of constrained SI values and time, in both cases. In 
particular, the exponential decay over time from the commencement of SPRINT 
is qualitatively similar for both cohorts. 
 
 
Figure 5.3 Time course of the number of instances where the fitted SI parameter was 
constrained to non-negative values during the first 48 hours of SPRINT. The top 
panel shows the results for the 200 patient SPRINT > 48 hours cohort. The bottom 
panel shows the 10 patient poor fit cohort. 
 
Eight of the 10 patients in the poor fit cohort received no exogenous nutrition 
prior to the time at which the large BG fitting errors occurred. Thus, in these 
cases, the only possible source glucose appearance in the dynamics model was 
from endogenous production and there could be no error introduced through 
incorrectly modelling gastric absorption. The value of EGP used in the ICING 
model was clearly too low for these instances in particular as it could not provide 
a glucose rate of appearance high enough to match the measured data. 
 
The poor fit cohort was used to define the time course of EGP suggested by 
Figure 5.3. Figure 5.4 presents the distributions of EGP values for each 6-hour 
block that resulted in the minimum fitted SI = 10-5 l/mU.min. There is a general 
reduction over time in both the level and variability of EGP required to maintain 
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this level of SI. It is clear that the necessary early, higher EGP levels are very 
patient specific and exhibit significant inter-patient variability. Using the 75th 
percentile values of EGP from Figure 5.4 to fit a function over time provided a 
good balance between reducing the number of constrained SI values and 
modelling EGP at supra-physiologic levels to include outliers.  
 
Figure 5.4 Time course of minimum EGP values required to prevent non-physiologic 
negative fitted SI values for the poor fit cohort. The whiskers indicate the full range 
of EGP values. The model is fitted to the 75th-percentile points r2 = 0.87. 
 
The least squares fitted exponential model of EGP is shown in Figure 5.4. The 
model was fitted to the 75th-percentile points located at the midpoints of the 
time intervals (3, 9, 15… hrs). Equation 5.1 defines the model and its parameters 
with t expressed in minutes. With a coefficient of determination, r2 = 0.89, the 
model fitted the data points very well.  
 
                          5.1 
 
The values of EGP determined by the model approach 1.10 mmol/min 
asymptotically from 2.24 mmol/min at t = 0 hours. The value of EGP determined 
by the model is less than the currently used value of 1.16 mmol/min when t ≥ 33 
hours. These values of EGP compare well with data from the literature shown in 
Table 5.2 and the calculated combined values for fasted and fed patients. 
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In the studies shown in Table 5.2, subjects receiving nutritional support 
generally had lower EGP levels than fasted subjects. This trend includes critically 
ill patients, where it may have been supposed that elevated levels of stress 
hormones might mitigate the suppression of EGP by exogenous glucose.  
 
Eight of the 10 patients in the poor fit cohort received no nutrition prior to the 
time at which the large BG fitting errors occurred, so the proposed model may 
overestimate EGP for some patients when they are being fed. Equally, the values 
of EGP determined in the analysis are based on the minimum that drives SI to a 
very low physiological value. However, the unknown, true SI values may be 
anywhere in the typical range (10-4 – 10-3 l/mU.min) and, in this sense, the 
proposed model represents a minimum level and may underestimate EGP. 
 
The SI parameter balances the glucose appearance from EGP and nutrition with 
utilisation by modifying insulin-mediated glucose uptake so that the modelled 
glucose dynamics best fit the measured data. Using a value of EGP that is too low 
causes obvious modelling errors due to the non-negative constraint on SI. 
However, when the value of EGP used in the model is too large, the model can 
still fit the data very well, as SI increases to maintain the glucose balance and 
match the observed data.  
 
There is no obvious, physiological upper limit on this model-based SI parameter 
that can provide an indication that the value of EGP was too large. Hours where 
SI must be constrained to non-negative values provide extra data that suggest 
the value of EGP must be increased. However, once EGP has been raised to the 
point where SI > 0, there is little further information available to define the exact 
level. A prior distribution could be applied to place SI within the typical range 
(10-4 – 10-3 l/mU.min). However, this approach would still result in a wide range 
of EGP values. The problem thus becomes functionally unidentifiable once SI 
enters a physiologically reasonable range, as SI and EGP cannot be determined 
uniquely with just BG measurements. 
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The aim of this analysis was to model EGP as a function of time on the SPRINT 
protocol. However, arguments can be made that the proposed model may over- 
or under- estimate EGP depending on levels of nutrition and assumptions about 
the true SI level. Additionally, the model was developed on a small cohort of 10 
patients with acute jumps in BG and may not generalise well to a normal ICU 
population. To properly define EGP over time and with different levels and types 
of nutrition, a series of studies would need to be conducted.  
 
The fitted exponential function of Figure 5.4 matches clinical expectations. The 
acute phase of critical illness is characterised by a stress response diminishing 
over 12-48 hours as the concentrations of counter-regulatory hormones decline 
[Frayn 1986; Weissman 1990]. Overall, while the proposed model provides some 
insight into the possible behaviour of EGP over time, it is not well founded on 
measured data and suffers from an identifiability problem. Equally, the range of 
possible EGP levels is wide and patient-specific, even while the overall trend is 
clinically realistic. Therefore, the best course may be to continue using constant 
EGP for most applications. In special circumstances, during real-time control in 
clinical situations, it may be prudent to increase EGP temporarily. 
 
5.3.4 EGP in control during special circumstances 
During real-time control of BG in a clinical setting, particular circumstances may 
warrant a temporary increase in modelled EGP to ensure adequate control 
performance. When a patient has a poor fit to measured data due to a 
constrained value of SI, particularly if receiving no nutrition, then EGP is the 
most likely source of the error. In these situations, temporarily increasing EGP 
ensures that control performance and safety is maintained.  
 
The duration and degree to which EGP should be increased likely varies between 
patients and over time. However, the results of this analysis and reported values 
from the literature suggest a wide range of possibilities. Hence, raising EGP up to 
2.0 mmol/min to ensure SI = 10-5 l/mU.min as a minimum value with good fit 
(<5% error) to measured BG data is potentially prudent. This change can be 
checked each hour to determine if it is still required. 
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5.4 Summary 
Modelling EGP as a function of BG concentration, proved unsatisfactory in this 
investigation. The relationship between EGP and BG fitting error and the 
potential for positive feedback causing instability during simulation make 
modelling EGP as a function of BG unfeasible for this particular model and data 
set.  
 
Modelling EGP as a function of time on the SPRINT protocol proved successful at 
reducing fitting error due to constrained SI values. While the values of EGP 
determined from the model compare well with those from published literature, 
arguments can be made that they may over- or under- estimate EGP, depending 
on levels of nutrition and assumptions about SI. Without additional data that are 
currently unavailable in clinical real-time, the problem is fundamentally 
unidentifiable when SI values are in the physiologic range. Additionally, this 
model was developed on a small cohort of 10 patients with acute jumps in BG 
and may not generalise well to a normal ICU population.  
 
The best course may be to continue using constant EGP for most applications. 
However, during real-time control in clinical situations, if a patient has poor fit to 
measured data due to a constrained value of SI while receiving no nutrition, then 
EGP should be temporarily increased. Raising EGP up to 2.0 mmol/min and 
assessing the necessity hourly is proposed. 
 
Finally, one major outcome of both analyses presented was confirmation of the 
wide inter- and intra- patient variability in EGP. This variability appeared in both 
functions of BG and time. This significant variability in EGP is a further aspect 
that confounds clinical glycaemic control efforts through intrinsic SI variability. 
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Chapter 6. ICING-2 Model Summary 
6.1 Introduction 
To conclude this section on intrinsic variability, the ICING model, modified with 
the proposed changes is presented. This modified model is designated ICING-2 to 
differentiate it from the original. 
 
The changes to the original ICING model detailed in this section were: 
 A model of pancreatic insulin secretion as a function of blood glucose 
concentration (Chapter 3). 
 Improved insulin kinetics (Chapter 4). 
 
Endogenous glucose production remains a population constant as discussed in 
Chapter 5. 
 
6.2 Pharmacokinetic-pharmacodynamic model and parameters 
The ICING-2 model is presented in Equations 6.1 - 6.7. The associated parameter 
values and descriptions are listed in Table 6.1. Table 6.2 shows the exogenous 
input variables to the model. 
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Table 6.1 Parameter values and descriptions for the ICING-2 model.  
Parameter Value Unit Description 
pG 0.006 min
-1 Non-insulin mediated glucose removal 
EGP 1.16 mmol/min Endogenous glucose production rate 
CNS 0.3 mmol/min Central nervous system glucose uptake 
VG 13.3 L Plasma glucose distribution volume 
VI 4.0 L Plasma and interstitial insulin distribution volume 
αG 0.0154 L/mU Insulin binding saturation parameter 
αI 0.0017 L/mU Hepatic insulin clearance saturation parameter 
nI 0.006 min
-1 Trans-endothelial diffusion rate  
nC 0.006 min
-1 Interstitial insulin degradation rate 
nK 0.0542 min
-1 Renal insulin clearance rate 
nL 0.1578 min
-1 Hepatic insulin clearance rate 
xL 0.67   Fractional first-pass hepatic insulin extraction 
d1 0.0347 min
-1 Glucose transport rate from stomach to gut 
d2 0.0069 min
-1 Glucose transport rate from gut to plasma 
Pmax 6.11 mmol/min Maximum glucose flux from gut to plasma 
umin 16.7 mU/min Minimum pancreatic secretion rate 
umax 266.7 mU/min Maximum pancreatic secretion rate 
k1 
ND: 14.9 
mU.L/mmol.min Pancreatic insulin secretion glucose-sensitivity T2DM: 4.9 
T1DM: 0.0 
k2 
ND: -49.9 
mU/min Pancreatic insulin secretion offset T2DM: -27.4 
T1DM: 16.7 
 
Table 6.2 Exogenous input variables to the ICING-2 model. 
Variable Unit Description 
PN(t) mmol/min Intravenous glucose input rate (parenteral nutrition) 
D(t) mmol/min Oral glucose input rate (enteral nutrition) 
uex(t) mU/min intravenous insulin input rate 
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Chapter 7. Patient Type and Condition 
In contrast with the previous thesis section, this section investigates extrinsic SI 
variability resulting from changes external to the specific pharmacokinetic-
pharmacodynamic model. SI varies over time and between patients and patient 
groups as a result of physiological factors and measurement errors that are not 
explicitly modelled. To reduce the impact of these variations, while using the 
model for glycaemic control or analysis, the variability of these factors must be 
understood, and used to enable improved means of applying or implementing 
the model applied. 
 
7.1 Introduction 
The metabolism of critically ill patients evolves dynamically over time 
[Cuthbertson 1942; Frayn 1986; Weissman 1990]. The counter-regulatory 
hormones: cortisol, glucagon, the catecholamines, as well as growth hormone, 
are significantly elevated almost immediately post critical-insult, but decline 
rapidly over the first 12-48 hours [Chernow et al. 1987; Frayn 1986; Jaattela et 
al. 1975; Weissman 1990]. These hormones have a direct physiological impact 
on the SI parameter of the ICING-2 model, through altered endogenous glucose 
production, peripheral and hepatic insulin-mediated glucose uptake and 
endogenous insulin secretion. However, the specific level and time-course of the 
acute stress-response to critical illness varies significantly between patients. 
Hence, the level and variability of SI changes over time and between different 
patients and patient groups.  
 
Understanding the variability of SI, over hours and days, is important for safely 
and effectively managing glycaemic levels with exogenous insulin. The metabolic 
balance represented by SI is an important consideration in clinical blood glucose 
control, as it determines a body’s glycaemic response to exogenous insulin and 
nutrition. Several patient- and treatment related factors are thought to influence 
insulin sensitivity, such as cardiovascular surgery and glucocorticoid therapy. 
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Importantly, Bagshaw [2009] reported an association between hypoglycaemia 
and variability during the first 24 hours of ICU stay, and mortality. Not only does 
glycaemic variability pose a risk through hypoglycaemia, it is also detrimental in 
its own right. Several studies [Egi et al. 2006; Egi et al. 2010; Hermanides et al. 
2010; Krinsley 2008] have shown that glycaemic variability is independently 
associated with mortality in critically ill patients. Hence, glycaemic variability is a 
critical factor to mitigate during control. 
 
The objective of this study was to assess the evolution of insulin sensitivity level 
and variability over the first four days of ICU stay. Once this variability was 
understood, the means to reduce the impact on glycaemic control are proposed.  
 
7.2 Subjects and Methods 
7.2.1 Patients 
This analysis was performed on a cohort of 164 patients from the SPRINT tight 
glycaemic control  study in the Christchurch Hospital ICU [Chase et al. 2008]. All 
patients from the TGC cohort were included where SPRINT was commenced 
within 12 hours of ICU admission and continued for at least 24 hours.  
 
A separate, sub-analysis was performed on cardiovascular surgery (CVS) 
patients from the full cohort.  CVS patients form an important ICU population 
subgroup with regard to TGC [Van den Berghe et al. 2001], and are present in 
sufficient numbers in the SPRINT cohort to permit analysis. Table 7.1 presents a 
summary of the cohort details.  
 
The Upper South Regional Ethics Committee, New Zealand granted approval for 
the audit, analysis and publication of this data. 
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Table 7.1. Summary details of the study subjects. The CVS patients are also included 
in the ICU cohort. Data are presented as median [interquartile range] where 
appropriate. 
 ICU CVS 
N 164 22 
Age (years) 65 [56-74] 73 [66-76] 
Gender (M/F) 102/62 16/6 
APACHE II score 19 [16-25] 17 [16-21] 
APACHE II ROD (%) 32 [17-52] 21 [12-36] 
Operative/Non-operative 66/98 22/0 
Diabetic history: Type I/Type II 10/22 1/3 
Hospital mortality 25% 18% 
ICU length of stay (hours) 142 [70-308] 100 [67-257] 
 
 
7.2.2 Analyses: 
SI level was identified hourly using the ICING-2 model for each patient. 
Variability of SI was calculated as the hour-to-hour percentage change in SI 
(Δ%SI), defined in Equation 7.1. Use of percentage change, rather than absolute 
change, normalised the metric so that patients with very different absolute levels 
of SI could be compared fairly. 
 
           
           
   
 7.1 
 
SI level and variability were analysed on overall cohort and per-patient bases 
using two separate timescales. The evolution of SI over the first four days of ICU 
stay was analysed in 24-hour blocks. Bagshaw et al. [2009] reported an 
association between hypoglycaemia and variability during the first 24 hours of 
ICU stay, and mortality. Therefore, the acute evolution of SI over the first day 
using 6-hour blocks was also analysed.  
 
Cohort analysis examined hourly values of SI and variability for the entire cohort 
grouped together and shows trends in the overall group behaviour. To quantify 
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per-patient variability, the interquartile range (IQR: 25-75th percentile) of Δ%SI 
was examined for each patient within each timescale. This metric captures the 
width of the variability distribution for each patient. Per-patient SI level was 
defined by the median value within each timeframe. 
 
The analyses were linked to time on the SPRINT protocol, rather than time in the 
ICU, to ensure sufficient insulin and nutrition data to accurately identify SI 
hourly [Hann et al. 2005]. Therefore, day 1 comprises the first 24 hours of 
SPRINT. However, as patients were included only if they commenced SPRINT 
within 12 hours of ICU admission, a minimum of half of the day 1 results for each 
patient occur during their first 24 hours in the ICU. The median delay between 
admission and commencement of SPRINT for this cohort was 1.9 hours and 81% 
of the cohort had started SPRINT within 6 hours. When a patient was taken off 
the SPRINT protocol, their SI profile for the last day was included in the analysis 
if it contained six or more hours of data.  
 
SI levels and variability are compared using cumulative distribution functions 
(CDFs) and non-parametric statistics. Distributed data was generally compared 
using the Wilcoxon rank-sum test (Mann-Whitney U-test), except for SI 
variability results. SI variability was compared using the Kolmogorov-Smirnov 
test as it has more power to detect differences in the shape of distributions than 
the rank-sum test when median values are similar. P-values of 0.05 were 
considered statistically significant. 
 
7.3 Results 
7.3.1 Twenty-four hour analyses: 
7.3.1.1 Insulin sensitivity level 
Figure 7.1 presents the cumulative distribution functions (CDFs) of hourly SI for 
each day by cohort (left panel) and median daily SI per-patient (right panel). 
Table 7.2 presents the increase in values from Figure 7.1 and associated p-values 
between successive days. Both per-patient and cohort analyses suggest that 
insulin sensitivity levels start low, but increase over time in the ICU. There was a 
62 
 
particularly significant increase between days 1 and 2 (p < 0.001). On 
subsequent days the increase continues, but to a lesser extent. Per-patient 
comparisons between days 2, 3 and 4 were not statistically significant. 
 
 
Figure 7.1. Insulin sensitivity level analyses by cohort (left) and per-patient median 
(right) using 24-hour blocks of data. 
 
Table 7.2. Increasing cohort and per-patient median insulin sensitivity over time 
(24hr blocks). P-values calculated using Wilcoxon rank-sum test. 
Level analysis 
Cohort analysis Per-patient analysis 
% Increase at 
median 
p-value 
% Increase at 
median 
p-value 
Days 1-2 34 <0.0001 33 0.0004 
Days 2-3 16 <0.0001 21 0.2559 
Days 3-4 6 0.0013 4 0.6306 
 
The results of Figure 7.1 and Table 7.2 are further reflected in Table 7.3, which 
shows that daily median insulin sensitivity increased for a large proportion of 
the cohort between days 1 and 2 with lesser proportions on subsequent days. 
Table 7.3 is a matrix where the value in a cell represents the proportion of 
patients for whom daily median insulin sensitivity is greater on the day of the 
associated column than the day of the associated row. For example, 72% of 
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patients showed an increase in median SI between days 1 and 2, and 54% when 
comparing days 2 and 3. 
 
Table 7.3. Proportion of patients for whom median insulin sensitivity increases 
between the days indicated in the rows and columns. 
 
Day 2 Day 3 Day 4 
Day 1 0.72 0.74 0.71 
Day 2 
 
0.54 0.64 
Day 3 
  
0.53 
 
7.3.1.2 Insulin sensitivity variability 
Insulin sensitivity variability reduced over time in the ICU, parallel to increases 
in SI level. Figure 7.2 and Table 7.4 present the CDFs and tabulated results for 
cohort and per-patient analyses of the hour-to-hour percentage changes in SI 
(Δ%SI). The cohort aggregate distributions of Δ%SI by day are shown in the left 
panel of Figure 7.2. The right panel presents the CDFs of the per-patient IQRs by 
day.  
 
 
Figure 7.2. Insulin sensitivity variability analyses by cohort (hour-to-hour percentage 
change) and per-patient interquartile-range using 24-hour blocks of data. 
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As with SI level, the largest improvement in variability was between days 1 and 
2. The reduction between days 2-3 and 3-4 was statistically significant or very 
nearly so for both cohort and per-patient analyses, but the change was much less 
than over the first day, and may not be clinically significant. 
 
Table 7.4. Reductions in the IQR and median per-patient range of hour-to-hour 
percentage insulin sensitivity change over time. P-values calculated using 
Kolmogorov-Smirnov test for cohort comparisons and Wilcoxon rank-sum test for 
per-patient comparisons. 
Variability analysis 
Cohort analysis Per-patient analysis 
% Reduction 
of IQR 
p-value 
% Reduction 
at median 
p-value 
Days 1-2 34 <0.0001 35 <0.0001 
Days 2-3 20 0.0022 18 0.0087 
Days 3-4 14 0.0339 16 0.0543 
 
7.3.2 Six hour analyses: 
7.3.2.1 Insulin sensitivity level 
Figure 7.3 presents the distributions of cohort and per-patient SI over the first 
24 hours in 6-hour blocks. Also shown for comparison is the day 2 distribution 
from Figure 7.1 (labelled 24-28 hours).  It is evident that insulin sensitivity level 
improves over the first day up to the level of the second day. Hence, the 
differences between day 1 and 2 seen in Figure 7.1 were a function of the low, 
but increasing insulin sensitivity during the first 12-18 hours.  
 
Table 7.5 lists the differences in median insulin sensitivity levels from the 
distributions shown in Figure 7.3. The increases in SI during the first 18 hours 
were large and statistically significant. Subsequent increases are unlikely to be 
clinically significant at less than 10%. Of particular interest is the comparison 
between 18-24 hours and day 2, which indicates that by 18 hours, the rapid 
improvement in SI was largely complete. 
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Figure 7.3. Insulin sensitivity level analyses by cohort (left) and per-patient median 
(right) using 6-hour blocks of data. 
 
Table 7.5. Increasing cohort and per-patient median insulin sensitivity over time (6hr 
blocks). P-values calculated using Wilcoxon rank-sum test. 
Level analysis 
Cohort analysis Per-patient analysis 
% Increase 
at median 
p-value 
% Increase 
at median 
p-value 
Block 1-2 (0-6 vs 6-12hrs) 42 <0.0001 40 0.0007 
Block 2-3 (6-12 vs 12-18hrs) 28 <0.0001 26 0.0123 
Block 3-4 (12-18 vs 18-24hrs) 1 0.0335 3 0.4829 
Block 4-5 (18-24 vs 24-48 hrs) 9 0.0451 7 0.3763 
 
 
Table 7.6 shows that during the first 18 hours, a large proportion of the patients 
saw an increase in insulin sensitivity using the 6-hour timescale. Past 18 hours, 
the proportion of patients with increasing SI was similar to that seen between 
days 2, 3 and 4 (Table 7.3) at a little over 50%.  
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Table 7.6. Proportion of patients for whom median insulin sensitivity increases 
between the blocks indicated in the rows and columns. 
 
6 - 12hrs 12 - 18hrs 18 – 24hrs 24 – 48hrs 
0 - 6hrs 0.74 0.78 0.77 0.79 
6 - 12hrs 
 
0.76 0.70 0.72 
12 - 18hrs 
  
0.55 0.64 
18 - 24hrs 
   
0.58 
 
7.3.2.2 Insulin sensitivity variability 
As with SI level, the majority of the improvement in SI variability occurred 
during the first 18 hours. Figure 7.4 shows the CDFs of the cohort and per-
patient variability metrics. However, Table 7.7 shows that only the differences 
between 0-6 hours and 6-12 hours were statistically significant in both analyses.  
 
Figure 7.4. Insulin sensitivity variability analyses by cohort (hour-to-hour percentage 
change) and per-patient interquartile-range using 6-hour blocks of data. 
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Table 7.7. Reductions in the IQR and median per-patient range of hour-to-hour 
percentage insulin sensitivity change over time. P-values calculated using 
Kolmogorov-Smirnov test for cohort comparisons and Wilcoxon rank-sum test for 
per-patient comparisons. 
Variability analysis 
Cohort analysis Per-patient analysis 
% 
Reduction 
of IQR 
p-value 
% Reduction 
at median 
p-value 
Block 1-2 (0-6 vs 6-12hrs) 36 0.0092 37 < 0.0001 
Block 2-3 (6-12 vs 12-18hrs) 24 0.0806 27 0.1031 
Block 3-4 (12-18 vs 18-24hrs) -1 0.0806 10 0.868 
Block 4-5 (18-24 vs 24-48hrs) 18 0.1639 15 0.1002 
 
7.3.3 Cardiovascular surgery patients 
Figure 7.5 and Figure 7.6 show the evolution of SI over the first four days of ICU 
stay for the 22 CVS patients. Also shown, for comparison, are the same data for 
the full 164 patient ICU cohort from Figure 7.1 and Figure 7.2, including these 22 
patients.  
 
The CVS patients exhibit similar trends over time to the full ICU cohort. Cohort 
analysis showed 21-32% increases in level for all days (p < 0.003) and a 34% 
reduction in variability between days 1 and 2 (p < 0.02). More importantly, the 
CVS patients also exhibit lower and more variable SI than the ICU cohort for the 
first few days of ICU stay. The CVS patients had 25-34% lower SI than the full 
cohort during days 1-3 of ICU stay (p < 0.001), and were also significantly more 
variable on day 1 (p = 0.03). By day 4, there were no statistically significant 
differences in level or variability between the CVS cohort and the ICU cohort. 
 
The relatively small number of CVS patients that fulfilled the selection criteria for 
this study limited the reliability of the per-patient analyses. The 6-hour analyses 
were omitted altogether as both the cohort and per-patient data were sparse. 
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Figure 7.5. Insulin sensitivity level analyses by cohort (left) and per-patient median 
(right) for cardiovascular surgery patients. The grey lines show the data from the full 
164 patient cohort for comparison. 
 
 
Figure 7.6. Insulin sensitivity variability analyses by cohort (left) and per-patient 
median (right) for cardiovascular surgery patients. The grey lines show the data from 
the full 164 patient cohort for comparison. 
 
7.4 Discussion 
7.4.1 Insulin sensitivity variability 
Both cohort and per-patient results suggest that ICU patients have significantly 
lower and more variable insulin sensitivity on day 1 than later in their stay. 
Further analysis showed that this day 1 result was primarily influenced by the 
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first 12-18 hours of ICU stay. Over this time, rapid improvements in insulin 
sensitivity level and variability occur so that there was no statistically significant 
difference between 18-24 hours and day 2. From day 2 onwards, changes in SI 
level and variability are not as large and of limited clinical and statistical 
significance.  
 
Within the analyses, there were some differences in significance between cohort 
and per-patient results for comparisons after day 2. The overall findings noted in 
the preceding paragraph are the only clear, consistent trends across both 
analyses.  
 
The counter-regulatory hormones: cortisol, glucagon, the catecholamines, as well 
as growth hormone, are significantly elevated almost immediately post critical-
insult, but decline rapidly over the first 12-48 hours [Chernow et al. 1987; Frayn 
1986; Jaattela et al. 1975; Weissman 1990]. These hormones are known to cause 
increased hepatic glucose production, inhibition of insulin release and peripheral 
insulin resistance [Weissman 1990], all of which cause a reduction in the model-
based SI metric used in this study. Hence, the low but rapidly increasing insulin 
sensitivity seen over the first 12-18 hours of ICU stay is likely due to the acute 
counter-regulatory response to critical illness. 
 
Cardiovascular surgical patients were examined in particular, as they constitute 
one of the largest single diagnostic subgroups treated with the SPRINT protocol 
[Chase et al. 2008] and are common in many study cohorts. Additionally, they 
have shown potential benefit from TGC, independent of broader cohorts 
[Furnary et al. 1999; Van den Berghe et al. 2006a; Van den Berghe et al. 2001]. 
The CVS cohort demonstrated the same increased level and reduced variability 
of SI over time as the full cohort. More importantly, the CVS cohort exhibited 
lower and more variable SI than the full cohort for the first few days of stay. 
 
The significantly lower and more variable results of the CVS cohort during the 
first 2 days may result from the high level of stress and inflammation inherent to 
cardiovascular surgery, particularly when cardiopulmonary bypass is used 
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[Warren et al. 2009].  Additionally, cardiovascular disease and insulin resistance 
(often undiagnosed) go hand-in-hand [Alberti et al. 2005; Cowie et al. 2009] and 
could account for some of the observed effect.  
 
Time in this study was referenced from the commencement of SPRINT, rather 
than ICU admission. However, the difference between admission time and 
commencing SPRINT was generally very short as noted in Section 7.2.2. Hence, 
these results are applicable to the first few hours and days of ICU stay.  
 
7.4.2 Reducing the impact of SI variability on outcome glycaemia 
This analysis investigates SI variability resulting primarily from physiological 
changes in patients’ external to the glucose-insulin system model. Equally, where 
the impact of the physiological and hormonal changes is evident in the model, 
they cannot be directly measured at the bedside or in real-time to enable better 
models. Hence, rather than modifying or expanding the model, improved means 
of applying or implementing it during control and analysis are necessary. 
 
The primary use of this glucose-insulin system model is enabling model-based 
TGC in critical care. During TGC, greater variability with lower SI early in a 
patient’s stay greatly increases the insulin required to maintain control. High 
levels of circulating insulin coupled with the observed variability in insulin 
sensitivity result in increased glycaemic variability and an increased risk of 
hypoglycaemia, particularly during the first 24 hours of ICU stay. Both glycaemic 
variability and hypoglycaemia have been associated with poor outcomes in the 
ICU [Egi et al. 2006; Egi et al. 2010; Hermanides et al. 2010; Krinsley 2008]. 
 
There are two complementary ways to reduce the impact of SI variability on 
outcome glycaemia. The simplest, intervention-based method relies on adapting 
the control protocol to minimise the impact of SI variability. Greater blood 
glucose measurement frequency and conservative insulin dosing can lower the 
impact of SI variability on glycaemia and risk [Lonergan et al. 2006]. Modulation 
of carbohydrate nutrition, within limits [Krishnan et al. 2003], can also reduce 
the need for exogenous insulin to better manage glycaemia [Suhaimi et al. 2010]. 
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Complementing the intervention-based methods are model-based methods for 
reducing the impact of SI variability. The controllers currently used in the 
Christchurch ICU are implemented on tablet computers and use the ICING-2 
model to forecast outcome BG for a series of possible interventions and then 
select the most optimal [Evans et al. 2011]. This forward-prediction is enabled 
by a stochastic model of SI for hour n+1, based on the value identified for hour n 
[Lin et al. 2008]. With the understanding gained from this analysis, several 
stochastic models could be used based on day of stay and/or diagnosis, rather 
than just one to improve performance. 
 
Using separate stochastic models where SI level and variability are atypical 
would allow the controller to capture this behaviour and titrate insulin and 
nutrition accordingly. Results from this investigation suggest that at least 3 
stochastic models would be appropriate: 
 
1. All patients, for use more than 24 hours after ICU admission (day 2 on). 
2. All non-CVS patients for use between ICU admission and 24 hours. 
3. CVS patients for use between ICU admission and 24 hours. 
 
Further investigation may identify other important diagnostic subgroups that 
would benefit from separate stochastic models. However, to be effective, each 
stochastic model must be generated from a sufficient number of data points. As a 
guide to a possible lower limit, Lin et al. [2006] validated a model based on 1300 
hours of data from 18 ICU patients.  
 
The stochastic model for all patients more than 24 hours after ICU admission 
would likely look very similar to the current model. However, models for use 
during the first 24 hours in the ICU for both CVS and other patients would have 
wider bounds reflecting the increased hour-to-hour variability. The result of this 
widening, under the current STAR protocol [Evans et al. 2011] would be more 
conservative and consistent insulin dosing to manage the risk of glycaemic 
variability and hypoglycaemia.  
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7.5 Summary 
The results of this study indicate that critically ill patients have significantly 
lower and more variable insulin sensitivity on day 1 than later in their ICU stay, 
particularly during the first 12-18 hours. Cardiovascular surgery patients were 
shown to be even lower and more variable than the general ICU cohort 
(including themselves). This effect is likely due to the acute counter-regulatory 
response to critical illness. Greater variability with lower SI early in a patient’s 
stay greatly increases the insulin required, potential glucose flux due to variation 
in SI, and thus the risk of glycaemic variability and hypoglycaemia. Both 
glycaemic variability and hypoglycaemia have been associated with poor 
outcomes in the ICU. 
 
To manage this extrinsic SI variability and its evolution over time, the use of 
several stochastic models was proposed. Using different models for the early 
part of ICU stay and for different diagnostic subgroups would permit control 
algorithms to reduce the impact of the SI variability on outcome glycaemia. The 
three models proposed from this analysis were:  
 
1. All patients, for use more than 24 hours after ICU admission. 
2. All non-CVS patients for use between ICU admission and 24 hours. 
3. CVS patients for use between ICU admission and 24 hours. 
 
Additionally, intervention-based measures such as greater blood glucose 
measurement frequency, conservative insulin dosing and modulation of 
carbohydrate nutrition can lower the impact of SI variability on glycaemia and 
risk.  
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Chapter 8. Drug Therapies 
Similar to the impact of patient condition, a number of drug therapies often 
administered in the ICU are known to impact SI in healthy individuals. The use of 
these drugs may add to the extrinsic SI variability that needs to be mitigated for 
optimal use of the ICING-2 model in analysis and real-time control applications.  
 
8.1 Introduction 
Glucocorticoids and β-blockers are two drug therapies common to critical care. 
Glucocorticoid steroids are administered to treat a variety of inflammatory and 
allergic disorders [Rhen & Cidlowski 2005]. β-blockers are used to reduce 
cardiac output and essential hypertension [Khan 2007]. Both classes of drugs 
have been shown to have an effect on insulin sensitivity in healthy individuals 
[Binnert et al. 2004; Elliott & Meyer 2007; Jacob et al. 1996; Larsson & Ahren 
1996; Nicod et al. 2003; Pagano et al. 1983; Perry et al. 2003; Pollare et al. 1989]. 
However, there is a lack of data about whether these effects are equally valid, or 
equally large, for critically ill patients 
 
The effects of different glucocorticoids on the insulin sensitivity of healthy 
subjects are fairly consistent. Several studies reported 30-62% decreases in 
insulin sensitivity of healthy subjects after short-term administration of 
dexamethasone [Binnert et al. 2004; Larsson & Ahren 1996; Nicod et al. 2003; 
Perry et al. 2003]. Pagano et al. [1983] documented a similar change with 
prednisone.  
 
In contrast, the reported effects of β-blockers on insulin sensitivity range from 
detrimental to beneficial, depending on the specific drug [Jacob et al. 1996; 
Sarafidis & Nilsson 2006]. Thus, while the impact of different glucocorticoids on 
SI can be analysed together, β-blockers must be treated separately. This study 
analyses the impact of metoprolol on SI, as it is currently one of the most 
commonly used β-blockers in the Christchurch intensive care unit (ICU) 
 
74 
 
Metoprolol is a competitive antagonist to the β1-adrenergic receptor 
[Kindermann et al. 2004] and is indicated for use in several diseases of the 
cardiovascular system. Three studies have investigated the effects of metoprolol 
on insulin sensitivity using the gold-standard euglycaemic-hyperinsulinaemic 
clamp method [Falkner & Kushner 2008; Jacob et al. 1996; Pollare et al. 1989]. 
Two of the studies [Jacob et al. 1996; Pollare et al. 1989] reported reductions in 
insulin sensitivity of 14-27% associated with metoprolol in non-diabetic 
individuals when used to treat hypertension. The study by Falkner et al. [2008] 
showed a statistically non-significant 2% reduction in insulin sensitivity due to 
metoprolol in type-2 diabetic subjects. 
 
There is a lack of data about whether the impact of glucocorticoids and 
metoprolol on SI are equally valid, or equally large, for critically ill patients. In 
terms of glucose metabolism, critically ill patients are very similar to type 2 
diabetic individuals, thus, studies on healthy individuals may not translate fully. 
The aim of this investigation was to assess the impact of these agents, on the 
level and variability of SI in critically ill patients. Once the effects were 
understood, means to mitigate the impact on glycaemic control could be 
implemented.  
 
8.2 Subjects and Methods 
These studies were conducted as retrospective analyses of data from patients 
admitted to the Christchurch Hospital ICU between 2005 and 2007. The analyses 
of glucocorticoid and metoprolol data were conducted independently. Two 
matched cohorts were used for each analysis. All of the patients spent at least 24 
hours on the SPRINT glycaemic control protocol [Chase et al. 2008].  
 
The Upper South Regional Ethics Committee, New Zealand granted approval for 
the audit, analysis and publication of this data. 
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8.2.1 Glucocorticoid study subjects 
Two cohorts of 40 patients were used for the glucocorticoid analysis. The cohort 
details are shown in Table 8.1. The steroid cohort received one or more of the 
steroids listed in Table 8.2. Patients were excluded if they received β-blockers or 
ACE-inhibitors, as these therapeutic agents can affect glucose metabolism and 
insulin sensitivity [Deibert & DeFronzo 1980; Henriksen & Jacob 2003a; Rizza et 
al. 1980]. A control cohort of 40 patients, who did not receive any glucocorticoid, 
β-blocker or ACE-inhibitor therapy, was also selected so that the overall cohort 
parameters (age, sex, outcome, severity of illness), matched the steroid cohort as 
closely as possible. 
 
Table 8.1. Glucocorticoid analysis cohorts. Data are shown as median [interquartile 
range] where appropriate. P-values were calculated using Fisher’s exact test for 
categorical data and the Wilcoxon rank-sum test for continuous data. 
  
Control 
Cohort-S 
Steroid 
Cohort 
 p-value 
N 40 40   
Hospital Mortality (%) 38 40 1.00 
Operative/Non-operative 12/28 11/29 1.00 
Gender M/F 23/17 20/20 0.65 
AGE (yrs) 65.5 [51-73] 61.5 [52-74] 0.74 
Diabetic history (T1DM/T2DM) 3/5 1/4 0.67 
APACHE II Score 20.0 [18-27] 22.5 [18-28] 0.83 
APACHE II Risk of death (%) 38.3 [23-64] 39.7 [23-62] 0.95 
Patient time on SPRINT (hrs) 103 [42-155] 102 [66-153] 0.63 
Patient median blood glucose (mmol/l) 5.7 [5.3-6.1] 5.9 [5.3-6.3] 0.49 
Total time on SPRINT (hrs) 5259 4914   
Total time on Steroids (hrs) 0 3489   
Equivalent daily dose of hydrocortisone (mg/d) 0 200 [80-200]   
 
Table 8.2 lists the potencies and half-lives used in analysis of the steroids for this 
research. Relative potencies and biological half-lives of the glucocorticoids were 
based on data for anti-inflammatory effects as these closely parallel the effects 
on glucose metabolism [Schimmer & Parker 2006]. The relative potencies enable 
calculation of the equivalent hydrocortisone dose in Table 8.1. 
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Table 8.2. Glucocorticoids and their properties used in this study [Derendorf et al. 
1993; Melby 1977; Schimmer & Parker 2006]. 
Compound 
Relative anti-
inflammatory potency 
Duration of action / 
Effective biological half-life 
(hrs) 
Hydrocortisone 1 10 
Prednisone 4 24 
Prednisolone 4 24 
Methyl-prednisolone 5 24 
Dexamethasone 25 45 
 
 
8.2.2 Metoprolol study subjects 
Two cohorts of 17 patients were used for the metoprolol analysis. The cohort 
details are shown in Table 8.3. The treatment cohort did not receive any other β -
blockers besides metoprolol (oral or intravenous) and did not receive 
glucocorticoid or ACE-inhibitor treatment. The restrictions on other treatments 
significantly reduced the number of patients eligible for consideration as 
hypertension is often treated with a combination of drugs. However, these other 
agents are known to affect glucose metabolism [Henriksen & Jacob 2003b; Lithell 
1992; Lithell 1995; Pollare et al. 1989; Pretty et al. 2010] and thus may have 
confounded the results. Similarly to the glucocorticoid analysis, a control cohort 
was selected to match overall parameters. 
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Table 8.3. Metoprolol analysis cohorts. Data are shown as median [interquartile 
range] where appropriate. P-values were calculated using Fisher’s exact test for 
categorical data and the Wilcoxon rank-sum test for continuous data. 
  
Control 
Cohort-M 
Metoprolol 
Cohort 
 p-value 
N 17 17   
Hospital Mortality (%) 35% 24% 0.71 
Operative/Non-operative 4/13 4/13 1.00 
Gender M/F 12/5 13/4 1.00 
AGE (yrs) 63 [45-71] 57 [45-67] 0.69 
Diabetic history (T1DM/T2DM) 1/2 0/1  0.60 
APACHE II Score 19 [16-27] 20 [16-26] 0.70 
APACHE II Risk of death (%) 33.6 [20-53] 40.8 [13-61] 0.74 
Patient time on SPRINT (hrs) 141 [88-293] 178 [73-339] 0.45 
Patient median blood glucose (mmol/l) 5.7 [5.0-6.4] 5.8 [5.1-6.5] 0.11 
Total time on SPRINT (hrs) 3369 4126   
Total time on Metoprolol (hrs) 0 3079   
Daily dose of Metoprolol (mg/d) 0 100 [50-200]   
 
 
8.2.3 Analyses 
SI level was identified hourly using the ICING-2 model for each patient. 
Variability of SI was calculated as the hour-to-hour percentage change in SI 
(Δ%SI), defined in Equation 8.1 from Chapter 7.  
 
           
           
   
 8.1 
 
SI level and variability were compared between matched cohorts to determine 
the impact of the drug therapies. Overall cohort comparisons of insulin 
sensitivity were possible with the matched cohorts. However, as individual 
patients could not be explicitly matched, percentile patients were used as a 
surrogate for explicit per-patient analyses as described by Pretty et al. [2010]. As 
the percentile patient distributions are not sampled data and are composed from 
an arbitrary number of points, they cannot fairly be compared with standard 
hypothesis tests for statistical significance. However, comparison of percentile 
patients between cohorts does provide confirmation of the cohort analysis 
results. 
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Where patients did not receive a drug therapy for the entire time they were on 
SPRINT, SI was considered to be affected by the drug for some period after the 
last dose. For glucocorticoids, this period was one effective biological half-life 
(Table 8.2). Metoprolol was considered to affect SI for 12 hours following the last 
dose. Both these periods are relatively short and the drugs have been reported to 
remain active for longer periods. The short periods ensured that any effects on SI 
had not decreased so far as to be undetectable.   
 
The effective biological half-lives of the glucocorticoids listed in Table 8.2 are the 
median values of ranges reported by Melby [1977]. Metabolism of metoprolol is 
extremely variable between patients [Chrysostomou & Kazmerski 2008]. 
However, a number of studies have shown that oral doses of 100-200 mg/day 
result in a duration of action for heart-rate and blood-pressure effects of 12-
24 hours [Åblad et al. 1975; Freestone et al. 1982; Johansson et al. 1980; 
Johnsson et al. 1975; Reybrouck et al. 1978]. Previous investigations have 
targeted the effects of chronic metoprolol dosing on insulin sensitivity, showing 
that a reduction in SI is present even 20 hours after the last dose [Jacob et al. 
1996; Pollare et al. 1989]. The variable and prolonged effects of both drugs made 
comparison of the SI values within each cohort between periods on- and off 
treatment infeasible, as there were few hours of data that could confidently be 
considered unaffected by the treatment. 
 
SI level and variability distributions are compared using CDFs and non-
parametric statistics. Comparisons were generally made using the Wilcoxon 
rank-sum test (Mann-Whitney U-test) for continuous data and two-sided Fisher’s 
exact test for categorical data. Hour-to-hour SI variability was compared using 
the Kolmogorov-Smirnov test as it has more power to detect differences in the 
shape of distributions than the rank-sum test when median values are similar. P-
values of 0.05 were considered statistically significant. 
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8.3 Results 
8.3.1 Glucocorticoid analysis 
Analysis of changes to SI level and variability associated with glucocorticoid 
treatment were investigated using two cohorts with matched overall 
parameters. The temporal location of SI data compared in this Section was also 
similar between cohorts. For the steroid cohort, 18% and 35% of the SI values 
considered affected by the drug came from the first 24 and 48 hours of SPRINT, 
respectively.  The corresponding proportions for the control cohort were 19% 
and 34%. Hence, the results are unlikely to have been confounded by the timing 
of the treatments. 
 
8.3.1.1 SI level analysis 
SI level in patients receiving glucocorticoids was lower than control patients in 
an overall cohort comparison. The median value of the ‘on-steroid’ data was 33% 
lower than the control data (2.83x10-4 and 4.19x10-4 l/mU.min, p < 0.0001). The 
left panel of Figure 8.1 shows the CDFs for both cohorts. There is a clear 
separation between the control cohort and the steroid cohort (while receiving 
steroids) distributions at all percentile values.   
 
The CDF of SI level for the steroid cohort is also shown for periods when the 
patients were not receiving steroid treatment, for the purposes of comparison 
only. This data is primarily composed of SI values from periods after patients had 
completed glucocorticoid therapy. Only 2% of data was from the first 24 hours of 
SPRINT (compared to 18-19% for the on-steroid and control data). This data is 
likely biased by improved patient condition, as described in Chapter 7, and thus 
may not make a fair comparison with on-steroids hours. In addition, the chosen 
on/off steroids cut-off point of one half-life means that some of this data is likely 
still affected by exogenous glucocorticoids.  
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Figure 8.1. CDFs of SI level for the control and steroid cohorts. The left panel shows 
the overall cohort comparison. The right panel shows the 25th-, 50th- and 75th 
percentile patients. 
 
Analysis of the percentile patient data also shows a reduction in SI at all 
percentiles for patients receiving glucocorticoids. Figure 8.2 (right panel) shows 
the CDFs for the 25th, 50th and 75th-percentile patients from both cohorts. The 
reductions in median SI for the percentile patients receiving steroids were 22%, 
26%, and 17% for 25th-, 50th- and 75th percentile patients, respectively. While the 
percentile patient distributions cannot be compared with standard hypothesis 
tests, they do provide confirmation of the magnitude of the cohort result. 
 
8.3.1.2 SI variability analysis 
Figure 8.2 shows that glucocorticoid therapy was associated with an increase in 
the hour-to-hour variability of SI compared to the controls in both cohort and 
percentile patient analyses. The 90% range (5th-95th percentile) of Δ%SI for the 
steroid cohort was 50% larger than the control cohort (p < 0.0001). For the 
percentile patients, steroid treatment was associated with increases to the 90% 
range of 27%, 50% and 39% for the 25th-, 50th- and 75th percentile patients, 
respectively. 
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Figure 8.2. CDFs of SI hour-to-hour variability for the control and steroid cohorts. The 
left panel shows the overall cohort comparison. The right panel shows the 25th-, 50th- 
and 75th percentile patients (top to bottom). 
 
It is interesting to note that the variability of the steroid cohort while not 
receiving steroids is almost identical to the control cohort. However, as 
mentioned in the preceding section, improving patient condition likely 
confounds this comparison. 
 
8.3.2 Metoprolol analysis 
The temporal location of SI data compared in this analysis was not as well 
matched as for the glucocorticoid analysis. For the metoprolol cohort, 6% and 
10% of the SI values considered affected by the drug were during the first 24 and 
48 hours of SPRINT, respectively.  The corresponding proportions for the control 
cohort were 13% and 23%. The disparity between these values and those of the 
glucocorticoid analysis cohorts is primarily due to the median length of time 
spent on the SPRINT protocol being 40-80% longer for patients in the 
metoprolol analysis. The disparity between the treatment and control cohorts 
may be due to the clinical practise for administering metoprolol. However, with 
only 6-13% of the total hours occurring during the first 24 hours of SPRINT, 
evolving patient condition is unlikely to confound the results. 
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8.3.2.1 SI level analysis 
SI level in patients receiving metoprolol was typically lower than control patients 
in an overall cohort comparison, although the difference was noticeably less than 
in the glucocorticoid analysis. Median cohort insulin sensitivity was reduced 
10.5% from 4.28x10-4 to 3.83x10-4 l/mU.min (p < 0.0001). Figure 8.3 (left panel) 
shows the CDFs for both cohorts. There was a clear separation between the 
control cohort and the metoprolol cohort (while receiving metoprolol) 
distributions between the 10th- and 90th percentile values. Outside this range, 
factors such as variable metabolism and dosing of metoprolol between patients, 
as well as patient condition, may be the cause of the SI distributions crossing 
over each other. 
 
Figure 8.3. CDFs of SI level for the control and metoprolol cohorts. The left panel 
shows the overall cohort comparison. The right panel shows the 25th-, 50th- and 75th 
percentile patients. 
 
The CDF of SI level for the metoprolol cohort is also shown for periods when the 
patients were not receiving treatment, although only for comparison. As with the 
glucocorticoid analysis, the variable metabolism and selected on/off metoprolol 
cut-off point of 12-hours means that some of this data is likely still affected by 
the drug.  
 
Analysis of the percentile patient data showed no clinically significant reduction 
of SI for patients receiving metoprolol. Figure 8.3 (right panel) shows the CDFs of 
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the 25th, 50th and 75th-percentile patients from both cohorts, where the 
differences at the median were -5%, 7% and -4%, respectively. Note that a 
positive value represents a reduction in SI for the metoprolol percentile patient 
compared to the control. 
 
8.3.2.2 SI variability analysis 
Figure 8.4 shows that metoprolol was not associated with any change in hour-to-
hour SI variability on an overall cohort basis (left panel). The 90% range of Δ%SI 
for the metoprolol cohort was 8.5% lower than the control cohort. However, this 
difference was not statistically significant (p = 0.44, Kolmogorov-Smirnov test). 
 
Figure 8.4. CDFs of SI hour-to-hour variability for the control and metoprolol cohorts. 
The left panel shows the overall cohort comparison. The right panel shows the 25th-, 
50th- and 75th percentile patients (top to bottom). 
 
The variability of the metoprolol percentile patients was not very different from 
the controls. Differences in the 90% ranges were 12%, 12% and -8% for 25th-, 
50th- and 75th percentile patients, respectively. The negative value indicates that 
the 90% range was smaller for the metoprolol percentile patient than the control 
percentile patient. 
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8.4 Discussion 
These analyses indicate that both glucocorticoid and metoprolol administration 
in critically ill patients are associated with reductions in SI level. However, the 
reductions are considerably less than those reported by studies on healthy 
subjects. Additionally, there is an increase in hour-to-hour variability of SI 
associated with glucocorticoid use, but not with metoprolol.  
 
8.4.1 Glucocorticoids 
Both cohort and percentile patient analyses indicate reductions in SI associated 
with glucocorticoid treatment of 17-33%. These values are significantly less than 
the 30-62% reductions in insulin sensitivity reported in healthy subjects 
[Binnert et al. 2004; Larsson & Ahren 1996; Nicod et al. 2003; Pagano et al. 1983; 
Perry et al. 2003]. Differences in steroid dosages are unlikely to be responsible 
for the disparity, as the patients in this study received higher equivalent daily 
doses than the healthy subjects in the published studies referenced. 
 
The dosage and particular drug received by patients in this study varied between 
individuals and over the course of treatment. However, over the entire cohort 
the median daily dose of glucocorticoid was equivalent to 200 mg/d (IQR: 80-
200 mg/d) of hydrocortisone per patient. In contrast, healthy subjects in the 
published studies  [Binnert et al. 2004; Nicod et al. 2003; Pagano et al. 1983; 
Perry et al. 2003] were administered either 2 mg/d of dexamethasone, 
equivalent to 50 mg/d of hydrocortisone [Binnert et al. 2004; Nicod et al. 2003; 
Perry et al. 2003], or 15 mg/d of prednisone, equivalent to 60 mg/d of 
hydrocortisone [Pagano et al. 1983]. Larsson and Ahren [1996] reported a 54% 
reduction in insulin sensitivity with 6 mg/d dexamethasone (equivalent to 150 
mg/d hydrocortisone). Hence, the results of this study show lower reductions in 
SI compared to results reported for healthy individuals, despite glucocorticoid 
doses that are 1.3-4.0 times larger. This result indicates a significantly reduced 
impact of glucocorticoids on insulin sensitivity in the critically ill. 
 
In addition to the reduced SI level, a 27-50% increase in hour-to-hour variability 
was also associated with glucocorticoid treatment. However, there are no known 
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published studies investigating the effects of glucocorticoids on SI variability 
with which to compare these results. 
 
Although a great deal of research has been conducted on the effects of 
glucocorticoids on insulin sensitivity, very little is known about the specific 
mechanisms of action. Glucocorticoids reduce insulin sensitivity directly, as well 
as disrupting glucose metabolism at the liver, pancreas and peripheral tissues. 
Several studies have indicated that decreased cellular glucose uptake is at least 
partly responsible [Pagano et al. 1983; Paquot et al. 1995; Tappy et al. 1994]. 
Impaired intracellular glucose oxidation has also been shown to have a role in 
glucocorticoid induced insulin resistance [Paquot et al. 1995; Tappy et al. 1994]. 
In addition, endogenous glucose production is enhanced by glucocorticoids 
[Besse et al. 2005; Binnert et al. 2004; Nicod et al. 2003; Pagano et al. 1983], 
possibly through their enhancement of the synthesis and action of 
catecholamines [Barth et al. 2007; Paquot et al. 1995; Rizza et al. 1980; Taylor & 
Hancox 2000]. 
 
Delaunay et al. [1997] and Lambillotte et al. [1997] showed that glucocorticoids 
suppress insulin secretion through a direct action on the pancreatic β-cells. 
However, the results from Binnert et al. [2004], Besse et al. [2005] and Nicod et 
al. [2003] show a clear increase in glucose-induced insulin secretion after 
administration of dexamethasone. It is possible that there are competing 
pathways with the net effect depending upon specific physiological conditions.  
 
In summary, the elevated levels of counter-regulatory hormones often present in 
critically ill patients [Bessey & Lowe 1993; Mizock 2001] may cause saturation of 
the physiological impact of these agents. For example, the increased endogenous 
glucose production associated with glucocorticoids may be blunted as EGP is 
often already significantly enhanced in critically ill patients. Healthy individuals, 
in contrast, typically have much lower levels of circulating catecholamines and 
cortisol. Therefore, they may show more significant reductions in SI and 
increases in EGP with additional, exogenous glucocorticoids than critically ill 
patients.  
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8.4.2 Metoprolol 
Both cohort and percentile patient analyses indicate changes to SI associated 
with metoprolol treatment ranging from a 5% increase to a 10.5% decrease, 
compared with controls. These values are significantly less than the 14-27% 
reductions in insulin sensitivity due to metoprolol, when used to treat essential 
hypertension in otherwise healthy individuals [Jacob et al. 1996; Pollare et al. 
1989]. A similar study in hypertensive subjects with non-insulin dependent 
diabetes mellitus [Falkner & Kushner 2008] reported a statistically non-
significant 2% reduction in insulin sensitivity associated with metoprolol. 
Differences in metoprolol dosages are unlikely to be responsible for the disparity 
as the patients in this study received similar daily doses to the healthy subjects 
in the previously published studies. 
 
The dosage received by patients in this study varied between individuals and 
over the course of treatment. However, over the entire cohort the median daily 
dose of metoprolol was 100 mg/d (IQR: 50-200 mg/d). This dose range is 
comparable to the doses of 200, 100 and 50-200 mg/d administered in the 
studies by Pollare et al. [1989], Jacob et al. [1996] and Falkner et al. [2008], 
respectively. Hence, the reduction in impact of metoprolol on SI is unlikely to be 
a result of the dosing.  
 
In the study by Falkner et al. [2008], metoprolol was added to the participants’ 
existing hypertension treatment regime. Studies have indicated that these other 
hypertension treatments; angiotensin-converting enzyme (ACE) inhibitors or 
angiotensin II receptor blockers (ARBs), lead to improved insulin sensitivity 
[Lithell 1992; Perkins & Davis 2008]. Therefore it is possible that reductions in 
insulin sensitivity associated with metoprolol were mitigated by increases in 
insulin sensitivity due to the concomitant use of ACE-inhibitors and ARBs, 
resulting in no significant change, as reported by Falkner et al. [2008]. 
 
The mechanisms by which β-adrenoceptor antagonist treatment (β-blockade) 
modifies insulin sensitivity are not fully understood. Both Pollare et al. [1989] 
and Jacob et al. [1996] suggest a possible haemodynamic explanation for the 
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reduced insulin sensitivity. The reduced heart-rate and contractility caused by 
metoprolol lowers blood flow to the skeletal muscles. Thus, there is lower 
glucose availability to these prime target tissues for glucose disposal at given 
insulin levels [Jacob et al. 1996; Pollare et al. 1989], and an apparent reduction in 
insulin sensitivity, as defined by the rate of insulin mediated glucose uptake. 
Jacob et al. [1996] also suggest that β-blockade appears to reduce insulin 
clearance rates and the resulting hyperinsulinaemia may down-regulate insulin 
receptors, directly lowering insulin sensitivity. The actual mechanism of action 
may be a combination of these factors or an as yet unidentified pathway. 
 
As discussed in Section 8.4.1, the critical condition of the patients in this study 
may moderate the physiological impact of the proposed mechanisms of action 
attributed to metoprolol. Critically ill patients already have significant peripheral 
insulin resistance [Black et al. 1982] and may thus be less likely to show further 
large reductions caused by reduced blood flow or receptor down-regulation 
compared to healthy subjects. This saturation of the physiological effect may 
explain the limited reduction of SI in critically ill patients seen in this study, 
compared with ‘healthy’ individuals. 
 
8.4.3 Impact of drug therapies on SI and outcome glycaemia 
The results presented in this study indicate that metoprolol is associated with a 
small effect on the insulin sensitivity of critically ill patients, but it is unlikely to 
be clinically significant. The 17-33% reduction in SI level and increased 
variability associated with glucocorticoids is clinically significant and large 
enough to warrant measures to mitigate these changes on outcome glycaemia. 
 
The primary use of this glucose-insulin system model is enabling model-based 
tight glycaemic control in critical care. In this context, increased variability and 
lower levels of SI greatly increases the insulin required to maintain blood 
glucose concentrations in a desired band. High levels of circulating insulin 
coupled with the observed variability in insulin sensitivity result in increased 
glycaemic variability and an increased risk of hypoglycaemia. Importantly, 
glycaemic variability and hypoglycaemia have been associated with poor 
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outcomes in the ICU [Egi et al. 2006; Egi et al. 2010; Hermanides et al. 2010; 
Krinsley 2008]. 
 
The 17-33% reductions in SI level and 27-50% increases in SI variability 
associated with glucocorticoids are of similar magnitude to the changes seen 
over the first few days of ICU stay reported in Chapter 7. Therefore, the two 
measures proposed in Chapter 7 are also applicable to reducing the variability of 
outcome glycaemia for patients receiving glucocorticoids.  
 
Intervention-based methods rely on adapting the control protocol to minimise 
the impact of SI variability. Greater blood glucose measurement frequency and 
conservative insulin dosing can lower the impact of SI variability on glycaemia 
and risk [Lonergan et al. 2006]. Modulation of carbohydrate nutrition, within 
limits [Krishnan et al. 2003], can also reduce the need for exogenous insulin to 
better manage glycaemia [Suhaimi et al. 2010]. 
 
Model-based methods, employing separate stochastic models where SI level and 
variability are atypical were also proposed. Separate models would allow the 
controller to capture this behaviour and titrate insulin and nutrition accordingly. 
Results from this investigation suggest that an additional stochastic model to the 
three proposed in Chapter 7 be generated for patients receiving glucocorticoid 
treatment. 
 
The limited reduction in SI seen in this investigation is thought to result from the 
saturation of the physiological impact of endogenous cortisol and the 
catecholamines due to elevated levels in critical illness. The impact of exogenous 
glucocorticoids on SI during the acute phase of critical illness (0-24 hours) may 
thus be further reduced. Hence, a single additional stochastic model for use more 
than 24 hours after ICU admission, while receiving glucocorticoids, is likely 
sufficient. 
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8.5 Summary 
The results presented in these analyses indicate that two drug therapies, 
relatively common to the ICU, have less impact on SI in critically ill patients than 
would be presumed from published studies on healthy subjects. Treatment with 
glucocorticoids was associated with 17-33% reductions in SI level, significantly 
less than the 30-62% reductions in insulin sensitivity reported in healthy 
subjects. In addition to the reduced SI level, glucocorticoid treatment was also 
associated with 27-50% increased hour-to-hour variability. 
 
Treatment with metoprolol was associated with changes to SI level ranging from 
a 5% increase to a 10.5% decrease compared with the control cohort. These 
values were also less than the 14-27% reductions reported for otherwise 
healthy, hypertensive subjects. At the levels observed in this study, the effects of 
metoprolol on SI are unlikely to be clinically significant in critically ill patients. 
 
The limited reductions in SI observed in these analyses may be due to the 
saturation of the physiological impact of glucocorticoids and metoprolol in 
critically ill patients. Critically ill patients already have significant peripheral 
insulin resistance, and other metabolic changes captured by the SI parameter 
and may therefore be less likely to show further large reductions caused by these 
drugs in healthy subjects. 
 
To manage the extrinsic SI variability associated with glucocorticoid treatment, 
and reduce the impact on outcome glycaemia, the two methods described in 
Chapter 7 are applicable. A single additional stochastic model for use more than 
24 hours after ICU admission, while receiving treatment, would permit control 
algorithms to mitigate the effects. Additionally, intervention-based measures 
such as greater blood glucose measurement frequency, conservative insulin 
dosing and modulation of carbohydrate nutrition can lower the impact of SI 
variability on glycaemia and risk. 
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Chapter 9. Measurement Errors 
The final source of extrinsic SI variability investigated in this thesis results from 
errors in blood glucose measurement timing and concentration. These factors 
can alter the identified values of SI, which in turn may impact glycaemic 
variability during control.  
9.1 Introduction 
In the busy ICU environment, blood glucose measurements are rarely taken at 
the exact, scheduled time during glycaemic control. Sensor errors add 
uncertainty to measured BG concentration. Both errors propagate through to the 
value of SI during parameter identification and impact overall SI variability.  
 
SI variability from timing error can affect glycaemic control through the 
stochastic models in two ways. Stochastic models are currently built with data 
from the SPRINT tight glycaemic control study [Chase et al. 2008]. The maximum 
resolution for measurement data during SPRINT was one hour. Therefore, any 
discrepancies between scheduled and actual measurement times smaller than 
one hour are unknown and can impact the level and variability of SI, and thus, 
the form of the resulting stochastic model.  
 
The one-hour resolution of SPRINT necessitates a corresponding resolution for 
stochastic models derived from the data. Thus, while the more recent, 
computerised and model-based, STAR protocol [Evans et al. 2011] records more 
accurate measurement times, the interventions are determined by 1, 2 and 3 
hour forward prediction of BG, based on the stochastic models derived from 
SPRINT. Therefore, if measurements are not performed at the scheduled time, 
the likelihood of achieving the predicted BG concentration is reduced, 
particularly for infused insulin, where the total insulin administered is time 
dependant. 
 
Even with perfect timing, BG measurement errors also affect the identified 
values of SI. Typical point-of-care glucometers have measurement errors in the 
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range 2-10% [Abbott 2010; Arkray 2007; Roche 2007,2008; Solnica et al. 2003]. 
The glucometer used in the Christchurch Hospital ICU (Super-Glucocard II, 
Arkray Inc., Japan) typically has an error of less than 10% [Arkray 2007]. The 
uncertainty in BG concentration resulting from sensor error impacts the 
identified values of SI through altering the glucose flux that must be balanced by 
the insulin-mediated glucose disposal term in the glucose-insulin system model. 
 
The objective of this investigation was to assess the impact of both measurement 
timing and sensor error on SI variability. Having quantified the impact on SI, 
decisions could be made about whether means to reduce the magnitude of these 
errors, such as improved BG sensors, are necessary for improved control or 
safety. Equally, existing or new protocols might be optimised to be robust in the 
face of these errors. 
 
9.2 Subjects and Methods 
9.2.1 Patients 
This study was conducted as retrospective analyses of data from 270 patients 
admitted to the Christchurch Hospital ICU between 2005 and 2007. All patients 
were on the SPRINT protocol for at least 24 hours [Chase et al. 2008]. Table 9.1 
shows a summary of the cohort details.  
 
Table 9.1. Cohort details summary. Data are shown as median [interquartile range] 
where appropriate. 
N 270 
Age (yrs) 65 [49-73] 
Gender (M/F) 165/105 
Operative/Non-operative 104/166 
Hospital mortality (%) 27% 
APACHE II score 19 [16-25] 
APACHE II ROD (%) 30 [17-53] 
Diabetic status (T1DM/T2DM) 10/34 
ICU length of stay (hrs) 160 [77-346] 
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The Upper South Regional Ethics Committee, New Zealand granted approval for 
the audit, analysis and publication of this data. 
 
9.2.2 Error modelling 
9.2.2.1 Timing error 
Measurements and interventions during the SPRINT protocol were 1 or 2-hourly 
and intended to be taken on the hour. These measurements were recorded by 
hand and attributed to the nearest hour on the standard paper 24-hour charts 
used in the Christchurch Hospital ICU. Hence, any discrepancies between the 
actual measurement time and the ‘nearest hour’ were lost. 
 
Recent pilot trials of the STAR protocol at Christchurch Hospital ICU [Evans et al. 
2011] provide data to generate a timing error model (1651 measurements on 20 
patients). Measurements and interventions during STAR are designed to be 1, 2 
or 3-hourly, as selected by clinical staff. However, because the protocol is 
implemented on a tablet computer, the exact time when BG measurements are 
entered is recorded. Using the discrepancies between scheduled and actual BG 
measurements, a model of timing error can be generated and applied to data 
from the SPRINT protocol. Although the STAR protocol is different to SPRINT, 
particularly with its computerised interface, it is used by the same clinical staff, 
in the same unit. Hence, it may be assumed that timing errors in making 
measurements will be similar. 
 
From the STAR data, a vector of timing errors was extracted for each 
measurement interval. There were 765 one-hour measurement error values, 
with a mean value of -0.5 minutes. The two and three-hour errors (886 errors) 
were combined and applied to the SPRINT 2-hour measurements. These values 
had a mean value of +0.1 minutes. The low mean values indicate that the errors 
reflected both early and late measurements relatively equally. Errors were 
limited to a maximum of 20 minutes. The empirical error distributions are 
shown in Figure 9.1. 
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Figure 9.1. Timing error models based on data from the STAR pilot trials [Evans et al. 
2011]. Errors from 1-hour measurements are shown on the left and 2-hour 
measurements on the right. 
 
Errors from these distributions were applied additively to the SPRINT data by 
randomly sampling from the error vectors. The errors were applied to both the 
measurement and intervention timing. Thus, the measurements and 
interventions remained synchronised, as they would in the hospital.  
 
9.2.2.2 BG sensor error 
Sensor error consists of two components that vary independently, depending on 
the BG concentration being assayed. Bias is an offset defined as the difference 
between the mean of a set of measurements from a single sample and the 
reference value. Precision defines the spread of measured values about the mean 
and is often reported as a coefficient of variation (CV = standard 
deviation/mean).  
 
Bias was determined from the correlation data reported for the glucometer test 
strips, [Arkray 2007] and was therefore known at all BG concentrations. 
Precision was reported at three BG concentrations, 4.3, 6.9 and 21.0 mmol/L. For 
this analysis, the CV was interpolated for BG concentrations within the reported 
range and held constant outside this range. These data were used to construct an 
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additive error model for the glucometer used in this investigation. Table 9.2 
presents the bias and precision components for a range of glycaemia. 
 
Table 9.2. Error components of the Arkray Super-Glucocard II glucometer [Arkray 
2007]. 
Blood glucose 
(mmol/L) 
2.0 4.3 6.9 10.0 21.0 30.0 
Bias (%) +7.9 +2.1 +0.2 -0.8 -2.0 -2.3 
Precision, CV (%) 3.5 3.5 2.8 2.8 2.7 2.7 
 
 
The data used in the study was collected by trained clinical staff, minimising the 
potential for additional error through device misuse [Bergenstal 2008]. Blood 
samples tested were typically arterial, although, when an arterial line was not 
present, capillary blood was used.  
 
9.2.3 Analyses 
To assess the effects of random timing and sensor errors on SI, Monte Carlo 
simulations were performed.  The SI profile of each patient in the cohort was 
refitted 100 times with randomly sampled errors applied to the observed timing 
and BG concentrations. The SI profiles identified without additional random 
errors were thus considered the ‘true’ profiles, and the Monte Carlo profiles 
were compared to these to assess their impact. Comparisons of both SI level and 
hour-to-hour variability were made. 
 
Three separate sets of Monte Carlo simulations were performed for this analysis. 
Each set had either BG sensor error, timing error or both applied to the SPRINT 
data. SI level and variability of the simulated data were compared to the true 
data to assess the impact of each of the sources of error, both individually and 
combined. 
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To facilitate comparisons when timing errors were applied, SI was identified in 
60-minute intervals, rather than between BG measurements. This use of fixed, 
60-minute fitting intervals is consistent with the methodology used for 
glycaemic control by the STAR protocol. 
 
9.2.3.1 SI level analyses 
To analyse the impact of errors on the identified SI level, the variation induced 
by the simulated errors at each hour was compared. To characterise the 
distribution of differences in SI level at each hour, between the true and 
simulated profiles, the width of the IQR was used. Figure 9.2 illustrates the 
methodology for SI level comparisons between the n = 100 Monte Carlo 
simulations and the true data.  
 
This analysis method resulted in one ‘IQR width’ per patient hour. For the 270 
patient SPRINT cohort, there were 47120 hours of data. These 47120 IQR widths 
were presented as cumulative distributions to show the overall effect of the 
errors on the cohort. 
 
 
Figure 9.2. SI level comparison method for the Monte Carlo simulations with added 
sensor and timing error. The width of the IQR of differences, expressed as 
percentages, was used to characterise the variability in level induced by the errors. 
 
9.2.3.2 SI variability analyses 
The hour-to-hour variability of simulated data could not be compared to the true 
variability using ratios, as the variability distribution of any given patient was 
 
hour k hour k+1 
True SI 
Simulated SI 
0 
Distribution of 
differences at hour k 
across n simulations 
Interquartile 
range width 
    
              
      
 
96 
 
centred on approximately zero. Therefore, many values are close to zero, causing 
any comparison ratio to approach zero or infinity, providing an effectively 
meaningless metric. Hence, another method of comparison was necessary. 
 
For any given patient and hour, the median SI variability across the (n = 100) 
Monte Carlo simulations was approximately equal to the true value. This 
equivalence is a consequence of the approximately zero-mean error 
distributions and a large number of Monte Carlo simulations. This fact was 
utilised to characterise the variability of the variability as the IQR width for each 
hour, across the n = 100 Monte Carlo simulations, without explicit comparison to 
the true value. Hence, the SI variability analysis data can be interpreted in a 
similar way to the level analysis.  
 
A comparison to the actual variability is provided by the distribution of ‘ΔMedian 
SI.’ For any given hour, this metric is defined as the difference between the 
median hour-to-hour variability (%), across the simulations, and the actual value 
(%). Typically, the distribution was tightly centred about zero, justifying the use 
of simulation IQR width without explicit reference to the actual variability. 
 
9.3 Results and Discussion 
9.3.1 Timing error 
Figure 9.3 shows the impact of timing errors on identified SI level (left panel) 
and variability (right panels). For 95% of hours, the IQR width of SI level was less 
than 12.4%. Thus, for those 44334 hours, half the simulations resulted in SI 
values within approximately ±6.2% of the true value, assuming a symmetrical 
distribution. Similarly, for variability, 95% of hours had an IQR width of hour-to-
hour changes of less than 17.8%, or ±8.9% about the simulation median. The top 
right panel of Figure 9.3 shows the simulation median was typically very close to 
the true value for variability, justifying the assumptions made. 
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Figure 9.3. The impact of timing error on SI level (left panel) and variability (right 
panels), characterised by the variability of these parameters determined by Monte 
Carlo simulation. The panels on the right show the location of the median simulated 
variability, compared to the actual (top) and the variability about that median 
(bottom).  
 
These results suggest that typical timing errors in isolation have limited impact 
on the level and variability of SI. With a median absolute difference between the 
simulated and actual measurement intervals of 9 minutes and using bolus insulin 
delivery, this result is not too surprising. Unlike infused insulin, bolus delivery 
ensures that the entire prescribed dose is always administered, regardless of the 
time between measurements. In addition, timing discrepancies only affect the 
later parts of the interstitial insulin profile, where concentrations are lowest and 
thus contribute least to the area under the curve used in fitting SI [Hann et al. 
2005]. 
 
9.3.2 Blood glucose measurement error 
Figure 9.4 shows the impact of BG sensor errors on SI level (left panel) and 
variability (right panels). The variability induced in both SI level and variability 
is greater than that due to timing error. The increases at the median values for 
level and variability compared to timing error of Figure 9.3 were 4.9% and 2.2%, 
respectively (p = 0, Wilcoxon rank-sum test). However, with so many data points, 
a statistically significant difference is almost guaranteed.  
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Figure 9.4. The impact of BG sensor error on SI level (left panel) and variability (right 
panels), characterised by the variability of these parameters determined by Monte 
Carlo simulation. The panels on the right show the location of the median simulated 
variability, compared to the actual (top) and the variability about that median 
(bottom). 
 
The effect of the sensor bias is evident in the minimum value of the level IQR 
seen in the left panel of Figure 9.4. The minimum value was 2.7%. This non-zero 
minimum value was not present with the zero-mean timing error simulations of 
Figure 9.3.  
 
9.3.3 Combined measurement error 
Figure 9.5 shows the impact of the combined timing and BG sensor errors on SI 
level (left panel) and variability (right panels). The previous two sections have 
characterised the individual contributions of timing and sensor error. This 
analysis combines them, simulating errors seen in the real, clinical situation.  
 
For 95% of hours, the IQR width of SI level was less than 23.9%. Thus, assuming 
a symmetrical distribution, half the simulations resulted in SI values within 
approximately ±12% of the true value. Similarly for variability, the 95th 
percentile was 34.9%, indicating that for half the simulations the hour-to-hour 
variability of SI was within ±17.5%. 
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Figure 9.5. The impact of combined timing and BG sensor error on SI level (left panel) 
and variability (right panels), characterised by the variability of these parameters 
determined by Monte Carlo simulation. The panels on the right show the location of 
the median simulated variability, compared to the actual (top) and the variability 
about that median (bottom). 
 
9.3.4 Implications of results 
The clinical impact of changes to SI level induced by sensor and timing errors is 
likely to be limited. Given the hour-to-hour variability and longer-term evolution 
of SI in critically ill patients discussed in the previous chapters, deviations from 
the true SI caused by these errors are likely to be swamped by changes due to 
physiological variability. For example, changes in SI greater than 20% were seen 
with glucocorticoid treatment (Chapter 8) and improving patient condition over 
the first 18 hours of ICU stay (Chapter 7).  
 
There is no way to reduce the impact of these errors as they are random and 
apply equally to all patients. The only available option is to reduce the magnitude 
of the errors. The timing error distribution shown in Figure 9.1 shows that more 
than 85% of measurements are within 10 minutes of the scheduled time, which 
is a very good result in a busy ICU environment. In contrast, BG sensor errors can 
be reduced with better, more accurate, but likely more expensive equipment.  
 
To compare the impact of sensor errors from glucometers with a state of the art 
blood gas analyser (BGA), an error model was developed for the Bayer RapidLab 
0 10 20 30 40 50 60 70 80 90 100
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Width of SI level IQR [%]
F
(x
) -100 -80 -60 -40 -20 0 20 40 60 80 100
0
0.2
0.4
0.6
0.8
1
Median SI variability [%]
F
(x
)
0 10 20 30 40 50 60 70 80 90 100
0
0.2
0.4
0.6
0.8
1
Width of SI variability IQR [%]
F
(x
)
100 
 
860 (Bayer Diagnostics, Tarrytown, NY) [2004; Peet et al. 2002]. Errors for this 
BGA consist of very little bias (≤ 0.06 mmol/L) and CV in the range 1.7%-4.9%, 
depending on BG concentration. The RapidLab 860 is used in the Christchurch 
Hospital Neonatal ICU [Le Compte 2009], and thus represents a realistic option 
for the adult ICU in Christchurch. An n = 50 run Monte Carlo simulation was 
performed with both timing and BG sensor errors from the BGA for a basic 
comparison. 
 
The results show only a minor improvement by using the BGA.  The 95th 
percentile of IQR widths reduced from 23.9% to 21.0% and from 34.9% to 30.2% 
for level and variability, respectively. These limited improvements hardly 
warrant investing NZ$50,000-100,000, plus per-sample costs [Pearson et al. 
2006], for the device, solely for BG measurement.  
 
The cause of the close results between glucometer and BGA appear surprising. 
They may be due to the relatively low reported errors of the glucometer. Data for 
the error model was taken from the manufacturer’s data-sheet [Arkray 2007]. 
However, a published report  [Solnica & Naskalski 2005] failed to recreate these 
results, possibly due to user error, sample type, abnormal hematocrit or 
interfering substances [Bergenstal 2008].  
 
In contrast to SI level, the increase in hour-to-hour variability may be clinically 
significant. The relatively large, ±17.5%, range of variability about the median 
caused by errors, indicates that much of the IQR of a stochastic model at a given 
SI level may be dominated by these errors, rather than physiological variability. 
Hence, to avoid inadvertently basing control decisions on this artificial 
variability, the 5-95 range of the stochastic model should be used. SI values at 
these more extreme percentiles are less likely to be influenced by random sensor 
or timing errors. 
 
A second potential clinically significant impact is on analytical use of SI as a 
marker of injury or change in state.  Much of the true hour-to-hour change of this 
SPRINT cohort was smaller than the variability induced by sensor and timing 
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errors. The IQR of true hour-to-hour variability across the entire cohort was -
9.7% to 13.9% and 63% of all values lay in the range ±17.5%. Thus, using 
changes in SI level as a diagnostic must be done with caution, potentially looking 
at longer-term trends, where the effects of random errors may be cancelled by 
averaging over time. 
 
9.4 Summary 
The objective of this chapter was to assess and quantify the impact of typical 
timing and BG sensor errors on the level and variability of model-based SI. 
Specifically, the variability of level and the variability of SI hour-to-hour 
variability were investigated under the influence of these sources of error, both 
separately and combined. Measurement timing errors were shown to have a 
relatively small impact on the SI parameter. The BG concentration errors of the 
Arkray glucometer had a larger effect on SI and tended to dominate the 
combined analysis. 
 
The results of this study indicate that the impact of errors on SI level is unlikely 
to be clinically significant and probably swamped by physiological factors arising 
from the critical condition of the patients. In contrast, the impact of errors on 
hour-to-hour SI variability is more pronounced and may impact the way the SI 
parameter is utilised for control and analysis. 
 
This analysis indicated that for a given SI level, variability induced by errors 
might dominate the IQR of the probability density function describing SI for the 
subsequent hour. Hence, to avoid inadvertently basing control decisions on this 
artificial variability, the 5-95 percentile range of the stochastic model should be 
used. In addition, using changes in SI level as a diagnostic must be done with 
caution, potentially looking at longer-term trends, where the effects of random 
errors may be cancelled by averaging over time. 
 
Given the random nature of these errors, the only feasible method of mitigation 
is to use BG sensors with smaller errors. However, a comparison with results 
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from a state of the art, clinical blood gas analyser showed that the limited 
improvement in performance probably doesn’t justify the significantly increased 
cost of the device. However, understanding the effect of sensor and timing errors 
on SI allows their impact to be taken into account when using the parameter for 
control and analysis. 
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Chapter 10. Model Validation 
Having enhanced the model to reduce intrinsic variability and proposed means 
to mitigate the effects of extrinsic variability of SI, these developments must be 
validated. The validation is conducted in two stages, described in the following 
two Chapters. This Chapter presents the validation of the model itself and thus 
its suitability for ‘virtual trials’ following the changes to reduce intrinsic 
variability of SI.  Chapter 11 validates the proposals to mitigate extrinsic 
variability by analysing the outcomes of a (validated) virtual trial. 
 
10.1 Introduction 
The key parameter of the ICING-2 model is SI, characterising the whole-body 
glycaemic response to exogenous insulin and glucose inputs over time. In an 
effective glucose-insulin system model, SI permits accurate fitting and forward 
prediction of blood glucose, while being independent of the insulin and glucose 
inputs used to identify it. These characteristics enable successful model-based 
glycaemic control in clinical real-time. In addition, an accurate SI profile over 
time that is independent of exogenous inputs can be used in ‘virtual trials’ to 
enable rapid testing of new glycaemic control protocols and analysis of existing 
protocols in different clinical or implementation scenarios.  
 
In this study, validation of the ICING-2 model is carried out in two parts. First, BG 
fitting and one-hour-ahead prediction performance is assessed to validate SI for 
forward prediction in control decision-making. The second part is a self- and 
cross- validation analysis between two separate, clinically matched cohorts, 
indicating the suitability of the model and independence of SI to insulin and 
nutritional inputs.  
 
This validation is performed on clinically matched cohorts based on clinical data 
from an ICU independent to that used in the development of the model. The 
cohorts used for validation are a subset of the Glucontrol trial from Liege, 
Belgium [Preiser et al. 2009]. These cohorts were treated with two different 
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glycaemic control protocols. The independence of the ICU ensures a cohort that 
may be different in treatment, insulin sensitivity or other factors [Suhaimi et al. 
2010] from patients in the Christchurch ICU whose data underlie the 
development of the models and methods validated in this study [Chase et al. 
2007; Lin et al. 2011]. 
 
The objective of this study is to validate the ICING-2 model for clinical glycaemic 
control and ‘virtual trial’ purposes.  The validation is performed by assessing the 
BG fitting and forward prediction, as well as self and cross-validation 
performance on cohorts independent to those on which the model was 
developed. In effect, this study is an updated version of that conducted by Chase 
et al. [2010], using the ICING-2 model instead. Hence, the overall validation 
approach has previously been published, and this work focuses solely on model 
validation. 
 
10.2 Subjects and Methods 
10.2.1 Patients 
Data was used from a subset of the 350 patients treated using the Glucontrol 
protocol at CHU de Liege, Belgium, between March 2004 and April 2005. Thus, 
the Glucontrol data used in this study is from only one centre out of the full 
study, but represents approximately 25% of all patients [Preiser et al. 2009]. The 
Glucontrol trial randomised patients to two different protocols (A and B), each 
with different glycaemic targets. Patients were eliminated from this analysis if 
they received no insulin for their entire stay (per protocol), had less than 5 BG 
measurements or received little or no (recorded) carbohydrate administration 
(in any form) for more than 48 hours of their stay. Of the 350 patients enrolled in 
both arms of the study in Liege, 211 were included in this analysis. 
 
Clinical details of the resulting cohorts are shown in Table 10.1 and Table 10.2 
totalling 29,777 hours and 7,391 BG measurements. Patients in Population A 
were slightly older than Population B. However, there were no significant 
differences in sex, weight, BMI, severity of illness as measured by APACHE II 
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score, or initial BG level. Population B received less insulin and more 
carbohydrate, in alignment with its higher glycaemic target. 
 
Table 10.1. Glucontrol cohort characteristics. Data are shown as median 
[interquartile range] where appropriate. P-values were calculated using the Chi-
squared test and Wilcoxon rank-sum test. 
 
 
Table 10.2. Clinical glucose control characteristics. Data are shown as median 
[interquartile range] where appropriate.  
 Population A Population B 
Total hours 16, 831 12, 946 
Length of treatment (hrs) 68 [38 - 138] 89 [43 – 229] 
BG measurements 4, 571 2, 820 
BG (mmol/L) 6.3 [5.3 – 7.6] 8.2 [6.9 – 9.4] 
BG target band (mmol/L) 4.4 - 6.1 7.8 - 10.0 
Insulin rate (U/hr) 1.5 [0.5 – 3.0] 0.7 [0.0 – 1.7] 
Carbohydrate admin 
(all sources) (mmol/min) 
0.30 [0.00 – 0.90] 0.60 [0.10 – 1.00] 
 
 
This validation is performed on cohorts matched for overall clinical parameters. 
The clinical data is from an ICU independent to that used in the development of 
the ICING-2 model. These cohorts were treated with two different glycaemic 
control protocols, which are also very different to that used on the development 
cohort. These factors ensure a cohort different in treatment, insulin sensitivity or 
other factors [Suhaimi et al. 2010] from patients in the Christchurch ICU whose 
 Population A Population B P-value 
N 142 69  
Gender (M/F) 92/50 39/30 0.25 
Age (years) 71 [61 – 80] 69 [53 – 77] 0.035 
Weight (kg) 72 [62 - 85] 75 [68 - 81] 0.38 
 BMI 25.4 [22.6 –29.3] 26.0 [23.2 - 29.3] 0.46 
APACHE II score 17 [14 – 22] 17 [14 – 21] 0.76 
Initial BG (mmol/L) 6.6 [5.6 – 8.6] 6.6 [5.7 – 9.4] 0.58 
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data underlie the development of the models and methods validated in this study 
[Chase et al. 2007; Lin et al. 2011]. 
 
Figure 10.1 shows the cumulative distributions of SI for the two cohorts. The 
SPRINT cohort on which the model was largely developed tends to have a lower, 
more variable SI distribution than the Glucontrol cohort (Populations A and B 
combined) used for validation in this study. Hence, the patients used for this 
model validation are not only independent from the data used to create the 
model, but are also metabolically different. 
 
Figure 10.1. SI level (left panel) and hour-to-hour variability (right panel) 
distributions of SPRINT and Glucontrol patients.  
 
10.2.2 Glucontrol protocols 
The Glucontrol trial [Preiser et al. 2009] randomised patients into two groups: 
Populations A and B. Population A received intensive insulin therapy and 
Population B received conventional insulin therapy, with target ranges of 4.4-6.1 
mmol/L and 7.8-10.0 mmol/L, respectively. Insulin was administered by 
continuous intravenous (IV) infusion.  
 
The protocol specified insulin infusion rates are shown in Table 10.3 for the 
intensive protocol used on Population A, and Table 10.4 for the conventional 
protocol used on Population B. Nutritional input was left to local and/or clinician 
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standards, and was not explicitly considered in the Glucontrol glycaemic control 
protocols [Suhaimi et al. 2010]. 
 
Table 10.3. Glucontrol A protocol. The starting insulin infusion rate is shown in the 
top part of the table. The maintenance infusion rates or increments are shown in the 
lower part. All values have been converted to mmol/L from mg/dL. 
 
Table 10.4. Glucontrol B protocol. The starting insulin infusion rate is shown in the 
top part of the table. The maintenance infusion rates or increments are shown in the 
lower part. All values have been converted to mmol/L from mg/dL. 
STARTING INSULIN INFUSION RATE SCALE 
Glycaemia Insulin infusion rate 
< 6.1 mmol/L On hold 
6.1 – 7.8 mmol/L 1 U/hr 
7.8 – 10.0 mmol/L 2 U/hr 
> 10.0 mmol/L 4 U/hr 
MAINTENANCE INFUSION RATE CHANGES 
Glycaemia Incremental insulin infusion rate 
> 16.7 mmol/L + 3 U/hr 
10.0 – 16.7 mmol/L + 2 U/hr 
7.8 – 10.0 mmol/L + 1 U/hr 
6.1 – 7.8 mmol/L + 0.5 U/hr 
4.4 – 6.1 mmol/L + 0 U/hr (target range) 
2.2 – 4.4 mmol/L 
Stop insulin, 
Hourly measurement of glycaemia until > 4.4 mmol/L 
< 2.2 mmol/L 
Stop insulin, 10gr glucose IVD, 
Call physician immediately, 
Hourly measurement of glycaemia until > 4.4 mmol/L 
STARTING INSULIN INFUSION RATE SCALE 
Glycaemia Insulin infusion rate 
< 10.0 mmol/L On hold 
10.0 - 13.9 mmol/L 1 U/hr 
13.9 - 16.7 mmol/L 2 U/hr 
> 16.7 mmol/L 4 U/hr 
MAINTENANCE INFUSION RATE CHANGES 
Glycaemia Incremental insulin infusion rate 
> 16.7 mmol/L + 3 U/hr 
13.9 - 16.7 mmol/L + 2 U/hr 
10.0 - 13.9 mmol/L + 1 U/hr 
7.8 – 10.0 mmol/L + 0 U/hr (target range) 
4.4 – 7.8 mmol/L Decrease 50% rate insulin 
2.2 – 4.4 mmol/L 
Stop insulin,  
Hourly measurement of glycaemia until > 4.4 mmol/L 
< 2.2 mmol/L 
Stop insulin, 10gr glucose IVD,  
Call physician  immediately,  
Hourly measurement of glycaemia until > 4.4 mmol/L 
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Hourly BG measurements were taken when the glycaemic level was not within 
the target range. Otherwise, 2-hourly measurements were taken in the case of 
limited variation of glycaemia, defined as less than a 50% change from the 
previous glycaemia in 2-hour range. 4-hourly measurements were permitted 
when the glycaemic level was less than 50% of the highest glycaemia of the four 
last hours.  
 
10.2.3 Fitting and prediction 
To validate SI for forward prediction in control decision making, BG fitting and 
one-hour-ahead prediction errors were assessed. Model fit and prediction errors 
were used to show the ability of the model to fit the data and predict the 
expected patient state. Fitting error was calculated by solving the model 
equations with the identified SI profile and known insulin and nutritional inputs 
and comparing these results with the clinically measured data. Thus, fit error 
quantifies the ability of the model to capture the observed dynamics. 
 
Prediction results were generated by holding SI constant for one hour into the 
future. Specifically, taking the identified value of SI for hour n and holding it 
constant for hour n+1, then simulating BG one hour into the future using 
recorded clinical insulin and nutritional inputs. This BG prediction was 
compared to clinically recorded BG or a linear interpolation between 2-hourly 
measurements. Prediction errors assess the ability of the model and identified 
parameters to predict intervention outcomes and are highly relevant for 
validating models used in model-based TGC [Chase et al. 2007; Kovatchev et al. 
2009]. 
 
10.2.4 Self and cross-validation 
As described in Chase et al. [2010], the self- and cross- validation procedures 
rely on the ‘virtual trial’ method. The SI profile identified from clinical data for a 
given patient (‘virtual patient’) is used to simulate the glycaemic response to 
other combinations of insulin and glucose inputs, specified by a different 
protocol. The critical assumption of a virtual trial is that the identified SI profiles 
are (largely) independent of the clinical data used to derive them.  
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10.2.4.1 Self-validation 
Self-validation tests the ability of the in silico virtual patient modelling method to 
reproduce the clinical data from which a virtual cohort was derived. For the self-
validation on Glucontrol A, the Glucontrol A protocol defined in Table 10.3 was 
simulated on Population A virtual patients. These virtual trial results were then 
compared to the clinical data from Population A. This step was repeated for self-
validation on Glucontrol B.  
 
Differences between clinical and virtual trial results can be attributed to model 
errors, and/or lack of perfect compliance in the clinical study compared with the 
perfect compliance and timing in silico. Hence, two self-validation virtual trials 
were simulated on each group considering:   
 
 Actual measurement timing used in the clinical trials (clinical timing). 
 Measurement timing strictly dictated by the protocol (protocol timing).  
 
Because the Glucontrol protocols modify insulin incrementally, different 
measurement timing could significantly change dosing and thus impact the 
results of the virtual trials [Chase et al. 2010]. 
 
10.2.4.2 Cross-validation 
Cross-validation uses the matched A and B cohorts to determine the ability of the 
modelling method to reproduce the clinical data on a matched, but independent, 
cohort. Thus, Protocol A is simulated on virtual patients derived from Population 
B clinical data, with results compared to clinical data from Glucontrol Population 
A. Similarly, Protocol B is tested on virtual patients from Population A and the 
results are compared to Population B clinical data.  
 
In theory, if patients were perfectly matched in all ways, the in silico and clinical 
data would also match if the in silico virtual trials method were exact. 
Differences using large matched cohorts can thus be largely ascribed to how well 
the assumption holds that these virtual patient SI profiles are independent of the 
clinical insulin and nutrition inputs used to derive them. If cross-validation 
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results match the clinical results well, for clinically matched cohorts, then this 
assumption can be considered valid. Hence, this validation tests the underlying 
assumption of this virtual trial method. 
 
10.3 Results and Discussion 
10.3.1 Fitting and prediction validation 
Table 10.5 shows the model fit and prediction errors for the Glucontrol 
populations. Results are shown on a cohort and a per-patient basis. Model fit 
error was consistent across all both groups, with median fit error ≤ 0.3%. 
Population B had the lowest prediction error at almost half that of population A. 
However, median cohort and per-patient results are considerably less than 
typical sensor errors of 10% (Chapter 9).  
 
Table 10.5. Fitting and one-hour-ahead prediction errors for Glucontrol populations 
with ICING-2 model. Data are shown as median [interquartile range].  
Population 
Fit error Prediction error 
Cohort (%) 
Patient 
median (%) 
Cohort (%) 
Patient 
median (%) 
A 0.3 [0.1 - 0.7] 0.3 [0.2 - 0.4] 2.7 [1.1 - 5.8] 3.0 [2.2 - 4.1] 
B 0.2 [0.1 - 0.4] 0.2 [0.1 - 0.3] 1.5 [0.6 - 3.3] 1.6 [1.1 - 2.2] 
A+B 0.2 [0.1 - 0.6] 0.3 [0.2 - 0.4] 2.1 [0.9 - 4.6] 2.6 [1.7 - 3.6] 
 
 
Fitting errors are typically very small and a result of assumptions made during 
the identification of SI. Larger values (typically > 2%) indicate instances where 
the model cannot fit clinical data, for instance when an identified value of SI 
should be negative (mathematically), but is constrained to a non-negative value, 
as discussed in Chapter 5. 
 
Prediction errors are an assessment of the models ability to make accurate 
patient-specific predictions of the outcomes of known interventions. Given low 
fit errors, prediction error indicates whether the identified and constant model 
parameters are accurate. In this study, prediction error serves to validate the 
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model identification method [Kovatchev et al. 2009] and approach [Chase et al. 
2007; Lonergan et al. 2006] used to create virtual patients and virtual trials. 
 
10.3.2 Self and cross validation 
Figure 10.1 shows the distributions of measured and simulated blood glucose on 
a cohort basis. The distributions show a clear separation between the Glucontrol 
A and B clinical results, as expected, but also for all the respective simulations 
using those protocols.  
 
The Glucontrol A clinical median cohort BG value of 6.3 mmol/L agrees well with 
the 6.1 mmol/L medians for both the self-validation trials.  The cross-validation 
median BG of 6.4 mmol/L is also in close agreement with the clinical result. The 
overall curves, and thus median and variability, are very similar. 
 
 
Figure 10.2. Distributions of blood glucose results of clinical Glucontrol data and 
virtual trials on a cohort basis. 
 
The four BG distributions for the Glucontrol B protocol show a slightly wider 
spread in results, particularly below the Group B target of 8.0 mmol/L. However, 
the median cohort clinical BG value of 8.2 mmol/L still agrees well with the 
medians of 8.2 and 8.4 mmol/L for Glucontrol B self validation with clinical and 
per-protocol measurement frequency, respectively. It also agrees well with the 
cross-validation median result of 7.8 mmol/L. Overall, the curves agree very 
well, in general. 
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For the cross-validation, Protocol A on Population B is a very good match with 
errors similar to the self-validation results for Population A. Protocol B on 
Population A is only just outside the range of the Population B self-validation, but 
still very close to the slope and trends of the clinical data. Thus, the insulin 
sensitivity independence assumption behind this virtual trials approach is valid, 
independently validating this concept and the virtual trial method based on this 
model.  
 
Figure 10.3 shows similar results for the CDFs of the per-patient median blood 
glucose levels across all patients in each group. This per-patient comparison has 
the same whole-cohort trend seen in Figure 10.2, where the variation in BG 
distributions under a given protocol is significantly less than the variation 
between protocols. The differences between the clinical and simulated cross-
validation results are more obvious in this per-patient analysis, but the median 
values are still within 8% of the clinical in both cases, and as with the cohort 
results, the slope, or variability is also similar. 
 
 
Figure 10.3. Distributions of per-patient median blood glucose results of clinical 
Glucontrol data and virtual trials. 
 
Figure 10.4 presents the distributions of absolute paired differences between 
clinical and simulated median BG values for each patient. As expected, the 
differences are generally smaller for the simulations using clinical timing 
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compared to those following strict protocol timing. For the clinical timing 
simulations, 90% of patients had median simulated BG within 12% and 9% of 
their clinical results for protocols A and B, respectively. The corresponding 
values for the strict protocol timing were 14% and 13% for protocols A and B, 
respectively. These results indicate good self-validation, but also provide insight 
to the level of protocol violation that occurred.  
 
In a perfect trial, with no protocol violations, the distributions of paired 
differences should approach the fitting error distributions (Table 10.5). 
However, once a simulation BG trajectory deviates from the clinical trajectory, 
modelling errors can add to the differences between the final results. Hence, the 
differences between median fitting errors of 0.2-0.3% and the medians of Figure 
10.4 at 2-6% may be a result of both compliance and modelling issues and thus 
indicates a moderate level of non-compliance.  
 
 
Figure 10.4. Per-patient median absolute BG comparison between simulated and 
clinical results. 
 
This study focuses on the Glucontrol protocol from one centre (Liege, Belgium; 
pilot centre).  Glucontrol was a multi-centre study stopped early to a high rate of 
unintended protocol violations [Preiser et al. 2009]. The self-validation results, 
in particular, capture and show the impact of these protocol violations. 
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Table 10.6 shows the comparison of outcomes between the actual clinical data 
and the self- and cross- validation simulations for the Glucontrol A protocol. 
These per-patient results show very good agreement between the actual data 
and the clinical timing self-validation. The increased measurement and insulin 
rates seen for the self-validation with protocol timing result are closely related. 
Given the incremental nature of the protocol insulin specification, timing non-
compliance automatically translates into different insulin rates as more 
measurements provide more opportunities to increase the insulin rate, per the 
protocols in Table 10.3 and Table 10.4. 
 
Table 10.6. Glucontrol A clinical and simulation results. Data are shown as median 
[interquartile range] where appropriate.  
Glucontrol A 
  Self-validation Cross-validation 
Clinical Clinical timing Protocol timing Protocol timing 
No. of patients 142 142 142 69 
Insulin rate 
[U/hr] 
1.4 [0.9-2.1] 1.7 [1.1-2.8] 2.7 [1.4-4.7] 6.2 [3.2-10.1] 
Glucose rate 
[g/hr] 
1.1 [0.5-7.6] 1.1 [0.5-7.6] 1.2 [0.5-7.5] 3.0 [0.7-7.4] 
BG 
 [mmol/L] 
6.4 [5.9-6.9] 6.2 [5.8-6.8] 6.2 [5.8-6.7] 6.6 [6.0-7.1] 
BG 
measurements 
4571 4560 9907 7614 
BG meas. freq. 
[/patient/day] 
6.5 6.5 14.1 14.1 
 
 
The high insulin dosing for Population B in the cross-validation is likely a result 
of using the clinically administered nutritional data. Population B received 
almost 3-times the glucose administration as population A, and therefore 
required significantly more insulin to control glycaemia to the protocol A target. 
In addition, cross-validation can only be performed with protocol timing and 
thus the associated increased measurement and insulin rates. These results are 
mirrored in the complementary cross-validation of protocol B on Population A 
shown in Table 10.7. 
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Comparison of clinical trials with self and cross-validation on Glucontrol B is 
summarised in Table 10.7. The trends are similar to those seen for Glucontrol A, 
where the clinical timing simulations closely match the actual clinical results and 
the protocol timing simulations have high measurement and insulin rates. 
However, protocol B clinical data had a measurement rate much closer to the 
strict protocol rate than protocol A. Hence, this lesser degree of measurement 
non-compliance translated into closer insulin rates between the clinical and 
protocol timing simulations.  
 
Table 10.7. Glucontrol B clinical and simulation results. Data are shown as median 
[interquartile range] where appropriate. 
Glucontrol B 
  Self-validation Cross-validation 
Clinical Clinical timing Protocol timing Protocol timing 
No. of patients 69 69 69 142 
Insulin rate 
[U/hr] 
0.6 [0.3-1.2] 0.6 [0.3-1.3] 0.8 [0.2-2.1] 0.1 [0.0-0.8] 
Glucose rate 
[g/hr] 
2.9 [0.7-7.4] 2.9 [0.7-7.4] 2.9 [0.7-7.4] 1.1 [0.5-7.4] 
BG  
[mmol/L] 
8.3 [7.6-8.8] 8.2 [7.8-8.8] 8.4 [7.8-9.1] 7.7 [6.9-8.3] 
BG 
measurements 
2820 2818 4076 5282 
BG meas. freq. 
[/patient/day] 
5.2 5.2 7.5 7.5 
 
 
The self-validation results of Table 10.6 and Table 10.7 clearly indicate 
significant measurement non-compliance. Comparison between the protocol 
timing simulation and clinical results show 54% and 31% fewer measurements 
in the clinical data for protocols A and B, respectively.  Although it is not strictly 
correct to simply compare the tabulated numbers of measurements, due to 
potentially different BG trajectories, the outcome BG distributions are similar in 
these cases. Hence, these values likely provide a good estimate of the level of 
measurement timing non-compliance. 
 
Differences between self- and cross- validation results can mostly be attributed 
to any remaining differences between patient groups, despite clinical matching. 
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More importantly, the relatively small differences show the strength of the SI 
parameter as a description of patient metabolic state, rather than as a therapy-
specific parameter value.  
 
Other causes for remaining differences may also be a function of model 
approximations or errors. Inter- and intra- patient variability in some fixed 
model parameters and insulin secretion rate (Chapters 3 and 4) is at least one 
cause of model limitations and errors. However, the limited blood glucose data 
with no added or real time plasma insulin data limits the ability to uniquely 
identify these parameters [Hann et al. 2005; Hann et al. 2008]. 
 
Despite these model approximations, the close correlation of self- and cross- 
validation results to clinical data validates both the ICING-2 model and 
independence of the SI parameter from insulin and nutritional inputs. In 
addition, these results validate the idea that these in silico virtual trial 
simulations can accurately predict the expected clinical results of a glycaemic 
control protocol. 
 
10.4 Summary 
The objective of this study was to validate the ICING-2 model for clinical 
glycaemic control and virtual trial purposes. The validation was accomplished by 
assessing the BG fitting and forward prediction as well as self- and cross- 
validation performance on cohorts independent to those on which the model 
was developed. 
 
The low fitting and prediction errors, considerably less than typical 10% BG 
sensor errors, indicated that the model captured the clinically observed BG 
dynamics and variation. In particular, the low prediction error validates the 
ability of the model and identified SI parameter to predict intervention 
outcomes. This forward predictive ability is highly relevant for model-based 
glycaemic control. 
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The close correlation of self- and cross- validation results to clinical data 
validates both the ICING-2 model and independence of the SI parameter from 
insulin and nutritional inputs. Self-validation indicated a clinically insignificant 
error in these virtual trial methods due to model and/or clinical compliance. 
They also showed the impact of some non-compliance independent of model 
error. Cross-validation clearly showed that the virtual patient methods and 
models enabled by patient-specific SI profiles are effective and the assumption 
that the SI profiles are independent of the clinical inputs used to generate them is 
valid. Together, these results validate the concept that these virtual trial 
simulations can accurately predict the expected clinical results of a glycaemic 
control protocol. 
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Chapter 11. Implementation Validation 
Chapter 10 validated both the ICING-2 model and the independence of the SI 
parameter from insulin and nutritional inputs, enabling accurate virtual trial 
simulations. Virtual trial simulations are used in this Chapter to validate the 
implementation of the model using separate stochastic models to reduce the 
impact of the extrinsic SI variability during glycaemic control. 
 
11.1 Introduction 
Extrinsic SI variability derives from factors external to the specific 
pharmacokinetic-pharmacodynamic model, such as changes in patient condition, 
drug therapies and measurement errors. These factors were discussed and 
quantified in Chapters 7, 8 and 9. The common, model-based method proposed 
to reduce the impact of this variability, while using the model for glycaemic 
control, was to use more than one stochastic model. However, this approach 
requires validation. 
 
The objective of this study was to validate the use of separate stochastic models 
to reduce the impact of extrinsic SI variability during glycaemic control. A 
number of separate stochastic models were proposed in the preceding Chapters 
for different patient conditions, diagnostic categories and drug therapies. 
However, there is currently not enough data to create all these models, while 
ensuring the data used in each one is independent of the others and 
comprehensive.  
 
The results of Chapter 7 showed that the first 24 hours of ICU stay were 
characterised by significantly reduced SI level and increased variability for all 
patients. There are enough data points from the first 24-hours to ensure an 
accurate, comprehensive stochastic model for this group. Hence, this study 
presents a limited validation using a specific model generated for the first 24 
hours of ICU stay.  
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This validation was conducted using the virtual trial method validated in the 
previous Chapter. These virtual trials were conducted with the STAR protocol 
[Evans et al. 2011], employing the ICING-2 model and two separate stochastic 
models. The outcome glycaemia of these virtual trials was assessed and 
compared with the results using a single stochastic model. 
 
11.2 Subjects and Methods 
11.2.1 Patients 
This study used data from 371 patients admitted to the Christchurch Hospital 
ICU between 2005 and 2007 and treated with the SPRINT glycaemic control 
protocol [Chase et al. 2008].  This cohort was essentially the same as that used in 
the studies by Chase et al. [2008] and Evans et al. [2012], enabling comparison 
with these previously reported results. Of the 371 patients, 293 commenced 
SPRINT within 24 hours of ICU admission. Hence, these patients contribute data 
to, and would be controlled for some period by the 0-24 hour stochastic model. 
Table 11.1 shows a summary of the cohort details. The Upper South Regional 
Ethics Committee, New Zealand granted approval for the audit, analysis and 
publication of this data. 
 
Table 11.1. Cohort and sub-cohort summary statistics. 
 
All patients 
Patients that started 
SPRINT within 24 hrs 
of ICU admission 
N 371 293 
Age (years) 65 [49-74] 65 [52-74] 
Gender (M/F) 236/135 184/109 
APACHE II score 18 [15-24] 18 [15-24] 
APACHE II ROD (%) 26 [13-49] 26 [13-48] 
ICU length of stay (hrs) 98 [41-251] 77 [29-191] 
Operative/Non-operative 170/201 136/157 
Diabetic status (T1DM/T2DM) 14/49 12/41 
Hospital mortality 16% 17% 
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11.2.2 Virtual trial simulation 
The method of virtual trial simulation was described in detail by Chase et al. 
[2010] and validated for this model in the previous Chapter. Briefly, the method 
involves using SI profile of one or more patients, identified from actual clinical 
data, as the underlying bases of virtual patients. A virtual trial consists of 
simulating the BG trajectory for the virtual patients by solving the ICING-2 model 
equations with the known SI profile and a control algorithm to select insulin and 
nutrition interventions 
 
Virtual trial simulations, from a validated model, provide accurate information 
about expected glycaemic levels and interventions resulting from a given 
controller. This information can be used to assess the performance of the 
controller or aspects of it, such as the possible benefits of using separate 
stochastic models.  
 
11.2.3 STAR protocol 
The STAR (Stochastic TARgeted) glycaemic control protocol recommends insulin 
and nutrition interventions based on the predicted BG response over a 1-3 hour 
timeframe using forecasted SI from one or more stochastic models. The STAR 
approach explicitly targets a BG range by maximising the likelihood of achieving 
that range given certain constraints, such as an acceptable risk of hypoglycaemia 
and insulin and nutritional limits. The STAR protocol is described in detail by 
Evans et al. [2012; 2011], and its targeting approach illustrated in Figure 11.1. 
 
With relatively stable BG, the STAR protocol allows 2 and 3-hour BG 
measurement options. In clinical use, nurses select the next measurement time 
from the permitted intervals. For this analysis, the in silico STAR controller 
always selects the longest available measurement interval, as this represents 
both the optimum balance between the level of control and nurse workload, and 
a likely scenario given heavy nurse workloads [Aragon 2006]. 
 
121 
 
 
Figure 11.1. Controller forecast schematic for BG targeting the range 4.4 – 8.0 
mmol/L. A BG measurement was taken at 4 hours, and forecasts of BG have been 
generated (points A-F) for 1-3 hours ahead using the 5th and 95th percentile SI values 
from the stochastic model and some possible insulin and nutrition intervention. 
 
During the clinical pilot trials of the STAR protocol [Evans et al. 2011], a single 
stochastic model was used for all patients for the entire duration of glycaemic 
control (general stochastic model). For this study, a specific model was 
generated from, and used only during the first 24 hours of patient stay in the ICU. 
In practise, a 24+-hour model would cover all subsequent time. For example, if a 
patient commenced SPRINT 13 hours after ICU admission, only data from the 
first 11 hours of glycaemic control would contribute to the 0-24 hour stochastic 
model, and the remainder to the 24+-hour model. Similarly, during control, or a 
virtual trial with the STAR protocol, only the first 11 hours would employ the 0-
24 hour stochastic model.  
 
The 0-24 hour model was generated from data contributed by 293 patients that 
commenced SPRINT within 24 hours of ICU admission. The general model was 
generated from all 371 patients. The generation and validation of stochastic 
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models are described in detail elsewhere [Le Compte et al. 2009; Lin 2007; Lin et 
al. 2006; Lin et al. 2008]. 
 
11.2.4 Analyses 
The objective of glycaemic control is to drive patient blood glucose levels into a 
target band, while avoiding hypoglycaemia. Therefore, the appropriate metric to 
assess methods of mitigating the impact of extrinsic SI variability is outcome 
glycaemia. This study compares outcome glycaemia from virtual trials only for 
the first 24 hours of ICU stay, as this time period is where the additional 
variability captured by the specific 0-24 hour stochastic model can have an 
impact. The 24+-hour stochastic model is sufficiently similar to the general 
model that the results are essentially identical for this latter part of patient stay. 
Including these latter days in the results would only swamp the relatively few 
data points from the first 24 hours. Both stochastic models and virtual trials used 
the ICING-2 model in this analysis.  
 
11.3 Results and Discussion 
Figure 11.2 shows the 0-24 hour and general stochastic models used in this 
analysis. The lines represent the 5th, 25th, 50th, 75th and 95th percentiles, from the 
lower part of the plot, upwards. The 0-24 hour model is noticeably wider than 
the general model and the data points are concentrated at lower SI levels, 
corresponding with the reduced level and increased hour-to-hour variability 
reported in Chapter 7.  
 
Figure 11.3 presents the outcome glycaemia results of the virtual trials for the 
first 24 hours of ICU stay. Thus, this plot only contains data from 293 patients. 
Clinical data from the SPRINT protocol are also shown for context, although the 
target band of SPRINT differed from that of STAR (Table 11.2). 
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Figure 11.2. Comparison of 0-24hr and general stochastic models generated from 
the ICING-2 model. 
 
 
Figure 11.3. Virtual trial simulation BG results during the first 24 hours of ICU stay. 
The corresponding SPRINT clinical data are shown for context. 
 
The results for the simulation using the 0-24 hour stochastic model show a slight 
rightward shift in the BG distribution at low BG levels (< 7 mmol/L) compared to 
the general model. This result was expected, given the increased width of the 0-
24 hour stochastic model. To prevent hypoglycaemia, the STAR protocol 
constrains the 5th percentile BG prediction to a lower limit. Hence, the increased 
width of the stochastic model, particularly the 5th percentile causes a shift in the 
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BG distribution at lower levels. This shift represents a small reduction in overall 
cohort glycaemic variability. 
 
Table 11.2 shows that in general, the normoglycaemic and hyperglycaemic 
results were comparable between the two STAR simulations. The median BG of 
the 0-24 hour model result is still well within the target band and only 0.1 
mmol/L higher than the result from the general model. Additionally, the 
interquartile range of the simulation using the 0-24 hour model is narrower, 
quantifying the reduction in overall variability seen in Figure 11.3. 
 
Table 11.2. Virtual trial simulation BG results comparison for data within 24 hours of 
ICU admission. 
Whole cohort control 
statistics 
SPRINT Clinical STAR  
General model 
STAR 2 
0-24hrs model 
Num patients 293 293 293 
Total hours 4662 hours 4662 hours 4662 hours 
Num BG measurements 3915 3121 3204 
Target BG band (mmol/L) 4.0 - 6.1 4.4 - 8.0 4.4 - 8.0 
BG median [IQR] (mmol/L) 6.30 [5.20 - 7.90] 6.80 [5.70 - 8.50] 6.90 [5.80 - 8.50] 
% BG within 4.0 - 6.1 mmol/L 41.6 33.2 30.4 
% BG within 4.0 - 7.0 mmol/L 59.3 50.8 50.4 
% BG within 4.4 - 8.0 mmol/L 67.7 63.6 64.9 
% BG within 8.0 - 10 mmol/L 14.2 19.3 20.3 
% BG > 10 mmol/L 10.5 12.5 12.2 
% BG < 4.4 mmol/L 8.1 6.0 4.4 
% BG < 4.0 mmol/L 3.4 3.1 2.2 
% BG < 3.0 mmol/L 0.3 0.3 0.2 
Num patients < 2.2 mmol/L 2 0 0 
 
 
More importantly, the 0-24 hour stochastic model reduces the proportion of 
hypoglycaemic measurements. Absolute reductions of 1.6%, 0.9% and 0.1% 
were achieved for the amount of time spent below 4.4, 4.0 and 3.0 mmol/L, 
respectively. With 300-400 patients per year receiving glycaemic control in the 
Christchurch Hospital ICU, these results could reduce the number of patients 
experiencing a hypoglycaemic episode by up to 6, annually. The STAR protocol 
prevented any severe hypoglycaemic episodes, defined as BG < 2.2 mmol/L.  
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The SPRINT clinical data were shown in Table 11.2 for context. The SPRINT 
results show a slightly increased time in target band compared with STAR. 
However, the increased number of hypoglycaemic episodes offsets this result. It 
is also worth noting that the STAR results were achieved with approximately 
20% fewer BG measurements than SPRINT. 
 
Table 11.3 shows the insulin and glucose administration results from the virtual 
trials. Results for the two STAR trials were very similar. The slightly lower 
insulin administration during the trial with the 0-24 hour stochastic model may 
account for the slightly higher outcome glycaemia. It is interesting to note that 
very little nutrition was administered during this first 24-hour period. This was 
likely a consequence of low SI level while the controller was trying to bring BG 
down into the target band. Nutrition administration later in patient stay was 
generally much higher [Evans et al. 2012; Evans et al. 2011]. 
 
Table 11.3. Virtual trial simulation interventions within 24 hours of ICU admission. 
Data are shown as median [interquartile range] 
Whole cohort 
control statistics 
SPRINT Clinical STAR  
General model 
STAR 2 
0-24hrs model 
Insulin rate (U/hr) 3.0 [1.0 - 4.0] 3.0 [1.5 - 5.0] 2.5 [1.0 - 4.0] 
Glucose rate (g/hour) 0.0 [0.0 - 2.8] 0.0 [0.0 - 4.2] 0.0 [0.0 - 4.2] 
Glucose rate (% goal) 0.0% [0.0% - 40.0%] 0.0% [0.0% - 61.4%] 0.0% [0.0% - 63.8%] 
 
 
These virtual trial results indicate that the impact of extrinsic SI variability can 
be reduced, to some extent, by using more than one stochastic model. This study 
demonstrated a reduction in the prevalence of hypoglycaemia during the first 24 
hours of ICU stay, when patients tend to be more variable, using a specific 
stochastic model for that period. Additionally, a reduced BG interquartile range 
indicated a small reduction in overall cohort glycaemic variability. 
 
As noted in Chapter 7, Bagshaw [2009] reported an association between 
hypoglycaemia and variability during the first 24 hours of ICU stay, and 
mortality. Not only does glycaemic variability pose a risk through 
126 
 
hypoglycaemia, it is also detrimental in its own right. Several studies [Egi et al. 
2006; Egi et al. 2010; Hermanides et al. 2010; Krinsley 2008] have shown that 
glycaemic variability is independently associated with mortality in critically ill 
patients. Hence, the reduced hypoglycaemia and variability results using a 
specific stochastic model for the first 24 hours of ICU stay may appear small, but 
are potentially very important. 
 
Chapters 7, 8 and 9 have shown that a number of factors are associated with 
increased extrinsic SI variability and thus proposed separate stochastic models 
to reduce the impact on outcome glycaemia. Currently, there is not enough data 
to create specific stochastic models for all the proposed cases, while ensuring the 
data used in each one is independent of the others. For example, there are 
currently only 904 hours of data for cardiovascular surgery patients that 
commenced SPRINT within 24 hours of ICU admission. This data is too sparse to 
generate a reliable stochastic model. Hence, this study validated the concept 
using only one additional stochastic model. However, as more data becomes 
available, models could be generated for all the proposed circumstances, and 
potentially others that may come to light. 
 
11.4 Summary 
This study has validated the concept that using more than one stochastic model 
during control can reduce the impact of extrinsic SI variability on outcome 
glycaemia. Virtual trials were simulated with the STAR protocol using stochastic 
models generated with data taken from both entire ICU stay and only the first 24 
hours. Using a stochastic model specifically generated for the first 24 hours of 
ICU stay resulted in reduced variability and hypoglycaemia during this period, 
without adversely affecting the overall level of control. The increased variability 
and reduced level of SI during the first 24 hours was evident in the stochastic 
model, providing further justification for this approach. When more data 
becomes available, more models could be generated and used for specific 
diagnostic categories or drug therapies.  
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Chapter 12. Conclusions 
Tight glycaemic control in critical care has been shown to confer significant 
benefits on patient outcome. However, maintaining safe, effective control in 
critically ill patients has proven difficult, due to considerable inter- and intra- 
patient variability. Model-based control currently provides the only robust, 
adaptive and patient-specific solution to manage these highly dynamic patients.  
 
The model-based control practised in the Christchurch Hospital ICU uses a 
physiological model that relies on a single, time-varying parameter, SI, to capture 
the patient-specific glycaemic response to insulin. As an identified parameter, SI 
is prone to also capturing other, unwanted, dynamics that add variability on 
multiple timescales. The objective of this thesis was to understand and reduce 
unwanted variability of the SI parameter, and thus improve glycaemic control 
performance. 
 
Unwanted variability in SI was separated into two broad categories, intrinsic and 
extrinsic variability. The first part of this thesis addressed intrinsic variability by 
enhancements to reduce the influence of unmodelled artefacts within the model. 
The second part addressed extrinsic variability, by proposing ways of using the 
model in control to mitigate the effects on outcome glycaemia. The proposed 
changes to the model were validated in-silico. 
 
A simple model of insulin secretion as a function of blood glucose concentration 
was developed using data collected from a recent study at the Christchurch 
Hospital ICU. Separate models were identified for non-diabetic patients and 
diagnosed, or suspected type II diabetic patients, with R2 = 0.61 and 0.69, 
respectively. The gradients of the functions identified were comparable to data 
published in a number of other studies on healthy and diabetic subjects. These 
improved models provide a much better description of insulin secretion than the 
previous, relatively constant model and thus reduce unwanted intrinsic SI 
variability. 
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The population constant parameters describing key insulin kinetics were 
reviewed using data from published microdialysis studies. Specifically, values of 
the transcapilliary diffusion (nI) and cellular clearance (nC) rate parameters were 
optimised, as interactions between them determine maximum interstitial insulin 
concentrations available for glucose disposal, and thus directly influence SI. The 
optimal values of these parameters were determined to be nI = nC = 0.0060 min-1. 
These optimal parameter values are associated with an ‘effective’ interstitial 
insulin half-life t½ = 58 mins, within the range of 25-130 mins reported by others. 
 
A sub-model of endogenous glucose production was investigated to better 
capture the enhanced glucose appearance rate characteristic of the acute stress 
response to critical injury. Models of EGP as functions of blood glucose 
concentration and time were assessed, but proved unsatisfactory due to 
difficulties in identifying reliable functions with the available data set. Thus, until 
further information becomes available, the best course is to continue treating 
EGP as a population constant, despite the impact on intrinsic SI variability. 
However, during real-time control in clinical situations, if a patient has poor fit to 
measured data due to a constrained value of SI while receiving no nutrition, then 
EGP should be temporarily increased. 
 
The proposed insulin kinetic parameters and secretion enhancements were 
incorporated into the model and this updated definition was re-designated 
ICING-2. The ICING-2 model was subsequently validated for clinical glycaemic 
control and virtual trial purposes using self- and cross- validation analyses on a 
critically ill cohort, independent to that on which the model was developed. 
 
Several suspected causes of extrinsic SI variability were investigated with the 
ICING-2 model: Patient type and condition, drug therapies and measurement 
errors. As these factors are not explicitly modelled, they could be addressed by 
improved modelling. Hence, the impact of these elements could only be 
mitigated through understanding, and smarter use of SI in control and analysis 
applications. 
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The first 24 hours of ICU stay proved to be a period of significantly increased SI 
variability, both in terms of hour-to-hour changes and longer-term evolution of 
level. This behaviour was evident for the entire study cohort as a whole and was 
particularly pronounced during the first 12-18 hours. The subgroup of 
cardiovascular surgery patients, in which there was sufficient data for analysis, 
mirrored the results of the whole cohort, but was also found to have even lower 
and more variable SI.  
 
In addition to patient type and condition, the use of glucocorticoid steroids was 
also found to be associated with clinically significant reductions in overall level 
and increases in hour-to-hour variability of SI. To manage the extrinsic SI 
variability and its changes over time and between patient groups, the use of 
several stochastic models was proposed. Using different models for the early 
part of ICU stay and for different diagnostic subgroups as well as when patients 
were receiving certain drug therapies would permit control algorithms to reduce 
the impact of the SI variability on outcome glycaemia. Additionally, intervention-
based measures such as greater blood glucose measurement frequency, 
conservative insulin dosing and modulation of carbohydrate nutrition can be 
used to lower the impact of SI variability on glycaemia and thus risk. 
 
An analysis of the impact of measurement timing and BG concentration errors on 
the variability of SI was also conducted. Results indicated that the impact of both 
sources of errors on SI level was unlikely to be clinically significant and probably 
swamped by physiological factors arising from the critical condition of the 
patients. The impact of BG sensor errors on hour-to-hour SI variability was more 
pronounced. However, given the random nature of these errors, the only feasible 
method of mitigation is to use more accurate BG sensors, but the cost of these 
devices may be prohibitive. 
 
Understanding the effect of sensor and timing errors on SI allows their impact to 
be taken into account when using the parameter for control and analysis. For a 
given SI level, variability caused by measurement errors might dominate the IQR 
of the probability density function describing SI for the subsequent hour. Hence, 
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to avoid inadvertently basing control decisions on this artificial variability, the 5-
95 percentile range of the stochastic model should be used. In addition, using 
changes in SI level as a diagnostic must be done with caution, potentially by 
looking at longer-term trends, where the effects of random errors may be 
cancelled by averaging over time. 
 
The concept of using more than one stochastic model to reduce the impact of 
extrinsic variability on outcome glycaemia was validated using virtual trials. 
Virtual trials were simulated with the STAR protocol using stochastic models 
generated with data taken from both entire ICU stay and only the first 24 hours. 
Using a stochastic model specifically generated for the first 24 hours of ICU stay 
resulted in reduced glycaemic variability and hypoglycaemia during this period, 
without adversely affecting the overall level of control. 
 
The analyses of intrinsic variability led to improvements in the model that 
provided a more physiological basis and increased accuracy. The performance of 
the model incorporating these changes was validated for clinical glycaemic 
control and virtual trial purposes. The study of extrinsic variability addressed 
factors that were outside the explicit physiological model. The use of multiple 
stochastic models to reduce the impact of this extrinsic variability during 
glycaemic control was validated using virtual trials. 
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Chapter 13. Future Work 
The work presented in this thesis addressed several major causes of intrinsic 
and extrinsic SI variability. However, there remain other elements, both within 
the model and in the way it is used, that contribute to this variability that may 
provide avenues for further improvement in the future. 
 
13.1 Gastric model 
For patients being receiving nutrition through the enteral route, glucose 
appearance in current ICING family of models is handled by a gastric sub-model. 
This sub-model was adapted from that used by Wong et al. [2008] for type 1 
diabetic subjects. Being a compartment model, the total mass of glucose is 
conserved, and thus must eventually appear in the blood glucose compartment. 
However, inaccurate kinetic parameters may result in an incorrect rate of 
appearance, which could impact identified values of SI.  
 
Additionally, recent work within this research group suggests that an incretin 
effect is observable in the SI parameter. Incretins are a group of gastrointestinal 
hormones that potentiate insulin secretion in response to food. Thus, changes in 
nutritional content or rate may affect SI, through pathways independent of 
glucose appearance.  
 
Verification of the gastric model kinetics and an analysis of the potential impact 
of incretins on SI in critically ill patients would provide valuable information on 
other sources variability that may affect glycaemic control. 
 
13.2 Insulin delivery method 
Bolus insulin delivery is preferred in the Christchurch Hospital ICU. Most other 
hospitals typically favour constant infusions. Both methods have their 
advantages and disadvantages. However, the choice of delivery method may 
have an impact on SI.  
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The high, transient insulin concentrations associated with bolus delivery can 
interact with modelled saturation dynamics, but also ensure a rapid rise in the 
interstitial insulin concentration and receptor-bound fraction. A preliminary 
(unpublished) study comparing the efficacy of both delivery methods with the 
ICING model found that bolus insulin resulted in greater glucose disposal than 
the same dose given as an infusion over one hour. Thus, a study into the possible 
effects of delivery method on SI level and variability would be worthwhile. 
 
13.3 High frequency BG measurements 
With the recent, rapid, improvement in continuous glucose monitoring (CGM) 
sensor technology, these devices may soon become common in intensive care 
units. CGM devices offer a much higher measurement frequency, but currently, 
with lower accuracy than typical bedside glucometers. As the technology 
matures, and accuracy and reliability increase, the high data density available 
from these devices may enable other model parameters to be identified or, at 
least, characterised in a more patient-specific manner. For example, an accurate 
BG profile measured every 1-2 minutes following a bolus of insulin could 
potentially provide valuable information about the insulin kinetics and/or 
glucose-insulin dynamics of individual patients. This information could then be 
used to further reduce intrinsic SI variability and thus improve patient-specific 
glycaemic control. Thus, a study into the trade-off between measurement 
frequency and model parameter identifiability would be worthwhile. 
 
13.4 Endogenous insulin secretion and glucose production 
The analyses of insulin secretion and EGP presented in this thesis are by no 
means complete. The wide range of disorders and variability characteristic of 
critically ill patients ensure that more data and analyses will always be valuable. 
A refined study of pancreatic insulin secretion would combine greater 
measurement frequency with better knowledge about when best to take C-
peptide and insulin samples to accurately define the secretion profile. In 
addition, laboratory BG measurements, coinciding with the other samples would 
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provide a better basis for a model as a function of both BG and its time 
derivative. 
 
Accurate information about endogenous glucose production is difficult to obtain 
due to the complicated and intensive experiments required. This fact is further 
complicated in ICU patients, where variability over time and between patients 
means that a single value of EGP at a point in time is of limited utility. However, 
developments and new techniques may come along to improve access to the 
endogenous glucose production rate. In addition, high frequency data from CGMs 
may enable better, real-time, estimation of EGP. Thus, with new data and 
methods, the treatment of EGP within the ICING family of models should be 
reviewed. 
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